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ABBREVIATIONS 
 
Ac  Acetate 
AAG  Gastric Atrophy Autoimmune 
Ala  Alanine 
Asp Aspartate 
Arg  Arginine 
Asn  Asparagines 
At  Glycerol-3-phosphate acyltransferases 
Bet  Glycine-betaine  
13C  Carbon 13 
CHESS Chemical Shift Selective saturation standard 
Ck  Choline kinase 
CNS  Central Nervous System 
Cho  free Choline 
ChoCC/tCho Choline Containing Compounds or total Choline 
Chol  Cholesterol 
COSY  COrrelation SpectroscopY 
CPMG  Carr-Purcell-Meiboom-Gill 
Cr  Creatine 
Ct  Cytidylyltransferase 
CT  Computed Tomografy 
Cys  Cysteine 
D2O  Deuterated water 
1D  one-Dimensional 
2D  two-Dimensional 
E  Ethanolamine 
FA  Fatty Acids 
FID  Free Induction Decay 
FT  Fourier Trasformer 
GABA  γ-AminoButyric Acid 
α-, β-Glc α-, β-Glucose 
Gln  Glutamine 
Glu  Glutamate 
Glx  Glutamine plus Glutamate 
Gly  Glycine 
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G-Gly  Glycine intermediate 
GPC  Glycerophosphocholine  
GPE  Glycerophosphoethanolamine 
GSH  γ-Glutamylcysteinylglycine, glutathione 
1H  Proton 
His  Histidine 
HPF  High Power Field 
HR-MAS High-Resolution Magic Angle Spinning 
HMBC  Heteronuclear Multiple Bond Correlation 
HMQC Heteronuclear Multiple Quantum Coherence 
HSQC  Heteronuclear Single Quantum Coherence 
HTau  HypoTaurine 
Ile  Isoleucine 
Lac  Lactate 
LED  Longitudinal-Eddy current Delay 
Leu  Leucine 
Lip  Lipids 
Lpl  Lysophospholipase 
Lys  Lysine 
MRI  Magnetic Resonance Imaging 
MRS  Magnetic Resonance Spectroscopy 
Met  Methionine 
Man  Mannitol 
MM  MacroMolecoles or bonded amino-acids 
Myo-Ino Myo-Inositol 
NAA  N-acetylAspartate 
NMR  Nuclear Magnetic Resonance  
β-OHBut β-hydroxybutyrate 
Pap  Phosphatidate phosphohydrolase 
PCA  Principal Components Analysis 
PCr  Phosphocreatine 
PC  Phosphocholine 
PE  Phosphoethanolamine 
PEG  Polyethylene glycol 
Ph  Phospholipids 
Phe  Phenylalanine 
Pla  Phospholipase A 
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Plc  Phospholipase C 
Pld  Phospholipase D  
PLS-DA Partial Least Squares-Discriminant Analysis 
PNET  Primitive NEuroectodermal Tumor 
PRESS  Point Resolved Spectroscopy 
Pro  Proline 
Ptc  Phosphocholine cytidylyl-transferase 
RCC  Renal Cell Carcinoma 
Scy-Ino Scyllo-Inositol 
Suc  Succinate  
Tau  Taurine 
TG  Triglycerides 
Thr  Threonine 
TMA  Tetramethylammonium 
TOCSY TOtal Correlation SpectroscopY 
Tyr  Tyrosine 
UDP  Uridine diphosphate 
UMP  Uridine monophosphate 
Val  Valine 
VOI  Volume of interest 
WHO  World Health Organization 
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SUMMARY 
 
This thesis is focused on the metabolomic study of human cancer tissues by ex vivo 
High Resolution-Magic Angle Spinning (HR-MAS) nuclear magnetic resonance (NMR) 
spectroscopy. This new technique allows for the acquisition of spectra directly on intact 
tissues (biopsy or surgery), and it has become very important for integrated metabonomics 
studies. The objective is to identify metabolites that can be used as markers for the 
discrimination of the different types of cancer, for the grading, and for the assessment of the 
evolution of the tumour. Furthermore, an attempt to recognize metabolites, that although 
involved in the metabolism of tumoral tissues in low concentration, can be important 
modulators of neoplastic proliferation, was performed. In addition, NMR data was integrated 
with statistical techniques in order to obtain semi-quantitative information about the 
metabolite markers. In the case of gliomas, the NMR study was correlated with gene 
expression of neoplastic tissues. 
Chapter 1 begins with a general description of a new “omics” study, the 
metabolomics. The study of metabolism can contribute significantly to biomedical research 
and, ultimately, to clinical medical practice. This rapidly developing discipline involves the 
study of the metabolome: the total repertoire of small molecules present in cells, tissues, 
organs, and biological fluids. Metabolomic approaches are becoming increasingly popular in 
disease diagnosis and will play an important role on improving our understanding of cancer 
mechanism. Chapter 2 addresses in more detail the basis of NMR Spectroscopy, presenting 
the new HR-MAS NMR tool, that is gaining importance in the examination of tumour tissues, 
and in the assessment of tumour grade. Some advanced chemometric methods were used in an 
attempt to enhance the interpretation and quantitative information of the HR-MAS NMR data 
are and presented in chapter 3. Chemometric methods seem to have a high potential in the 
study of human diseases, as it permits the extraction of new and relevant information from 
spectroscopic data, allowing a better interpretation of the results.  
Chapter 4 reports results obtained from HR-MAS NMR analyses performed on 
different brain tumours: medulloblastoma, meningioms and gliomas. 
The medulloblastoma study is a case report of primitive neuroectodermal tumor 
(PNET) localised in the cerebellar region by Magnetic Resonance Imaging (MRI) in a 3-year-
old child. In vivo single voxel 1H MRS shows high specificity in detecting the main metabolic 
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alterations in the primitive cerebellar lesion; which consist of very high amounts of the 
choline-containing compounds and of very low levels of creatine derivatives and N-
acetylaspartate. Ex vivo HR-MAS NMR, performed at 9.4 Tesla on the neoplastic specimen 
collected during surgery, allows the unambiguous identification of several metabolites giving 
a more in-depth evaluation of the metabolic pattern of the lesion. The ex vivo HR-MAS NMR 
spectra show higher detail than that obtained in vivo. In addition, the spectroscopic data 
appear to correlate with some morphological features of the medulloblastoma. The present 
study shows that ex vivo HR-MAS 1H NMR is able to strongly improve the clinical possibility 
of in vivo MRS and can be used in conjunction with in vivo spectroscopy for clinical 
purposes.  
Three histological subtypes of meningiomas (meningothelial, fibrous and oncocytic) 
were analysed both by in vivo and ex vivo MRS experiments. The ex vivo HR-MAS 
investigations are very helpful for the assignment of the in vivo resonances of human 
meningiomas and for the validation of the quantification procedure of in vivo MR spectra. By 
using one- and two dimensional experiments, several metabolites in different histological 
subtypes of meningiomas, were identified. The spectroscopic data confirmed the presence of 
the typical metabolites of these benign neoplasms and, at the same time, that meningomas 
with different morphological characteristics have different metabolic profiles, particularly 
regarding macromolecules and lipids.  
The profile of total choline metabolites (tCho) and the expression of the Kennedy 
pathway genes in biopsies of human gliomas were also investigated using HR-MAS NMR, 
and microfluidic genomic cards. 1H HR-MAS spectra, allowed the resolution and relative 
quantification by LCModel of the resonances from choline (Cho), phosphorylcholine (PC) 
and glycerolphorylcholine (GPC), the three main components of the combined tCho peak 
observed in gliomas by in vivo 1H MRS spectroscopy. All glioma biopsies depicted an 
increase in tCho as calculated from the addition of Cho, PC and GPC HR-MAS resonances. 
However, the increase was constantly derived from augmented GPC in low grade NMR 
gliomas or increased PC content in the high grade gliomas, respectively. This circumstance 
allowed the unambiguous discrimination of high and low grade gliomas by 1H HR-MAS, 
which could not be achieved by calculating the tCho/Cr ratio commonly used by in vivo 1H 
MR spectroscopy. The expression of the genes involved in choline metabolism was 
investigated in the same biopsies. High grade gliomas depicted a significant upregulation of 
choline kinase and phospholipase C, as well as a downregulation of the cytidyltransferase 
gene, the balance of these being consistent with the accumulation of PC. In the low grade 
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gliomas, Phospholipase A and lysophospholypase were upregulated and Phospholipase D 
became downregulated, supporting the accumulation of GPC. The present findings offer a 
convenient procedure to classify accurately glioma grade using 1H HR-MAS, providing in 
addition the genetic background for the alterations of choline metabolism observed in high 
and low gliomas grade. 
Chapter 5 reports the study on human gastrointestinal tract (stomach and colon) 
neoplasms. The human healthy gastric mucosa, and the characteristics of the biochemical 
profile of human gastric adenocarcinoma in comparison with that of healthy gastric mucosa 
were analyzed using ex vivo HR-MAS NMR. Healthy human mucosa is mainly characterized 
by the presence of small metabolites (more than 50 identified) and macromolecules. The 
adenocarcinoma spectra were dominated by the presence of signals due to triglycerides, that 
are usually very low in healthy gastric mucosa. The use of spin-echo experiments enable us to 
detect some metabolites in the unhealthy tissues and to determine their variation with respect 
to the healthy ones. Then, the ex vivo HR-MAS NMR analysis was applied to human gastric 
tissue, to obtain information on the molecular steps involved in the gastric carcinogenesis. It 
is possible to identify glycine, alanine, free choline and triglycerides as possible molecular 
markers related to the human gastric mucosa differentiation from pre-neoplastic to neoplastic 
conditions. A microscopic investigation was also carried out in order to identify and locate the 
lipids in the cellular and extra-cellular environments. Correlation of the morphological 
changes detected by transmission (TEM) and scanning (SEM) electron microscopy, with the 
metabolic profile of gastric mucosa in healthy, gastric atrophy autoimmune diseases (AAG), 
Helicobacter pylori-related gastritis and adenocarcinoma subjects, were obtained. These 
ultrastructural studies of AAG and gastric adenocarcinoma revealed lipid intra- and extra-
cellularly accumulation associated with a severe prenecrotic hypoxia and mitochondrial 
degeneration. 
A deep insight into the metabolic profile of human healthy and neoplastic colon 
tissues was gained using ex vivo HR-MAS NMR spectroscopy in combination with 
multivariate methods: Principal Component Analysis (PCA) and Partial Least Squares 
Discriminant Analysis (PLS-DA). The NMR spectra of healthy tissues highlight different 
metabolic profiles with respect to those of neoplastic and microscopically normal colon 
specimens (these last obtained at least 15 cm far from the adenocarcinoma). Furthermore, 
metabolic variations are detected not only for neoplastic tissues with different histological 
diagnosis, but also for those classified identical by histological analysis. These findings 
suggest that the same subclass of colon carcinoma is characterized, at a certain degree, by 
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metabolic heterogeneity. The statistical multivariate approach applied to the NMR data is 
crucial in order to find metabolic markers of the neoplastic state of colon tissues, and to 
correctly classify the samples. Significant different levels of choline containing compounds, 
taurine and myo-inositol, were observed. Particularly, in this case, the presence of lipids it is 
not a marker of the tumor or of the grade of malignity.  
Chapter 6 deals with the metabolic profile of normal and tumoral renal human tissues 
obtained by ex vivo HR-MAS NMR. The spectra of human normal cortex and medulla show 
the presence of differently distributed osmolytes as markers of  physiological renal condition. 
The marked decrease or disappearance of these metabolites and the high lipid content 
(triglycerides and cholesteryl esters) is typical of clear cell renal carcinoma (RCC), while 
papillary RCC is characterized by the absence of lipids and very high amounts of taurine. This 
research is a contribution to the biochemical classification of renal neoplastic pathologies, 
especially for RCCs, which can be evaluated by in vivo MRS for clinical purposes. Moreover, 
these data help to gain a better knowledge of the molecular processes envolved in the onset of 
renal carcinogenesis. 
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RIASSUNTO 
 
Lo scopo di questa tesi è stato di effettuare uno studio di metabolomica (scienza 
relativa al pool dei metaboliti a basso peso molecolare presenti in un tessuto o in un fluido 
biologico) eseguito su neoplasie umane, attraverso l’utilizzo della ex vivo High Resolution-
Magic Angle Spinning (HR-MAS) Nuclear Magnetic Resonance (NMR) spectroscopy. 
Questa tecnica permette di ottenere spettri direttamente sul tessuto (ottenuto per biopsia o in 
seguito ad intervento chirurgico) senza nessun pretrattamento, ed è diventata molto 
importante per studi metabonomici, relativi all’integrazione del metaboloma con una robusta 
elaborazione statistica. Dopo aver identificato i pattern metabolici di vari tessuti e organi 
umani sani e quelli delle rispettive neoplasie di differente tipo e grado istologico, l’obbiettivo 
è stato quello di ricercare nel tessuto tumorale i metaboliti che potessero assumere il 
significato di markers delle neoplasie, in relazione anche al grado e all’evoluzione del tumore 
stesso, con evidenti implicazioni cliniche (diagnosi, trattamento e prognosi). Inoltre, si è 
cercato di individuare quei metaboliti, che anche se presenti in basse concentrazioni, appaiono 
tuttavia coinvolti nel metabolismo tumorale, e possono essere anch’essi importanti modulatori 
della proliferazione neoplastica. Come anticipato, per gli studi metabonomici, i risultati NMR 
sono stati integrati con analisi statistiche per ottenere informazioni semiquantitative sui 
marker metabolici. Nel caso dei gliomi lo studio di risonanza è stato inoltre correlato con 
l’espressione genica di enzimi coinvolti nel pattern delle “coline” a livello del tessuto 
neoplastico. La scelta delle “coline” si è resa indispensabile essendo ampiamente dimostrato 
che il ciclo di Kennedy è coinvolto in modo determinante nel processo tumorale. 
Il capitolo 1 presenta una introduzione generale alla metablomica. Lo studio del 
metabolismo tumorale può contribuire significativamente alla ricerca biomedica e in 
definitiva alla pratica medico-clinica, rendendo disponibili informazioni molecolari relative 
all’insorgenza ed alla progressione della neoplasia. Il rapido sviluppo di questa disciplina 
riguarda lo studio del metaboloma, cioè l’insieme delle piccole molecole presenti in cellule, 
tessuti, organi, e fluidi biologici. L’approccio metabonomico è diventato sempre più popolare 
nella diagnosi di malattie e avrà un ruolo importante nel migliorare la comprensione nei 
meccanismi molecolari coinvolti nell’insorgenza e nello sviluppo delle neoplasie umane. Nel 
capitolo 2, vengono riportate in dettaglio le basi della spettroscopia NMR. In particolare 
viene descritta la tecnica HR-MAS, che ha acquisito fondamentale importanza nell 
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valutazione dei profili metabolici che caratterizzano le neoplasie umane e le differenziano dai 
rispettivi tessuti funzionale. Nel capitolo 3 sono descritti alcuni metodi chemometrici 
avanzati, utilizzati per migliorare l’interpretazione e le informazioni quantitative dei dati 
spettroscopici ottenuti con l’HR-MAS. La combinazione dei dati biochimico-spettroscopici 
con l’elaborazione statistica nello studio delle malattie umane, permette non solo l’estrazione 
di nuove e rilevanti informazioni dai dati ottenibili con la spettroscopia NMR, ma anche una 
migliore interpretazione degli stessi assegnando una significatività statistica ai marker 
biochimici ipotizzati. 
Nel capitolo 4 sono presentati i risultati ottenuti attraverso l’analisi ex vivo HR-MAS 
NMR eseguita su differenti tipi di tumori cerebrali. Il primo tipo di neoplasia cerebrale 
riportata si riferisce al medulloblastoma, neoplasia a prevalente incidenza infantile. In 
particolare viene discusso il “case report” di un PNET (Neuro Ectodermal Primitive Tumour) 
localizzato nella regione cerebellare MRI (Magnetic Resonance Imaging) in un bambino di tre 
anni. La spettroscopia in vivo single voxel 1H MRS ha mostrato alta specificità nel rilevare le 
principali alterazioni metaboliche nella lesione cerebellare, come un alto contenuto dei 
composti contenenti colina e una ridotta quantità di creatina ed N-acetilaspartato. La ex vivo 
HR-MAS 1H NMR, eseguita a 9.4 Tesla sul campione neoplastico prelevato durante 
l’operazione, permette di identificare diversi metaboliti dando una approfondita e più ampia 
valutazione del pattern metabolico della lesione. Gli spettri HR-MAS mostrano che i dettagli 
spettrali sono maggiori rispetto a quelli che si ottengono dallo spettro in vivo. In più i dati 
spettroscopici sembrano essere correlati con alcune caratteristiche morfologiche del 
medulloblastoma. Lo studio mostra come l’ex vivo HR-MAS è capace di migliorare 
fortemente le possibilità cliniche della in vivo MRS e puo essere utilizzata in combinazione 
con la spettroscopia in vivo per scopi clinici. Tre sottotipi istologici di meningioma 
(meningoteliale, fibroso e oncocitico), neoplasia extracerebrale a carattere prevalentemente 
begnina, sono stati analizzati mediante spettroscopia in vivo ed ex vivo. L’analisi ex vivo HR-
MAS NMR ha permesso una accurata descrizione del profilo metabolico ed facilitano 
l’interpretazione e l’assegnazione dei segnali degli spettri in vivo dei diversi meningiomi e 
anche la validazione del procedimento di quantificazione degli spettri in vivo. Utilizzando 
esperimenti mono- e bidimensionali, sono stati identificati diversi metaboliti nei differenti 
sottotipi istologici. I dati spettroscopici confermano la presenza di metaboliti tipici delle 
neoplasie benigne, e nello stesso tempo che i meningiomi con differenti caratteristiche 
morfologiche presentano un pattern metabolico diverso soprattutto per quanto riguarda 
componenti riferibili a macromolecole e lipidi. 
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Il profilo metabolico dei composti contenenti colina e l’espressione genica del ciclo di 
Kennedy in biopsie umane di gliomi sono stati studiati utilizzando la spettroscopia HR-MAS 
NMR e sonde dedicate per lo studio di geni specifici. Lo spettro 1H HR-MAS permette la 
risoluzione e la relativa quantificazione attraverso un software particolare (LCmodel) delle 
risonanze della colina (Cho), fosforilcolina (PC) e glicerofoforilcolina (GPC), le tre 
componenti principali del singolo picco delle coline totali (tCho) osservato negli spettri in 
vivo di gliomi. Tutte le biopsie di glioma mostrano una aumento delle tCho, calcolato come 
somma delle risonanze rilevabili in HR-MAS di Cho, PC e GPC. Tuttavia il principale dato è 
relative all’aumento della GPC nei gliomi di basso grado e dall’aumento di PC nei gliomi di 
alto grado. Il comportameno di questi metaboliti permette una netta discriminazione tra gliomi 
di alto e basso grado con l’HR-MAS, situazione che non può essere ottenuta calcolando il 
rapporto tCho/Cr che comunemente viene considerato con la spettroscopia in vivo. Sulle 
stesse biopsie è stata studiata l’espressione genica del pattern enzimatico coinvolto nel 
metabolismo delle coline. I gliomi di alto grado mostrano una significativa up-regulation 
dell’enzima colina kinasi e fosfolipasi C, mentre mostra una down-regulation del gene che 
codifica per l’enzima citidil-trasferasi; l’andamento dell’espressione di questi enzimi 
giustifica l’accumulo della PC rilevato nella spettroscopia. Nei gliomi di basso grado, la 
fosfolipasi A e la lisofosfolipasi sono up-regulated, mentre la fosfolipasi D è down-regulated, 
spiegando in modo analogo l’accumulo di GPC. Questo studio presenta un’adatta procedura 
per classificare accuratamente il grado del glioma utilizzando l’HR-MAS, a condizione che 
parallelamente sia valutato il back-ground genetico alla base delle alterazioni del metabolismo 
delle coline osservato nei gliomi di basso e alto grado. 
Lo studio di neoplasie umane dell’apparato gastrointestinale è presentato nel capitolo 
5. Le caratteristiche dei profili metabolici della mucosa gastrica sana, della mucosa affetta da 
gastrite per infezione da Helicobacter Pilory, della mucosa affetta da una condizione 
preneoplstica quale la gastrite atrofica autoimmune (AAG) e dell’adenocarcinoma gastrico 
sono analizzate utilizzando spettroscopia ex vivo HR-MAS NMR. Il profilo metabolico della 
mucosa gastrica sana e affetta da Helicobacter Pilory è risultato molto simile.Le due 
situazioni sono caratterizzate dalla presenza di più di 50 metaboliti. Al contrario gli spettri di 
adenocarcinoma sono dominati dalla presenza di risonanze dovute a lipidi, trigliceridi in 
particolare. Il contenuto di questi ultimi è basso o quasi assente nella mucosa sana. Inoltre il 
tessuto affetto da AAG ha mostrato un pattern molecolare intermedio fra la situazione 
funzionale e quella neoplastica. L’uso della sequenza spin-echo ha permesso di rilevare alcuni 
metaboliti distintivi del tessuto neoplastico e di evidenziare la loro variazione rispetto al sano. 
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L’analisi HR-MAS applicata al tessuto gastrico ci ha fornito quindi informazioni su alcuni 
possibili step molecolari coinvolti nel processo della carcinogenesi gastrica. È stato infatti 
possibile identificare alcuni metaboliti che appaiono particolarmente significativi quali 
glicina, alanina, colina libera e trigliceridi come possibili marker legati alla differenziazione 
della mucosa gastrica a partire da una condizione sana, attraverso la condizione preneoplastica 
fino ad arrivare a quella neoplastica. È stata effettuata anche una indagine microscopica per 
localizzare i lipidi (i trigliceridi rilevati con L’HR-MAS) nei tessuti gastrici sani, affetti da 
AAG e da adenocarcinoma. Lo studio ha avuto come obbiettivo di correlare i cambiamenti 
morfologici, rilevati con la microscopia elettronica a trasmissione (TEM) e a scansione 
(SEM), col profilo metabolico della mucosa gastrica sana, dell’AAG, della gastrite dovuta a 
H. pylori e dell’adenocarcinoma. Gli studi ultrastrutturali della AAG e dell’adenocarcinoma 
gastrico rivelano che l’accumulo di lipidi, sotto forma di “goccioline lipidiche” (lipids bodies) 
avviene sia negli spazi intra- che in quelli extra-cellulari ed è associato ad una forte ipossia  
prenecrotica e ad una degenerazione mitocondriale.  
Nel capitolo viene riportata anche un’accurata analisi del profilo metabolico del 
tessuto sano e neoplastico del colon utilizzando la spettroscopia ex vivo HR-MAS NMR in 
combinazione con metodi statistici: Principal Component Analysis (PCA) e Partial Least 
Squares Discriminant Analysis (PLS-DA). Lo spettro NMR della mucosa sana presenta un 
profilo metabolico diverso rispetto al tessuto neoplastico e anche rispetto al tessuto prelevato 
a 15 cm di distanza dalla zona tumorale e definito macroscopicamente eistologicamente sano. 
Inoltre le variazioni metaboliche sono rilevate non solo tra carcinomi con diversa diagnosi 
istologica, ma anche per carcinomi che presentano la stessa diagnosi istologica. Questo 
suggerisce che la stessa sottoclasse tumorale è caratterizzata da un certa eterogeneità 
metabolica. L’analisi multivariata applicata ai dati NMR è stata determinante per identificare i 
marker metabolici del tumore del colon e per classificare correttamente il campione. 
Variazioni significative sono state osservate nelle quantità relative di metaboliti quali coline, 
taurina e mio-inositolo. I lipidi in questo tratto gastrointestinale non risultano essere un 
marker tumorale o del grado di malignità. 
Il lavoro riportato nel capitolo 6 presenta la caratterizzazione del profilo metabolico di 
parenchima renale umano funzionale e neoplastico ottenuto mediante ex vivo HR-MAS NMR. 
Gli spettri di campioni chirurgici renali relativi alle zone corticali e midollari mostrano una 
diversa distribuzione dei metaboliti ad attività osmotica (osmoliti). La marcata diminuzione o 
assenza dei metaboliti e un elevato contenuto di lipidi (trigliceridi e esteri del colesterolo) è 
tipica dei carcinomi renali a cellule chiare, mentre i carcinomi papillari sono caratterizzati da 
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assenza di lipidi e un elevato livello di taurina. Questa ricerca fornisce un contributo 
biochimico-molecolare ad una migliore comprensione delle patologie neoplastiche renali, 
soprattutto dei carcinomi a cellule chiare. Crea inoltre le premesse biochimiche fondamentali 
per future applicazioni cliniche della spettroscopia in vivo. Inoltre questi dati contribuiscono a 
migliorare la conoscenza del processo molecolare che è alla base della carcinogenesi renale. 
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GENERAL INTRODUCTION 
 
The final decades of the twenteth and the beginning of the twenty-first centuries, have 
witnessed a revolution in biomedical research that has made it possible to move from the 
study of single genes, single mRNA transcripts, single proteins, or single metabolites to 
studies that encompass entire genomes, transcriptomes, proteomes, and metabolomes (Figure 
1). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The biological organization of the ‘-omes’. The classical view of biological organization is to consider 
the flow of information from the genome to the transcriptome, to the proteome and then the metabolome. 
However, each tier of organization depends on the other, so a perturbation in one network can affect another. 
Furthermore, the environment has a important impact not only on the expression and concentrations of 
transcripts, proteins and metabolites, but also on the genome by selecting for adaptive changes in subpopulations 
of cells within a tumour. Metabolomics can potentially investigate much more than normal metabolism and 
metabolic disorders, it can also be used to monitor changes in the genome or to measure the effects of 
downregulation or upregulation of a specific gene transcript. 
 
Since the finalization of the sequencing of the human genome, the main goals of 
functional genomics have been to determine the role of the products of newly identified 
genes, as well as to determine those that might be therapeutically targeted. So far, functional 
genomic strategies have largely centred on gene-expression studies (transcriptomics) or 
protein profiles (proteomics) (1-3). These approaches have led to several successes in the field 
of cancer biology, such as the identification of new tumour subtypes, as well as transcriptional 
and protein biomarkers for certain types of cancer (4-8). Also, metabolomics, the study of 
metabolism at the global, has the potential to contribute significantly to biomedical research 
Enviroment 
Proteome 
Trascriptome 
Metabolome 
Genome 
Introduction to metabolomics 
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and, ultimately, to clinical medical practice. This rapidly developing discipline involves the 
study of the metabolome, the total repertoire of small molecules present in cells, tissues, 
organs, and biological fluids. Metabolic activity can also be quantified, as various analytical 
tools have been developed to measure concentrations of low-molecular-weight metabolites. 
This is a particularly challenging task as low-molecular-weight metabolites represent a 
diverse range of chemicals. Perhaps the best description of this approach was offered by Steve 
Oliver of Manchester University, who used the term ‘metabolomics’ to describe “the 
complete set of metabolites/low-molecular-weight intermediates, which are context 
dependent, varying according to the physiology, developmental or pathological state of the 
cell, tissue, organ or organism” (9). This definition arose from the term that was originally 
used to describe a powerful tool for phenotyping yeast mutants (9).  
Although ‘-omic’ technologies are complementary, analysis of the metabolome is an 
especially useful approach for identifying pathways that are perturbed in a given pathology, 
when compared with the transcriptome and proteome. Measuring metabolite concentrations is 
a more sensitive approach than following the rates of chemical reactions directly. Metabolic 
control analysis has demonstrated that although changes in enzyme concentrations and 
activities (‘the proteome’) have a small impact on metabolic fluxes (the rate of which 
metabolite passes through a given metabolic pathway), changes in flux have a significant 
impact on metabolite concentrations (10-12). This is because the control of the metabolic flux 
of a pathway is spread across all the enzymes present in the pathway, rather than being 
controlled by a rate determining step. Furthermore, there is not necessarily a good quantitative 
relation between mRNA concentrations and enzyme function, but as metabolites are 
downstream of both transcription and translation, they are potentially a better indicator of 
enzyme activity (13) (Figure 2). Metabolomic approaches also generate highly reproducible 
data sets. One disadvantage is that the number of metabolites that exist in a mammalian tissue 
is probably far smaller than the number of transcripts that are present in the mammalian 
transcriptome. Therefore, a given metabolite pattern can reflect several genomic changes. It is 
also not a trivial matter to connect the genome to the metabolome, complicating attempts of 
using metabolomics as a functional genomics tool in cancer research. Metabolomic 
approaches, however, will become increasingly popular in disease diagnosis and will have an 
important role in improving our understanding of the mechanisms of cancer. 
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Figure 2. The “Omics” sciences are characterized by complex data sets of related phenomena each of which 
taken as a whole constitute a picture of an organism. Different techniques are used to analyze the different 
“omics” sciences. 
 
The use of metabolic profiling to follow systemic changes in multicellular organisms has led 
Jeremy Nicholson to coin the word ‘metabonomics’. He defines metabonomics as “the 
quantitative measurement of the multivariate metabolic responses of multicellular systems to 
pathophysiological stimuli or genetic modification” (14). In addition to the terms 
‘metabolomics’ and ‘metabonomics’, researchers have felt it necessary to distinguish the 
types of analytical techniques used in these approaches (15). ‘Metabolic profiling’ has been 
proposed as a means of measuring the total complement of individual metabolites in a given 
biological sample, whereas ‘metabolic fingerprinting’ refers to measuring a subclass of 
metabolites to create a ‘bar code’ of metabolism (16,17). 
Metabolomics can be used to monitor tumour growth and regression, and can therefore 
increase our understanding of pathogenic mechanisms as well as improve monitoring of 
treatment regimens. It has already been used to analyse the function of Hypoxia Inducible 
Factor-1β in tumours and to monitor the progression of therapy-induced apoptosis in gliomas.  
Metabolomic analysis is therefore a promising approach to identify biomarkers that could be 
used in the non-invasive monitoring of anticancer therapies, particularly those that induce 
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apoptosis. This could also be used as a non-invasive tool for monitoring tumours progression 
in animal models, which cannot be achieved using histology, transcriptomics or proteomics.  
One drawback is that the number of metabolites that can be detected in vivo (directly on 
patients) is relatively small at present, making it difficult to determine exactly which 
metabolic pathways underlie a detected alteration. In vitro metabolomic studies, performed on 
the aqueous extracts of human tissues, have also demonstrated several differences between 
tumour types, in terms of various biochemical pathways (18,19) (Table I).  
 
Table I. Example of metabolic biomarker of human tumors.  
 
Metabolite  Metabolic function  Associated tumours/characteristics 
Alanine 
In conjunction with lactate, increases in tissues 
during hypoxia; made by transamination of pyruvate 
to prevent further increases in lactate (20) 
Brain tumours, including metastasis, gliomas, 
meningiomas and neuroepithelial tumours, clear 
cell renal carcinomas. 
ChoCC 
Include free choline, phosphocholine, 
glycerophosphocholine and phosphatidilcholine; 
these are key constituents of phospholipid bilayer 
cell membranes 
Levels change during apoptosis and necrosis; the 
tumour types that these changes have been found 
in include brain, sarcomas, prostate and 
hepatoma. 
Glycine An amino acid and an essential precursor for de  
novo purine synthesis 
Decreased following disruption of Hypoxia 
Inducible Factor (HIF-1) signalling pathway. 
Lactate An end product of anaerobic glycolysis 
Increases rapidly during hypoxia and ischaemia; 
poorly vascularised tumours have a low 
intracellular pH as a result of increased lactate 
production; increased rates of lactate production 
have been associated with a range of tumours 
and, in particular, certain types of neoplasms (21) 
Myo-Inositol Involved in osmoregulation and 
volume regulation 
Increased in colon adenocarcinoma, glioma, 
schwannomas,ovarian carcinoma, astrocytoma 
and endometrial cells, decreased in breast 
tumours 
Taurine 
Important in osmoregulation and volume regulation; 
hypotaurine is also an antioxidant and might protect 
cells from free-radical damage 
Increased in squamous-cell carcinoma, prostate, 
cancer and liver metastasis 
Fatty Acids Constituents of cell membranes 
Increased in glioma cells undergoing apoptosis 
and in dedifferentiated and pleomorphic 
liposarcomas 
 
Hence, metabolomics offers a particularly sensitive method to monitor changes in a 
biological system, through observed changes in the metabolic network. Different analytical 
techniques are utilized in metabolomic studies, including gas chromatography (GC), liquid 
chromatography (HPLC) and HPLC with electrochemical detection, mass spectrometry (MS) 
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and nuclear magnetic resonance (NMR) spectroscopy. In particular MS and NMR are used as 
tools to monitor changes in tumour metabolism (22,23) (The NMR in vitro was performed on 
the aqueous extracts obtained from the human tissues; the ex vivo was performed on the 
human specimens without any pretreatment; and in vivo was performed directly on healthy 
and functional tissues and organs of the human body). Such metabolomic approaches are 
being used to profile cell lines, tumours and systemic metabolism in human cancer tissue ex 
vivo and in vivo, and will provide another functional genomic tool for cancer research (24).  
Understanding disease processes through metabolic profiling is not a new concept and the 
NMR spectroscopy has been widely used as metabolic profiling tools since the early 1970s 
(25-27). NMR spectroscopy has also been used to differentiate between different cancer cell 
lines (18,19) and to monitor metabolic processes that occur in cancer cells. There are 
numerous reasons for employing NMR as a primary tool for structure based metabolomic 
investigations, many of which are the same as those that have attracted structural biologists to 
NMR. Modern NMR makes it possible to perform rigorous structural analysis of many 
metabolites in crude extracts, cell suspensions, intact tissues, or whole organisms. Structural 
determination of known metabolites using various one-dimensional (1D) and two-
dimensional (2D) NMR methods is straightforward, whereas de novo structural analysis of 
unanticipated or even unknown metabolites is also feasible. In addition to popular high-
sample-throughput applications, NMR is particularly powerful for metabolite structural 
determinations, including the atomic positions of isotopic labels (e.g., 13C, 15N, or 2H) in 
different isotopomers generated during stable isotope tracer studies (28-31). These latter 
applications provide detailed maps of biochemical pathways or networks (32,33). As a result, 
metabolic pathways can now be systematically mapped by NMR with unprecedented speed. 
Using NMR-based approaches, 20–40 metabolites can typically be detected in tissue extracts, 
and 100–200 can be detected in urine samples.  
Today a new technique, called high-resolution magic angle spinning (HR-MAS) 1H 
NMR spectroscopy, can produce ex vivo high-resolution spectra from intact tissue (34-37). A 
biopsy or post-mortem sample of intact tissue is spun at an angle to the applied magnetic 
field. The spinning results in a significant improvement in the resolution of the spectrum 
obtained. This approach has several advantages over NMR spectroscopy of tissue extracts. 
The results from the ex vivo HR-MAS 1H NMR spectroscopy investigations of tumors have 
demonstrated the importance of being able to separate out co-resonant metabolites. It is also 
being used to confirm the metabolic events measured, in vivo, using MRS.  
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GENERAL INTRODUCTION 
 
Nuclear Magnetic Resonance (NMR) Spectroscopy is a powerful tool for the structure 
determination of organic compounds, biomolecules and natural compounds, for the study of 
tissue extracts or intact tissues, and for the obtainment of detailed three-dimensional maps of 
the human body and organs. In the field of biomedicine, the two areas of NMR are 
represented by Magnetic Resonance Imaging (MRI) and by the multi-branched Magnetic 
Resonance Spectroscopy (MRS), where MRS is the acronym utilized in place of NMR. MRI 
uses the strong signal from water protons (1H) to provide a detailed anatomical maps and has 
proven to be an indispensable tool for both researchers and clinicians, but its specificity in 
defining the pathology is limited to only some diseases. More diagnostic information can be 
obtained by MRS because it can detect the much weaker signals from nuclei as proton, carbon 
and phosphorous of metabolites.  
When MRS is applied to a small volume of interest (VOI) of an organ, exploiting the 
localization techniques employed in MRI, it is known as in vivo MRS. The in vivo MRS 
studies are focused on organs (muscles, liver, brain, breast and prostate) the study of which 
has been made accessible through the use of appropriate coils for the acquisition of the 
signals. In vivo MRS, owing to the low resolution experimentally obtainable, allows to detect 
and quantify the changes in concentration of a limited number of metabolites as lactate (Lac), 
N-AcetylAspartate (NAA), Creatine (Cr) plus phosphocreatine (PCr) and choline containing 
compounds (ChoCC) (1-4), and it can be used when the NMR molecular marker of the tissue 
states are well established by means of a detailed biochemical study. This important goal can 
be accomplished by the spectroscopic analysis on tissue extract, by in vitro MRS studies that 
can be performed both on water soluble and on lipid fractions (5-14), giving an overall profile 
of the metabolites present in the tissues (15). The biochemical detail attainable is far higher 
than that characteristic of in vivo MRS, and this renders in vitro studies extremely important 
for the correct interpretation of in vivo spectra (16-20). In these last years it has became 
possible to further improve the metabolite picture of a tissue, by using the ex vivo MRS 
directly on tissues specimens.  
A new technique, HR-MAS NMR (High Resolution Magic Angle Spinning Nuclear 
Magnetic Resonance), working under magic-angle-spinning conditions (21-33), permits to 
obtain spectra on samples, which are otherwise troublesome for classical high-resolution, 
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much better than that of in vivo spectra. Ex vivo HR-MAS NMR represents another powerful 
tool, whose potentiality and relations with in vivo and in vitro MRS measurements have to 
explored (34-37). 
 
BASIC PRINCIPLES 
 
NMR is a spectroscopic technique (38-40) based on a quantum property of nuclei 
called spin I, described as an intrinsic angular momentum of quantum particles, that can only 
assume integer or half-integer values (0, 1/2, 1, 3/2,…). The quantum angular momentum of 
particle with spin I is given by: 
 
L= 1/2 
 
where ħ=1.054x10-34Js is the Planck constant (h) divided by 2pi. Nuclei also possess a 
magnetic moment µ proportional to their spin angular momentum L, through a constant 
characteristic for each nucleus called magnetogyric ratio γ (in units of rad s-1T-1), in the 
equation: 
 
1/2
 
 
NMR spectroscopy can be in principle applied to all nuclei with spin I 0. The nuclei 
possessing I=1/2 are generally more easily studied than those having I>1/241 because they 
give sharper lines. The most important nuclei for organic chemists and biochemists are 1H, 
13C, 15N,19F and 31P, which all have I=1/2. 1H, 19F, and 31P are the most receptive nuclei, being 
characterized by both high isotopic percentages and high γ. Conversely, 13C and 15N are less 
abundant (1.1% and 0.37%) and have low γ, hence are less facile nuclei. When a static 
magnetic field B0 (in units of T-Tesla) is applied, the energy levels of a nucleus with spin I 
become 2I+1. For instance, for a spin ½ the energy levels are two, the corresponding spin 
states are denoted as α and β (Figure 1) and are related to the parallel (low energy) and 
antiparallel (higher energy) orientation of the magnetic moment µ with respect to the B0 field. 
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Figure 1: Energy separation between nuclear spin states. 
 
 The energy difference between the spin energy levels is equal to hν0 (Planck’s law) 
where ν0 is referred to as Larmor frequency (of the order of MHz). Over a large number of 
spins at thermal equilibrium, the lower energy state is slightly more populated than the higher 
one, and a net magnetization M0 of the sample (longitudinal magnetization) is present parallel 
to the applied B0 field direction (z axis). The application of the radio-frequency field B1, close 
to the Larmor frequency ν0, perpendicular to B0 and turned on for a short time (pulse), causes 
the rotation of M0 around the B1 direction towards a plane perpendicular to B0 (the xy plane) 
and permits the creation of a transverse magnetization, the detection of which generates the 
NMR signal (Figure 2). 
 
Figure 2. Outline of the simplest NMR experiment in the rotating frame. 
 
 After the perturbation caused by B1 the magnetization relaxes to its equilibrium. The 
reconstruction of the longitudinal magnetization towards equilibrium is characterized by a 
time constant called longitudinal relaxation time T1, whereas the decay of the transverse 
magnetization is characterized by another time constant called transverse relaxation time T2. 
m1= + 1/2 (α) 
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The effect of T2 on the FID and the signals is shown in Figure 3. To reach the desired signal-
to-noise ratio is often necessary to add more FIDs, waiting an appropriate delay (dependent on 
T1) between subsequent acquisitions to ensure that the magnetization has relaxed to its 
equilibrium value.  
 
Figure 3. Illustration of the fact that the more rapidly the FID decays the broader is the line in the corresponding 
spectrum. A series of FIDs are shown at the top of the figure and the corresponding spectra are below, all plotted 
on the same vertical scale. The integral of the peaks remains constant, so as they get broader the peak height 
decreases. 
 
 This signal, called FID (free induction decay), has to be processed with the Fourier 
transform (FT) algorithm to became interpretable, giving a spectrum consisting in a plot of 
signal intensity as a function of frequency (Figure 4). 
 
 
Figure 4. From FID (a) to spectrum (b) through FT transformation. Fourier transformation is the mathematical 
process which takes us from a function of time (the time domain), such as a FID, to a function of frequency, i. e. 
the spectrum.  
 
 The actions performed by the NMR spectrometer, pulses and delays of very precise 
lengths, can be programmed and constitute as a whole what is generally called a pulse 
sequence. Pulse sequences can be represented by simple diagrams in which pulses are denoted 
a b 
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by boxes of different lengths and are separated by time intervals which have to be accurately 
chosen in relation to specific NMR parameters. The simplest pulse is that commonly used to 
record 1H NMR spectra. (Figure 5) 
 
 
Figure 5. Pulse sequence scheme for acquisition of 1H NMR spectrum. The index n indicates the repetition times 
of the sequence and will be omitted later. 
 
13
 Carbon Nuclear Magnetic Resonance Spectroscopy 
The element carbon consists of a stable isotopes 12C and 13C with 98.9% and 1.1% 
natural abundance, respectively. Only the 13C nucleus has a magnetic moment and has a spin 
I=1/2 while the 12C nucleus of the major isotope is non magnetic. The main difficult in 13C 
NMR is the low natural abundance of the carbon 13 nucleus (1.108%) and its low gyro-
magnetic ratio γ. Low natural abundance and small gyro-magnetic ratio are the reason why 
13C NMR is much less sensitive (1.59%) than 1H NMR (100%). The acquisition of 13C is used 
for determine the structure of compounds. The 13C chemical shift scale spans some 250 ppm. 
Because the 13C nucleus is isotopically rare, it is extremely unlikely that any two adjacent 
carbon atoms in a molecule will both be 13C. As a consequence 13C-13C coupling is not 
observed in 13C NMR spectra, i. e. there is no signal multiplicity or splitting in a 13C spectrum 
due 13C-13C coupling.  
 
 
 
Figure 6. 1H decoupled 13C and then acquired the 13C signals. 
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13C couples strongly to any protons which may be attached (1JCH is typically about 125 Hz fro 
saturated carbon atoms in organic molecules). Spin coupling to one or more protons 
complicates the interpretation of the 13C spectra and thus it is normally removed using a 
variety of proton decoupling techniques (Figure 6). All decoupling procedures are based on 
the same principle, the broadband irradiation of all proton resonances with a high-power 
amplitude-modulated and monochromatic 1H frequency. The irradiation saturates the 
Boltzman energy levels of the proton spectrum, removing the macroscopic magnetization of 
all protons and making the scalar proton couplings disappear from the 13C spectrum. There are 
two main proton decoupling methods: broad band decoupling (BB) and composite pulse 
decoupling (WALTZ). They differ in the type of modulation of the proton frequencies. 
Whereas BB uses a continuous irradiation of proton frequencies with a train of rectangular 
pulses of identical duration and opposite phase (41) composite pulse decoupling uses blocks 
of 1H pulses of different pulse lengths and phases (42) WALTZ sequences are more efficient 
than BB, allowing decoupling 13C spectra using less decoupler power and diminishing also 
the potential dielectric heating of the sample.  
 
NMR PARAMETERS 
 
The structural identification of compounds is encoded into three principal spectral 
parameters: chemical shifts (δ, ppm), the spin-spin coupling constants (J, Hz) and the signal 
areas. The spectral shape is also dependent on the longitudinal and transverse relaxation 
times, T1 and T2, respectively. 
 
Chemical shift 
When a molecule is placed in a B0 field, the molecular electron distribution shields the 
applied magnetic field with respect to the nuclei, and being this distribution generally 
anisotropic, the magnetic field experienced by nuclei at different sites is slightly different, as 
well as their Larmor frequencies (i.e. their signals in the NMR spectrum). This phenomenon 
is called chemical shift and, in principle, we expect to find, in the NMR spectrum of a certain 
isotope, a different signals for each chemically different nucleus. These differences are very 
low in the MHz scale and spectroscopists prefer to express them in terms of part per million 
(δ, ppm) with respect to a reference compound, which varies from nucleus to nucleus. For 
instance, for 1H, 13C and 29Si spectroscopy the reference, when organic solvents are employed, 
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is tetramethylsilane (TMS) whose 1H ,13C and 29Si NMR signals are placed at δ = 0 ppm in 
the corresponding chemical shift scales. In the case of water solutions the reference is sodium 
2,2-dimethyl-2-silapentane-5-sulfonate (TSP). The chemical shift is very informative on the 
chemical environment of a given nucleus and permits the identification of the chemical 
groups present in a molecule. For organic compounds, 1H NMR signals are found in the range 
of 0-16 ppm (43), whereas 13C signals span approximately from 0 to 250 ppm [41, 43], 19F 
signals from +50 to -280 ppm (with respect to δ of trichlorofluoromethane set equal to 0), 31P 
signals from +250 to -180 ppm (with respect to δ of 85 % phosphoric acid set equal to 0) and 
15N signals from +500 to -400 ppm (with respect to δ of nitromethane set equal to 0). The 
chemical shift range is different for the different nuclei, being dependent on the atomic 
number of the elements specie.The literature reports collections of chemical shifts for the 
most important metabolites (44-45) that can be used for assignment purposes.  
 
Coupling constant 
NMR signal of nuclei with spin I=½ posses a fine structure that is due to the 
interaction among nearby spins, mediated by bonding electrons and it is referred to as 
spinning coupling or scalar coupling constant, denoted J and given in Hz unit. The J coupling 
is an intramolecular interaction, independent of the applied magnetic field and is denoted as 
homonuclear and  heteronuclear if the spins are of some or different isotopic type, 
respectively. The J coupling constants are shared between couples of spins. A group of spins 
coupled together is called spin system. The signal multiplicity of a nucleus in a spin system 
depends on the number of spins coupled with it and on the values of the coupling constants. 
The more observed proton-proton coupling constants J(H,H) are those over two and three 
bonds 2J(H,H) and 3J(H,H), respectively. The geminal coupling constants 2J(H,H) are 
observed only in the case of diastereotopic methylene protons. For the 3J a further dependence 
on the dihedral angle, expresses by a Karplus type relaxations, is found: the 3J value is larger 
for an angle of 180°, smaller for an angle around 90° and reaches a relative maximum at 180°. 
The one-bonded 1J(C,H) are the largest carbon-proton couplings, hence the more easily 
observed, whereas 3J(C,H) are usually higher than 2J(C,H) (41,43,46,47). The J coupling are 
strongly dependent on the chemical structure in terms of geometry and constitution. The 
factors which influence more the values of coupling constants are γ of coupled nuclei, 
hybridization, bond length, bond angle, substituent electro-negativity. The phenomenon of 
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spin coupling is not restricted to carbon and proton, but involves other interesting nuclei such 
as 31P and 19F,the presence of which can further complicate proton and carbon spectra. 
 
Integrated area 
 The area of NMR signals is directly proportional to the number of nuclei generating it, 
providing that an adequate delay between subsequent scans has to be used to allow for 
longitudinal relaxation. The estimate of the number of nuclei can be obtained from signal 
height only when comparing singlets of the same width at half height. Signal width is 
inversely proportional to transverse relaxation time, which, in turn, depends on molecular 
motion. Slowly tumbling molecules posses short T2 and give broad signals. 
 
 The peculiar advantage of NMR spectroscopy is based on its ability to identify a wide 
range of compounds present in complex mixtures, owing to the flexibility in the experimental 
implementation which, in turn, permits the choice among a great number of experiments in 
order to establish molecular connectivity and spatial relationships. 
 
High Resolution NMR in solution 
Liquid or powdered samples (e. g. those derived from perchloric acid -PCA- extraction 
and lyophilisation or from lyphophilic extraction) are usually dissolved in a suitable 
deuterated solvent, such as D2O or CDCl3. The usage of deuterated solvents permits to 
minimise the huge proton signals coming from the solvent itself, that can obscure the weaker 
ones from the solute. It also provides the deuterium lock signal utilised in high-resolution 
NMR for magnetic field stabilisation. When D2O is used signals coming from OH, NH and 
SH groups are lost due to proton-deuterium exchange. To avoid this effect a H2O/D2O 9/1 
mixture is generally used, and suitable solvent suppression techniques employed. 
 
HR-MAS (High Resolution Magic Angle Spinning) 
High-resolution NMR spectra of biological samples have been usually obtained from 
homogeneous clear liquid extracts of tissues or cells. Recently, a new technique, HR-MAS, 
which stands for high-resolution magic-angle spinning, has been introduced. HR-MAS NMR 
can be considered a hybrid technique between solid-state NMR and classical solution state 
NMR. It uses, similarly to solid-state NMR, the magic angle spinning (MAS), (48) but it 
retains the classical solution NMR experiments. Similar to solution NMR, HR-MAS NMR 
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involves direct polarization transfer and not cross-polarization transfer (CP-MAS) (49) 
between 1H and heteronuclei (13C or 15N), thus distinguishing it from CP-MAS experiments 
on true solid state.  
 In liquids, molecules do not generally experience significant motional restriction and 
tumble at rates faster than the NMR observation frequency. Thus, significant spectral 
broadening effects due to the fact that the molecules are not motionally free are averaged, 
resulting in narrow spectral lines. In tissues, restriction of molecular motions and areas of 
different magnetic susceptibility result in spectral broadening that is not effectively averaged. 
In this type of sample, interactions such as dipolar couplings and chemical shift anisotropy 
produce spectral broadening with an angular dependence of (3cos2θ-1), where θ is the angle 
between the static magnetic field and the inter-nuclear vector responsible for the interaction. It 
is known that if a sample is spun mechanically, at a rate faster than the spectral broadening 
originating from these interactions, and at the magic angle of 54.7° (which meets the criterion 
of [3cos2 (54.7°)-1 = 0], the contribution from these interactions to the broadening of spin-
one-half nuclei NMR bands can be significantly reduced (50,51). 
 
 
Figure 7. Schematic representation of HR-MAS probe (left); HR-MAS rotor (right). 
 
 A rotor, which is filled with the tissue sample, is placed in a stator block. This rotor is 
spun at the magic angle at an appropriate frequency and the RF coil in the stator block allows 
for the application of high-frequency pulses to the sample and serves as a receiver coil 
thereafter. Nowadays, a magnetic field gradient coil, aligned along the magic angle axis, can 
also be included to allow NMR experiment in which gradients are used to select specific spin 
coherences or to allow the measurement of diffusion properties of the substances present.  
 Nuclear Magnetic Resonance 
 
36 
 
HR-MAS uses dedicate probeheads capable of studying the samples in rapid rotation 
(3÷15 kHz) around an axis 54.7° tilted with respect to that of the static magnetic field (B0) 
(Figure 7). These probeheads drastically reduce contribution from dipolar couplings, chemical 
shift anisotropy, and susceptibly distortions, providing high-resolution spectra from semisolid 
samples, such as tissues. The quality of the obtained spectra is comparable to that obtained 
from aqueous extracts, and the acquisition techniques used are those employed in high-
resolution NMR in solution. The advantage is that of carrying out measurements on intact 
tissues specimens (34,23), without any pretreatment, enabling the extractions step to be 
omitted, and aqueous and lipid fractions to be detected simultaneously, enhancing the 
possibility of identifying biochemical markers with diagnostic and prognostic value. After the 
first application of HR-MAS NMR on human tissue specimens, some articles on ex vivo HR-
MAS spectroscopic studies on different organ tissues have appeared (52-64).  
In order to evidence the quality of the spectra obtained with the HR-MAS probe with 
respect to those obtained using high resolution probe, I report in Figures 7 and 8 the spectra of 
kidney tissue samples. The sample for the high resolution probe was prepared by putting a 
piece of kidney directly in a 5mm glass tube. It is evident (see Figure 7 and 8) the better 
resolution obtained with HR-MAS.  
 
Figure 7. 1D proton NMR spectra of kidney obtained with water-presaturation pulse sequence with composite 
pulse to a) HR-MAS probe and b) High Resolution probe. 
a) 
b) 
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Figure 8. 1D proton NMR spectra of kidney obtained with CPMG sequence with total spin-echo time 2nτ=360 
ms, to a) HR-MAS probe and b) High Resolution probe. 
 
Sample Selection and Treatment 
One major advantage of HR-MAS NMR spectroscopy is that the sample preparation is 
straightforward and relatively fast, although this still has to be carried out manually. Samples 
of as little as ~ 20 mg can be prepared (65). The original samples healthy or neoplastic (the 
tissues are to be considered healthy or neoplastic only when the histological examination 
confirms the macroscopic finding, mainly when these studies are undertaken for the first time) 
are to be put rapidly in liquid nitrogen and stored at -85°C until NMR analyses. The samples 
can be preserved up to 3 months without observing changes in the spectra, and the 
measurements should be taken within this period. Immediately before NMR analysis, the 
tissue sample is cut to have suitable dimensions and flushed with D2O to eliminate residual 
blood (thus reducing the iron content, with the aim to improve the homogeneity, and in turn 
the water suppression) and to add deuterium as nucleus for the lock system. The specimens 
are then transferred into the MAS zirconia rotors (4 mm OD) that are available in different 
capacities (12, 50, 90 µL), and are chosen in relation to the sample amount. A Teflon 
perforated insert is used to restrict the volume, to eliminate bubbles, and to improve the 
homogeneity of the sample. The insert is closed by a screw, then the rotor by a cap the star 
b) 
a) 
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shape of which provides the driving for the rotor (see Figure 7). The rotor are generally spun 
at frequencies between 2000 and 6000 Hz, when working on tissues. This is dependent on the 
spectrometer frequency and is chosen so that spinning side bands will be located outside the 
spectral region of interest, i.e. at an observation frequency of 400 MHz, a 4000 Hz rotation 
frequency is chosen in order to make sure that spinning side bands lie outside the 10 ppm 1H 
NMR spectral window. Maintenance of tissue integrity is the limiting factor in the selection 
of rotation speed. Signal line-widths decrease and signal intensities consequently increase 
with increasing spinning speed and these effects are reversible when returning to lower 
spinning speeds. However, after rotation at frequencies of about 8000 Hz, it has been found 
that spectral line widths remain sharper after returning to lower speeds, indicating some 
breakdown of cell structures, with the concomitant release and higher mobility of metabolites. 
Reasons for this are the moderate centrifugal forces if the tissue sample is not well packed 
into the rotor (66).  
The temperature in the MAS NMR experiments can be adjusted over a wide range and 
the current commercially available standard cooling devices, temperatures of 1-10° C are 
easily achieved. Especially for experiments which take long times, such as 2D acquisitions or 
extended sets of 1D experiments, it is advisable to cool the specimen in the rotor to 
temperatures below room temperature. Several studies have been performed at temperatures 
of 10-30° C, but it has been recommended that experiments be carried out at 4° C, to maintain 
stability over a longer period. It is very important to keep the tissue temperature as low as 
possible, since the intracellular reaction rates in the tissue increase 2-4 fold when the 
temperature is increased by 10° C. The rotor temperature is regulated using gas flow, the 
temperature of which can be adjusted. Although most published studies cite an operating 
temperature, it might not always accurately reflect the sample temperature, since it simply 
reflects that of the cooling gas. Higher spinning speeds can induce considerable frictional 
heating (24) and hence this provides an additional need for sample cooling. It is always 
important when carrying out HR-MAS NMR spectroscopic studies of tumor samples, to 
obtain data in a period as short as possible. Samples should be snap-frozen in liquid nitrogen 
straight after tumor excision in order to avoid post mortem changes (67-69). When defrosting 
samples for MAS NMR, tumor metabolism is not interrupted as is the case when carrying out 
freeze-clamped extraction studies. Therefore, it is best to defrost and process tumor samples 
in an ice bath and to keep the time short before the sample is placed in the rotor and kept at a 
low temperature. Although some studies have reported that sample freezing affects the NMR 
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profile of tissue metabolites (67,70), there is the need to keep the surgery to NMR experiment 
time at room temperature as short as possible, and, until further practical improvement, snap 
freezing and low temperature storage are the only real possibilities.  
 The measurements reported in the present thesis, unless otherwise indicated, are 
carried out maintaining the temperature of the sample at 278° K. Sample and instrument 
preparation takes about 20 min. 
 
NMR EXPERIMENTS 
 
One-Dimensional NMR Spectra 
The NMR experiments utilized to obtain HR-MAS spectra of tissues are the same as 
those used in solution. A generally employed basic set of experiments is formed by: 
 1. The 1D 1H NMR experiment with suppression of the residual HDO/H2O (Figure 9): 
it generates a spectrum containing signals from metabolites, macromolecules, and lipids It is 
necessary to suppress the water signal because its high intensity can obscure the resonances of 
the other components. Among several approaches that can be adopted (71), the presaturation 
one is that preferred by us. It consists in the irradiation of the HDO/H2O signal with a weak 
radiofrequency field B1 (50 Hz) for some seconds prior to the acquisition of the 1H spectrum 
(Figure 10). This method is more selective than others, but it is not recommended when peaks 
from protons involved in chemical exchange processes with water are studied, because their 
signals are reduced or lost. 
 
Figure 9. Pulse sequence scheme for acquisition of 1H NMR spectrum with low power pre-saturation of water 
signal during the relaxation delay. 
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Figure 10. 1D proton NMR spectra of healthy gastric mucosa obtained with water-presaturation pulse sequence 
with composite pulse. 
 
 2. The water-suppressed spin-echo experiment (Carr-Purcell-Meiboom-Gill, CPMG) 
(72) (Figure 11): it acting as a T2 filter cuts off signals from macromolecules and lipids, 
leaving only signals from small metabolites (Figure 12). The experiment employs the pulse 
sequence:  
 
       [d1-90°-(τ-180°-τ)n-AQ] 
 
Figure 11. Pulse sequences for the spin echo (T2 filter). 
 
where d1 is the relaxation delay, 2τ is the echo time, and AQ the acquisition time. The 90° 
pulse creates a transverse magnetization that decays during the spin-echo period (τ-180°-τ)n.  
Water residue  
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Figure 12. 1D proton NMR spectra of healthy gastric mucosa obtained with CPMG sequence with total spin-
echo time 2nτ=360 ms. 
 
 
 
Figure 13. Example of magnetization behavior in the spin-echo sequence. 
 
 After the delay (d1), P90° generates a My magnetization that precedes during τ; this 
magnetization can be resolved into y- and x-components as shown in b. The 180° pulse 
applied on the x-axis has not effect on the x-component of the magnetization; in contrast the 
y-component is rotated by 180° in the yz-plane, ending up along the opposite axis. The 
individual components after the 180° pulse are shown in c, and the corresponding vector is 
shown in d. The effect of the 180° pulse on the x-axis is to reflect the vector in the xz-plane. 
During the second time τ the vector precesses in the same direction (Figure 13). At the end of 
the sequence the vector always ends up along the y-axis, regardless of the time τ and the 
offset Ω; the sequence is said to “refocus the offset (or shift). 
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Macromolecules having short T2 [T2 can be estimated by the half-height line width lw1/2 by the 
equation lw1/2=1/(piT2)] should be completely relaxed and filtered out. The total echo time 2nτ 
can be varied in relation to the T2 of the macromolecules. The water suppression irradiation is 
used during d1 and in my experiments this parameter was set to 1.5 s. 
 
 3. The gradient-based stimulated-echo pulse sequence (with bipolar-gradient pulse 
pairs and longitudinal-eddy current delay, LED) (73) (Figure 14): it generates a spectrum in 
which signals coming from slowly diffusing molecules are retained at expenses of those from 
low molecular weight metabolites, which are, in turn, reduced (Figure 15). The experiment 
employs the following pulse sequence: 
 
[d1-90-g1-δ-180-g2-δ-90-g3-∆-90-g1-δ-180-g2-δ-90-g4-d21-90-AQ] 
 
 
Figure 14. . Pulse sequences for diffusion-edited spectra. 
 
where g2= -g1, the diffusion time d20= ∆-90-δ-180-δ-90 and d21 is the eddy-current time. The 
correct selection of d20 and the gradient strength permits to filter out signals from fast moving 
small molecules and to retain only macromolecules.  
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Figure 15. 1D proton NMR spectra of healthy gastric mucosa obtained with diffusion edited spectrum obtained 
with ∆=200 ms, δ=4 ms and gradient strength of 32 G/cm.  
  
 These last two experiments exploit the different relaxation and diffusion properties of 
small metabolites with respect to macromolecules and lipids. The accurate choice of the spin-
spin relaxation delay 2nτ and of parameters influencing diffusion (gradient-field pulse 
duration δ, gradient strength, and diffusion time ∆) enables two complementary sets of 
signals, corresponding to narrow and broad components, to be isolated.  
 The acquisition of a diagnostic set (comprehensive of 1, 2 and 3) of 1D HR-MAS 
spectra requires about 30 min. In the case of scarcely overlapping signals the chemical shifts 
and coupling constants of metabolites can be derived by direct inspection of the spectrum. 
The comparison of the data obtained with those reported in the literature, taking into account 
that pH can influence the chemical shifts, can lead to the identification of some compounds. 
Nevertheless, NMR spectra of intact tissues or biological extracts show generally a complex 
profile due to the overlapping of resonances of a wide type of molecules. Crowded spectra 
can be analysed to a greater degree through the use of two-dimensional techniques. 
 
Two-Dimensional NMR Spectra 
2D NMR spectra can be a valuable aid in elucidating complex NMR spectra, 
permitting identification of unknown compounds mainly by analyzing their spin-spin 
correlations through chemical bonds.  
In NMR the signal is recorded as a function of one time variable and then Fourier 
transformed to give a spectrum which is a function of one frequency variable. In two-
dimensional NMR the signal is recorded as a function of two time variables, t1 and t2, and the 
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resulting data Fourier transformed twice to yield a spectrum as a function of two frequency 
variables. The general scheme for two-dimensional spectroscopy is: 
 
In the first period, called the preparation time, the sample is excited by one or more 
pulses. The resulting magnetization is allowed to evolve during t1. Then another period 
follows, called the mixing time, which consists of a further pulse or pulses. After the mixing 
period, the signal is recorded as a function time variable, t2. This sequence of events is called 
a pulse sequence and the exact nature of the preparation and mixing periods determines the 
information found in the final 2D spectrum. It is important to realize that the signal is not 
recorded during the time t1, but only during the time t2 at the end of the sequence.  
The two-dimensional signal is recorded in the following way. First, t1 is set to zero, the 
pulse sequence is executed and the resulting free induction decay recorded. Then the nuclear 
spins are allowed to return to equilibrium. t1 is then set to ∆1, the sampling interval in t1, the 
sequence is repeated and a free induction decay is recorded and stored separately from the 
first. Again the spins are allowed to equilibrate, t1 is set to 2∆1, the pulse sequence repeated 
and a free induction decay recorded and stored. The whole process is repeated again for t1 = 
3∆1, 4∆1 and so on until sufficient data is recorded, typically 50 to 500 increments of t1. Thus 
recording a two-dimensional data set involves repeating a pulse sequence for increasing 
values of t1 and recording a free induction decay as a function of t2 for each value of t1. 
Among the plethora of 2D experiments found in the literature, the most effective, and thus 
most commonly employed, for the identifications of metabolites in mixtures are COrrelation 
SpectroscopY (COSY) (74), TOtal Correlation SpectroscopY (TOCSY) (75,76), and 
Heteronuclear Single Quantum Coherence (HSQC) (77) or Heteronuclear Multiple Quantum 
Coherence (HMQC) (78) experiments. 
COSY (79-81) experiment (Figure 16), and its variants, is one of the most popular and 
useful of all two-dimensional experiments. It is a homonuclear experiment, mostly used for 
analyzing proton spectra. During t1 the spin system evolves under the effect of J couplings 
and chemical shifts, the second 90 degree pulse transfers spin information between pairs of 
coupled nuclei which is detected during t2. The Spectra are 2D plots in which signals 
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corresponding to the 1D spectrum are on the diagonal, whereas off-diagonal peaks, called 
cross-peaks, are found between pairs of coupled spins (Figure 17). These correlations are 
usually due to connections through two and three bonds, but long-range connectivities can 
sometimes be observed. 
 
 
Figure 16. Pulse sequence for homonuclear COSY experiment. d1 relaxation delay, t1 evolution time, t2 
acquisition time. 
 
Figure 17. Schematic COSY spectrum, indicating how it is used to determine the chemical shifts of coupled 
spin. In this example there are five spins, A-E. Diagonal peaks, are filled and cross peaks are unfilled. Diagonal 
peaks have the same frequency coordinates (chemical shifts) in each dimension, whereas for cross peaks the 
coordinates are different. The appearance of the cross peak at ω1 frequency of B and the ω2frequency of A 
indicates that A and B are coupled. Using the same interpretation for the other peaks, we find that B is further 
coupled to D. Similarly, C is coupled to E. Overall, the COSY spectrum allow us to trace out the network of 
coupled spins in the molecule. 
 
As example of the used of COSY in the characterization of the gastric mucosa are shown in 
Figure 18.  
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Figure 18. COSY NMR spectrum of healthy gastric mucosa. This COSY spectrum is particularly useful for the 
distinction of Lac (labeled as number 6) and threonine (Thr, labeled as 5), whose doublets at 1.33 ppm overlap, 
and for the detection of α-hydrogens of several amino acids (circled). It also permits to distinguish 
glycerophosphocholine (GPC, labeled as 25) from phosphorylcholine (PC, labeled as 26), whose N+(CH3)3 
signals are usually unresolved, and to detect phosphorylethanolamine (PE, labeled as 22), whose signals are 
found in a very crowded region and often hidden under those of other metabolites (squared).  
 
TOCSY (82,83) experiments (Figure 19) enable all the components of a spin system to 
be detected (at least in principle). The core of these experiments is a spin-lock time, which 
allows transfer of information from one spin to another belonging to the same coupling 
network, even if these spins are separated by many bonds (Figure 20). The mixing time must 
be held long enough (from 60 to 140 ms) to complete the transfer process to all the spins. In 
our studies we have selected a mixing time of 100 ms. The TOCSY spectra permit the 
identification of 1H,1H connectivities up to five or six bonds.  
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Figure 19. Pulse sequence for the TOCSY experiment. The heart of the sequence is the period of isotropic 
mixing, indicated by the rectangle, which transfers magnetization between spins which are connected via an 
unbroken network of couplings.  
 
 
 
Figure 20. Schematic TOCSY spectrum for the same spin system as for the COSY spectrum show in Figure 17.  
 
As example of the used of TOCSY in the characterization of the gastric mucosa are shown in 
Figure 21.  
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Figure 20. TOCSY NMR spectrum of healthy gastric mucosa. Some metabolites, such as lysine (Lys, labeled as 
10) and arginine (Arg, labeled as 11) (circled), myo-Inositol (Myo) and β-glucosio (β-Glc) are better 
differentiated in TOCSY spectra that in the COSY one. More interestingly, some signals due to α-CH of bonded 
aminoacids [mainly alanine (Ala) and Thr] are detected in the region of the 2D spectrum close to the correlations 
of Lac and Thr (squared, labeled as 6 and 5, respectively). 
 
Heteronuclear chemical shift correlation experiments HMBC and HSQC, are basically 
heteronuclear COSY experiments that allow us to obtain information about directly connected 
or long-range relayed protons and heteronuclei. By heteronucleus I mean 13C, but the 
experiment can be applied to other nuclei, such as 15N, 31P, etc. In heteronuclear two-
dimensional NMR experiments the nucleus that evolves during t1 is different from that which 
is detected in t2. Classical 2D HETero-CORrelated experiments (HETCOR) (84) are based on 
the acquisition of the heteronucleus, whereas information about the proton is obtained in the 
second dimension, ω1. Conversely, inverse-detection experiments (Heteronuclear Multiple 
Quantum Coherence HMQC (85), Heteronuclear Single Quantum Coherence HSQC (86), and 
Heteronuclear Multiple Bond Correlation HMBC (87) relay on the acquisition of the more 
receptive nucleus, i.e. the proton, whereas the chemical shift of the heteronucleus is found in 
ω1. The two-dimensional heteronuclear NMR experiments are based on the existence of 
coupling constants between heteronuclei and protons, and due to the difference between one-
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bond and long-range coupling constants, it is possible to obtain separately spectra depending 
only on 1J(CH) or on nJ(CH)
. 
The inverse-detection method produces more information, 
spectra of a higher quality and in less time with respect to classical hetero-correlated 
experiments, even though it requires good suppression of the signals of protons bonded to the 
not-magnetic isotopomer of the X nucleus (e.g. 12C), and, when working in aqueous solution, 
the suppression of water signal. The pulse sequence for HSQC experiment is reported in 
Figure 21. The HSQC experiment is based on a double INEPT (88) polarisation transfer, first 
from proton to carbon, then from carbon back to proton after a time t1, during which the 
carbon chemical shift evolves. The experiment is usually applied in its decoupled (from 
heteronucleus) version. The knowledge of the carbon chemical shift associated to the proton 
one represents a key step in the identification of a metabolite. 
 
 
Figure 21. Pulse sequence for HSQC experiment. Decoupling from 13C carbon is achieved through a GARP 
pulse sequence (89). 
 
An example of HSQC spectra of gastric mucosa are reported in Figure 22. 
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Figure 22. HR-MAS HSQC spectrum of healthy gastric mucosa. a) One region of the major interest is usually 
that corresponding to the N+(CH3)3 of ChoCC, Tau, Arg, Myo and PE, which all contribute to the 3.2 ppm signal 
in the proton spectra. These molecules can readily be distinguished in HSQC spectra due to the large differences 
in their 13C chemical shifts (circled) and also to their multiplicity (CH3 vs CH2), if edited sequences are 
employed (90). Some problems are encountered in the interpretation of the region between 3.6 and 4.0 ppm, for 
the presence of overlapped correlations around 62 ppm, presumably due to glycerols and CH2OH of Glc. b) At 
low ppm the 13C chemical shifts dispersion is also useful for the assignment of the signals of aliphatic amino 
acids isoleucine (Ile), valine (Val) and leucine (Leu). 
 
To acquire a complete set of good-quality 2D spectra, 15–20 hours of acquisition are required. 
 
Details of the experiment used in the characterization of tissues 
Proton HR-MAS spectra were recorded with a Bruker Avance400 spectrometer 
equipped with a 1H/13C HRMAS probe (operating at 400.13 and 100.61 MHz, respectively) 
and with a Bruker Cooling Unit (BCU) for temperature control. Samples were spun at 4000 
Hz, and three different types of 1D proton spectra were acquired using sequences 
implemented in the Bruker software: (i) a standard sequence with 1.5 s water presaturation 
during relaxation delay, 8 kHz spectral width, 32k data points, 32–64 scans, (ii) a water-
suppressed spin-echo CPMG sequence with 1.5 s water presaturation during relaxation delay, 
1 ms echo time (τ) and 360 ms total spin-spin relaxation delay (2nτ), 8 kHz spectral width, 
32k data points, 256 scans, and (iii) a sequence for diffusion measurements based on 
stimulated echo and bipolar-gradient pulses with big delta 200 ms, eddy current delay Te 5ms, 
little delta 2*2 ms, sine-shaped gradient with 32 G/cm followed by a 200 µs delay for gradient 
a) b) 
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recovery, 8 kHz spectral width, 8k data points, and 256 scans. Two-dimensional COSY 
spectra were acquired using a standard pulse sequence and 0.5 s water presaturation during 
relaxation delay, 8 kHz spectral width, 4k data points, 32 scans per increment, and 256 
increments. Two-dimensional TOCSY spectra were acquired using a standard pulse sequence 
and 1 s water presaturation during relaxation delay, 100 ms mixing (spin-lock) time, 4 kHz 
spectral width, 4k data points, 32 scans per increment, and 128 increments. Two-dimensional 
HSQC spectra were acquired using a standard pulse sequence echo-antiecho phase sensitive 
and 0.5 s relaxation delay, 1.725 ms evolution time, 4 kHz spectral width in f2, 4k data points, 
128 scans per increment, 17 kHz spectral width in f1, and 256 increments. It is not necessary 
to add a reference standard for the chemical shift scale, such as TSP 
(trimethylsilylpropansulfonate), but our suggestion is to use a well known resonance as 
internal standard, such as H-1 of α-glucose (α-Glc) (a doublet at 5.24 ppm, J 3.8 Hz) or the 
methyl of Ala, Lac (doublets at 1.48 ppm, J 7.2 Hz, and 1.33 ppm, J 6.9 Hz, respectively). 
Attention should be paid when using the signal of HDO to calibrate the chemical shift 
scale, for it is highly temperature dependent. 
 
TEMPERATURE EFFECTS 
 
The samples were studied under temperature control conditions, at 278° K. This was 
necessary to slow down tissue degradation processes, which are found to be more evident at 
room temperature. As example,  two sets of representative 1D proton spectra obtained at 300° 
and 278° K at different times (0 and 18–21 h) from two samples of normal gastric mucosa are 
reported in Figure 23. They were all acquired using a water-presaturation sequence and are 
informative of small and large metabolites present in the tissue. The two spectra at t=0 (a and 
c) are similar, except for a different intensity of the signal at 3.72 ppm due to polyethylene 
glycol (PEG), used as an excipient in pharmaceutical preparations, and for a slightly better 
spectral resolution in the case of c). After almost 1 day, an increase in the signals of small 
metabolites, more evident at the higher work temperature (see b versus d), can be observed. 
These spectral changes are attributable to the increased mobility of some metabolites and to 
the partial disruption of subcellular structures, probably due to both temperature and spinning. 
Degradation symptoms only slightly affect the samples in the first hour of analysis and, in the 
view of future applications of HR-MAS with diagnostic purposes, they do not have to be 
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overemphasized. Nevertheless, these findings suggested to work at 278° K, especially to 
safely acquire 2D spectra, which are more time-consuming than the 1D ones. 
 
 
Figure 23. 1D water-presaturated 1H NMR spectra of healthy gastric mucosa: a) sample 1 at 300° K, t = 0 h; b) 
sample 1 at 300° K, t = 21 h; c) sample 2 at 278° K, t = 0 h; d) sample 2 at 278° K, t = 18 h. 
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GENERAL INTRODUCTION 
 
The data collected in science, technology, and almost everywhere else are 
multivariate, with multiple variables measured on multiples samples or at multiple time points 
(1-14). Multivariate data, accurately obtained on intelligently selected observations and 
variables, contain much more information than univariate data and, for this reason, an 
adequate multivariate characterization is a necessary first step in the investigation in both 
basic research and applied technology. Multivariate Data Analysis (MVDA) results have to be 
interpreted and related to the objectives of the investigation and the scientific-technical 
context. Nowadays, tables and data are abundant in all parts of research and development and 
the high quantity of data necessitates the use of appropriate analytical tools for extracting 
significant information from the large amount of raw data, capturing the systematic variation 
without throwing away useful notions intrinsic to the original nature of the experimental data 
set (14-17). 
Pattern-recognition tools are an important part of the process of metabolomics and are 
being used to fully analyse the large multivariate data sets that are produced by other ‘-omic’ 
technologies (18-20). Both supervised and unsupervised techniques (Figure 1) can be used to 
derive metabolic profiles. Supervised techniques use the information of class membership, 
such as disease status, to classify a given data set and therefore should be tested by data that 
are not used to build the pattern-recognition model. To investigate the innate variation in a 
data set in an unsupervised manner, techniques such as principal components analysis or 
hierarchical cluster analysis have been applied. However, in situations in which specific 
questions are being posed, supervised techniques might be more appropriate to either force 
classification (such as in determining which metabolites distinguish between groups) or 
regress a pattern against a trend (such as correlating a temporal progression with metabolic 
changes). Methods for supervised pattern recognition include for example prediction to latent 
structures through partial least squares (PLS). For all the supervised techniques it is necessary 
to test the sensitivity and reproducibility of the models produced, although the biological 
function of the metabolites identified can also indicate the success of the particular pattern-
recognition tool. 
 Multivariate data analysis was applied to different types of high resolution 1H NMR 
data ranging from 1D or 2D spectra. Several new approaches to data analysis of NMR data 
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have been studied and compared (21,22). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Exemple of chemometric methods that can be utilized during the analysis of HR-MAS NMR spectral 
data. (PLS: partial least squares, SIMCA: soft independent modeling of class analogies, PCA principal 
components analysis, TCA: tree cluster analysis.) 
 
In particular we combined 1H NMR data obtained with HR-MAS spectra and 
advanced chemometrics methods including multi-way methods in attempting to enhance the 
interpretation and to obtain quantitative information on the biological tissue samples. This 
combination seems to be very useful for the extraction of relevant information for the  study 
of human diseases. 
 
In particular I utilised two multivariate projection methods: 
 Principal Components Analysis, PCA. 
 Partial Least Squares-Discriminant Analysis PLS-DA, that is a variant of PLS, 
projections to latent structures (23).  
 
 One of the remarkably simple approach to multivariate data analysis is based on the 
so-called projection methods. This approach represents the “case” as a swarm of points in a 
K-dimensional space (K = number of variables), and then projects the point swarm down onto 
a lower dimensional plane or hyper-plane. The coordinates of the points on this hyper-plane 
provide a compressed representation of the observations, and the direction vectors of the 
HR-MAS NMR data 
Creation of data set for 
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Unsupervised  
methods 
PCA 
TCA 
Others 
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hyper-plane provide a corresponding representation of the variables (24). The projection 
approach can be adapted to a variety of data-analytical objectives and to any shape of 
multivariate values. 
In the early stage of a project, when little is known about a problem, a simple overview 
of the information in a data table is often required. Such an overview can be obtained with 
principal components analysis, which produces a summary showing how the observations are 
related and if there are any deviating observations or groups of observations in the data. In 
addition, PCA is also able to describe the relationship among the measured variables: which 
variables contribute similar information to the PCA model, and which provide unique 
information about the observations. In other words, PCA describes the correlation structure of 
a matrix X (N x K), in which observations, Ni, are arranged in rows and variables, Ki, in 
columns. Often, an initial PCA of a data set reveals groupings among observations and this 
may indicate the need for further PCA modelling of each such group (class) in order to fine-
tune the analysis and to understand the characteristic features of the different groups. Then, 
the last stage of data analysis could be represented by the regression modelling between two 
blocks of data, usually denoted X and Y, with the aim of predicting Y from X for new 
observations. This kind of modelling is accomplished with the PLS method. In process 
modelling and monitoring the X-factors or predictors are the signals which are frequently 
sampled, at regular time intervals, to monitor the status of the process, whereas the Y-
responses mirror properties like yield or quality of a product, and which are measured less 
frequently (23). 
 
Principal Components Analysis 
Principal components analysis forms the basis for multivariate data analysis. As shown 
in Figure 2, the starting point for PCA is a matrix of data with N rows (observations) and K 
columns (variables), here denoted by X. 
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Figure 2. Schematic representation of a data matrix X. 
The observations can be analytical samples, chemical compounds or reactions, process 
time points of a continuous process, batches from a batch process, and so on. Variables may 
be spectra or chromatographic signals (NIR, MIR, UV, etc.), parameters like temperatures, 
pressures, flows curves, etc. 
As previously mentioned, the most important use of PCA is indeed to represent a 
multivariate data set as a low dimensional plane, usually consisting of 2 to 5 dimensions, such 
that an overview of the data is obtained. Statistically, PCA finds lines, planes and hyper-
planes, in the K-dimensional space that approximate as well as possible in the least squares 
sense the original data. This means that a line or plane, that is the least squares approximation 
of a set of data points, makes the variance of the co-ordinates on the line or plane as large as 
possible. In particular, principal components analysis is able to decompose the initial matrix 
X (N x K) into a small number of components, J: 
X = APT + E 
where A (N x J) is the score matrix, P (J x K) is the loading matrix and both describe the 
systematic variation within the X data, and E is the stochastic component or, simpler, the 
residual matrix. 
These new matrices, A and P, can be analyzed graphically by means of two plots, the 
score and the loading ones. The score plot is a summary of the relationships among the 
observations and shows how they are projected in the new low dimensional hyper-plane. The 
loading plot is a similar summary of the variables and displays the relationships among them 
in the new PCs space. The two plots are complementary and super imposable, and a direction 
in one plot corresponds to the same direction in the other one. This means that an interesting 
pattern seen in the score plot can be interpreted by looking along that interesting direction in 
the loading plot. An important aspect of any PCA application is the choice of J, i.e. the 
number of components to be used in order to obtain a model representative of the real system. 
Several tests for determining the optimal value have been developed (25). Among them, 
cross-validation (CV), the one employed in this work, is a useful tool to chose the correct 
number of components to use and it provides more realistic residuals than those obtained by 
ordinary residuals of the fitted model. It consists of an internal resembling method. In 
particular, one, venetian blind, or some samples are left out at time and the model is built up 
again on the remaining data value. The model is used to predict the left out samples. The 
procedure is iteratively repeated until each data value has been left out once. The estimation 
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of the “internal” prediction is expressed through the Root Mean Square Error in Cross-
Validation, RMSECV, and the percent of captured variance by the model in cross-validation, 
R2CV, computed respectively by (1): 
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where n is the number of objects, k is the number of variables, ijxˆ  is the predicted value of 
variable j for the i-left out sample, ijx  is the i-row value of the X original data and jx  is the 
average value over samples for variables j. The lower the RMSECV and the higher R2CV, the 
better the prediction ability of the model is. Nevertheless, the right compromise between 
RMSECV and the cumulative variance explained by the model in fit has to be chosen. 
Furthermore, where scores and loadings are examined graphically, it is usually possible to 
assess if a component is meaningful or not from visual inspection. 
 
Partial Least Squares-Discriminant Analysis 
All PLS methods build a regression model between two blocks (data matrices) 
independent variables (X) and dependent variables (Y) using as a representation of these 
matrices latent variables calculated so that they explain the directions of maximum 
covariance. Y can be a vector (in PLS1) or a matrix (in PLS2). The general equation of all 
inverse calibration methods as PLS is:  
Y_XB (2) 
where X and Y are represented by their latent variables and B contains the determined 
regression coefficients in the calibration step. Different algorithms have been developed to 
calculate PLS models (26-29). 
PLS-DA is a variant of PLS used as a classification tool (30,32). 
 
Finally, prior to PCA and PLS-DA analyses, data are pre-treated, in order to transform 
them into a form suitable for the analysis. Sometimes, pre-processing techniques can make 
difference between a useful model and no model at all. There are several kind of pre-
processing that can be used depending on the nature and properties of the data sets. Among 
the various pre-processing tools available, mean-centering of data and block-scaling, which 
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are the pre-treatments used during my work, are briefly described. 
 
Mean-centering 
Mean-centering is a pre-treatment generally used to eliminate the systematic local 
difference between objects. With mean-centering the average value of each variable is 
calculated and then subtracted from the data (24). 
=
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knx , −knx , ∑
=
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k
kn
K
x
1
,
 
 This simply corresponds to moving the system coordinates in the origin of the 
multivariate space, conserving, at the same time, the geometry, i.e. the real information 
contained in the initial data matrix. 
 
Block-Scaling  
When there is the risk of dramatically up-weighting components present in very small 
amounts and showing little variation (such as spectral background or baseline) working with 
unscaled X arrays is preferable. However, e.g. when there are some compounds at 
concentration at least of one order to of magnitude higher with respect to every other 
components comparable influence in the data analyses (32). In order to do this, different 
blocks of variables are defined and Block-scaling (32) is accomplished. For multi-way arrays 
Block-scaling, e.g. within the second mode (variables mode) is accomplished by rearranging 
the three-way array to a bideimensional IK x J matrix and then weighting each variable 
belonging to the same block by: 
 
 
 
where SSTOT is the total sum of squares over all J’s variables, SSBLOCK is the sum of squares 
over the J’s variables belonging to the given block and nBLOCK is the number of defined 
blocks. Also in the block-scaling case, the same general considerations drawn for scaling 
hold. In fact, the only difference between autoscaling and block-scaling is the definition of the 
weighting factor not how it is applied. 
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GENERAL INTRODUCTION 
 
The clinical presentation of brain tumors varies greatly depending on tumor type and 
location. Seizure, hemiplegia, visual or hearing loss, diploidia, headache are common 
neurologic findings related to reised intracranial pressure. Neuroradiologic techniques 
represent the main tool in the diagnosis of brain tumours. Computed Tomography (CT) and 
digital angiography, have been widely used for clinical diagnoses and continue useful for 
tumors screening and for definition of calcified lesion. The advent of MRI greatly improved 
tumor characterization. The MRI technique is adequate for morpho-anatomical description, 
but it specificy is low (1). The information obtained from tomography and MRI examinations 
provide a precise histology in the majority of cases, non-distinctive images can be found 
difficulties in differentiation between malignant tumors and tipical benign tumor or abscess. 
This demonstrates the need for additional tools enabling non invasive histological diagnosis 
of a cranial lesion with a significantly higher degree of certainty than attainable from imaging 
modalities. There is a growing body of evidence that 1H NMR (or MRS) may contribute to 
the clinical evaluation of a number of pathologies and/or therapeutically induced changes in 
metabolite concentrations (2). In vivo MRS is a non-invasive method to detect the 
biochemical changes accompanying the disease. The clinical impact of MRS in medicine has 
been widely reviewed by Smith et al (3) and shows promise as a method to complement 
routine diagnostic investigation. However, the in vivo method suffers from some internal and 
external limitations that may strongly influence the results (4,5). In particular the poor in vivo 
spectral resolution leads to limited characterization of the real biochemical composition of 
explored tissue. Moreover, even among metabolites that are detectable with in vivo MRS, 
subtle concentration differences between normal and pathological tissue, such as a neoplasm, 
can go unnoticed and result in a diagnostic error. The detailed biochemical picture of tissue is 
the basis of correct interpretation by in vivo MRS, and can be used when the molecular 
markers are well established. A deep knowledge of the biochemical composition of tissue 
have been obtained by spectroscopic analysis on extracts obtained from tissue (in vitro MRS). 
The analysis is generally carried out of chemical extracts of tissue samples because the 
extraction procedure produces a homogenous, macromolecule-free solution with a low 
viscosity, which yields narrow, well-resolved 1H NMR spectra. Consequently, a large number 
of cellular metabolic databases have been compiled from 1H NMR studies of extracted tissues 
(6-9). Nevertheless, there are potential problems in the use of extracts. One drawback is that 
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histopathological structures are not preserved prohibiting pathological analysis of the same 
sample. Another disadvantage is that important molecular components may be lost by the 
extraction procedure. Nowadays, the biochemical composition of tissue can be obtained by 
spectroscopic analysis directly from tissue specimens through ex vivo HR-MAS NMR. The 
HR-MAS technique is a powerful analytical tool introduced in 1997 for the study of human 
tissue, potentially bridging the divide between in vitro and in vivo MRS. Ex vivo HR-MAS 
might help for brain tumor diagnosis. Cheng et al. (10) demonstrated that proton magnetic 
resonance spectroscopy (1H MRS) with HR-MAS can preserve tissue histopathology features 
while producing well-resolved spectra of cellular metabolites. HR-MAS can be very helpful 
for the assignment of the resonances in vivo of human brain cancer.  
 
Classification of Brain Tumor 
Brain tumour are the most frequent cause of death for CNS (Central Nervous System) 
pathology after stroke. The overall incidence of primary and secondary brain tumors in the 
European countries and in the United State is approximately 16 new case/100000 persons per 
year, with only slight variations among the different regions in the world and among different 
races (11-14). Primary intar-cranial tumor account for about 5-10% of all neoplasms. They 
represent the second most frequent category of tumors in young children after blood 
malignancies; as a metter of fact primary brain tumors show a first peak of incidence between 
0 and 4 year, then decrease from 15 to 24 years and subsequently a steady rise that reaches a 
plateau between 65 and 79 years.  
 Intra-cranial tumors represent a complex and heterogeneus group of neoplastic lesions. 
They include primary and secondary tumors of the encephalon, tumors arising from 
meninges, hypophysal and pineal glands, cranial nerves and intracranial blood vessels, from 
the skull and embryonic vestiges. Since this great and complex variety of neoplastic lesions, 
many classifications have been proposed, each based on a different criterion and conceived 
with a distinctive purpose. Brain tumors can be classiefied on their pathological, 
epidemiological, prognostic, topographic or neuroradiological features. However, the simplest 
way to categorize intra-cranial neoplasms is to distinguish between primary brain neoplasms 
and metastatic tumors. Brain metastase are more common than primary brain tumors since 
metastatic spread of the tumor to the brain and its coverings from extra-cranial sites (lung, 
breast, gastrointestinal, melanoma, etc.) is a relatively common occurrence, with intra-cranial 
metastases found in up to 24% of all patients who die from cancer. Among primary brain 
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neoplasms, the classification that is usually referred to, is the one proposed by the World 
Health Organization (WHO), which relies on the cellular origin of each tumor type and 
distinguishes among five different main groups: tumor originating from neuro-epitelial cells 
(gliomas, ependymal tumors, choroida plexus tumors, neuronal ,neoblastic, pineal and 
embryonic tumors), tumors arising from cranial and spinal nerves, from meningis, from 
lymphatic and haemathopoietic tissue and from germ cells (15,16). This new classification 
considers not only the clinical course and histological appearance of neoplasms but also their 
immunophenotypic features and molecular and cytogenetic profile, which are more likely to 
correlate with MRS metabolic patterns rather than with conventional MRI.  
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MEDULLOBLASTOMA 
 
Medulloblastoma is classified under the embryonal PNET (primitive neuroectodermal 
tumor), childhood medulloblastoma alter survival likelihood. The WHO classification of brain 
tumors recognizes desmoplastic/nodular medulloblastoma, medulloblastoma with extensive 
nodularity, large cell medulloblastoma, and anaplastic medulloblastoma, in addition to 
medulloblastoma with no other distinguishing features. All the tumors originate from 
primitive or undifferentiated neuroephitelial cells, so they are typically considered pediatric 
brain tumors (1). Brain tumors in paediatric patients are proportionally much more common 
malignancies diagnosed in this age group than those in adults. A large body of paediatric 
brain tumors show low degree of malignancy and therefore respond to therapy, but their 
anatomical localization, often adjacent to vital structures, makes diagnosis challenging. 
Histologically similar tumor types to those in adults, such as benign and malignant 
astrocytomas, and dissimilar ones, such as PNET, neuroblastomas and retinobaslatomas, are 
found.  
 
Clinical material. A 3-year-old child was admitted to the hospital because of persistent 
headaches, which started one month previously, and a refusal to eat due to persistent nausea. 
He underwent MRI and in vivo 1H MRS of the head on a 1.5 Tesla clinical imager (Philips 
Intera, Best, Netherlands), which revealed an intracranial tumor occupying most of the left 
portion of the posterior fossa. Compared to brain parenchyma, the lesion was predominantly 
hyperintense on T2-weighted images and slightly hypointense on T1-weighted images with 
restricted apparent diffusion coefficient (ADC). After intravenous gadolinium injection, the 
mass was enhanced strongly, but not uniformly due to internal small cystic components 
(Figure 1). Extension to supratentorial space through the Pacchioni foramen was clearly 
visualized, and an extra-axial subarachnoid location was initially suggested. Compression of 
the fourth and third ventricles and the aqueductus caused marked hypertensive triventricular 
hydrocephalus. Spine imaging revealed diffused leptomeningeal tumor localizations. The very 
large dimension of the tumor combined with the high cellular density, as suggested by the 
restricted ADC, and the apparent extra-axial localization into the subarachnoid space, raised 
the diagnostic hypotheses of a rare case of lymphoma to be differentiated from 
medulloblastoma. After MR examination, a ventricular-peritoneal shunt was positioned. 
Twelve days after MRI, the child underwent brain surgery, which revealed an intra-axial 
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tumor. Extemporaneous histological examination on a sample was diagnostic for 
medulloblastoma and extensive, but only partial resection of the tumor was possible. 
Subsequent histopathological analysis revealed apoptotic elements, necrosis, high 
proliferation activity (MIB1 =70%) and highly positive CD56 immunoassay. No nodular 
aspect was reported. In vivo 1H MR spectra were performed using a spin-echo sequence with 
144 ms echo time (TE), 2 sec repetition time (TR), and averaging the signal of 128 
consecutive scans, 512 data points and point resolved spectroscopy (PRESS) localization 
technique. Two volumes of interest (VOI) (3x2x2 cm) were placed respectively on the tumor 
mass (Figure 1) and on normal appearing cerebellar parenchyma. Water signal suppression 
was performed using a standard chemical shift selective saturation standard (CHESS) 
sequence with two Gaussian chemical shift selective pulses of 70 Hz. The data were 
processed using CSX2 (Kennedy Krieger Institute, Baltimore, USA). DC Correction, Zero 
Filling factor 2, Gaussian Filter with L.B. 3.0 Hz (time domain), High Pass Filter Bandwith 
50 Hz (to suppress water peak) and baseline correction was applied to both the spectra data.  
 
For the NMR experiments details see chapter II. 
 
 
Figure 1. Conventional MR imaging. (a) Axial diffusion weighted; (b) apparent diffusion coefficient; (c) axial 
T2 weighted; (d) saggital T1 weighted;(e) post-gadolinium sagittal T1 weighted; (f) sagittal T2 weighted; and (g) 
single voxel localizer displayed in green over T2 weighted axial and sagittal images. 
 
 
 Brain Tumours 
 
77 
 
Results and Discussion 
The single voxel in vivo 1H MR spectra obtained from the medulloblastoma and 
contralateral healthy cerebellum are reported in Figure 2a and b, respectively. The spectrum 
of the lesion (Figure 2a) displays one predominant signal at 3.2 ppm, which is usually 
attributed to ChoCC, accompanied by low intensity peaks at 3.0 ppm, attributable to Cr 
derivatives, at 2.3 ppm, attributable to glutamate plus glutamine (Glx); and at 2.0 ppm, 
attributable to NAA and Glx (2). The high ChoCC/Cr ratio found in the present case can be 
associated with the synthesis of new cell membranes. Several MRS studies correlate the 
increase of such compounds to the cell neoplastic proliferation (3,4). Moreover, it can be 
noted that signals downfield from ChoCC are nearly absent in the MR spectrum of the lesion 
with respect to that of the contralateral healthy cerebellum (Figure 2b). In fact, the in vivo MR 
spectrum of the contralateral VOI shows high signals from NAA at 2.0 ppm, Cr at 3.0 ppm, 
ChoCC at 3.2 ppm, and Myo at 3.5 ppm. Lower signals due to NAA at 2.5 ppm and to Glx at 
2.3 ppm are also observed. The signal at 3.5 ppm could receive contributions from both Myo 
and glycine (Gly). Signals at higher frequencies are poorly resolved. ChoCC/Cr metabolite 
signal intensity ratio is within the range measured for the cerebellar tissue of healthy children, 
while a reduction of NAA/ChoCC and NAA/Cr ratios is evident (5-7). We hypothesized that 
the reduction of NAA was an expression of mild oedema and neuronal dysfunction in the 
otherwise normal appearing brain tissue chosen for MRS, an effect in agreement with the high 
compression exerted by the tumor. 
 
  
 
Figure 2. In vivo 1H MR spectra of (a) medulloblastoma and (b) contralateral healthy cerebellum. 
 
Figure 3 reports the ex vivo 1H HR-MAS NMR spectra of the medulloblastoma performed 
with different experiments. A conventional presaturated 1D spectrum, which highlights both 
a b 
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lipid and small metabolite contribution, is displayed in panel a. Figure 3b shows a spectrum 
obtained using a CPMG spin-echo sequence, in order to separate signals according to their 
different T2 and enhance the resonance of metabolites with respect to those of 
macromolecules. Figure 3c represents the diffusion-edited spectrum displaying contributions 
from mobile lipids and macromolecules. 
 
 
Figure 3. 1H HR-MAS spectra of the medulloblastoma. (a) Conventional 1H spectrum obtained with water 
presaturation and composite pulse, (b) CPMG spectrum obtained with 360 ms total spin-echo time and (c) 
diffusion edited spectrum obtained with ∆= 200 ms, δ= 4 ms and gradient strength of 32 G/cm. 
 
The most abundant metabolites can be assigned by comparison with literature data, but 
a complete assignment requires the acquisition of selected 2D experiments such as COSY, 
TOCSY and HSQC. These experiments enable a complete and unambiguous identification of 
the metabolic pattern characterizing the examined tissue. The principal metabolites are 
labelled in Figure 4, and the 1H and 13C assignments of the observed pool of metabolites, 
particularly osmolites, free amino acids and a fraction of mobile lipids, are reported in Table 
a 
b 
c 
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I. A look at the HR-MAS spectra shows that the spectral detail is much higher than that 
obtainable in vivo, and that Myo, taurine (Tau) and PE, and a trace of arginine, contribute to 
the in vivo signal at 3.2 ppm, usually attributed to ChoCC [GPC, PC free choline (Cho)]. The 
H-5 proton signal of Myo at 3.28 ppm (triplet) is detected through the correlation with H 4,6 
at 3.63 ppm in the COSY spectrum, and the correlations with other protons of its spin system 
(4.06, 3.63, and 3.53 ppm) in the TOCSY spectrum (Figure 5a). The CH2N protons of PE at 
3.23 ppm (triplet) are detected in both homonuclear correlation spectra, through a correlation 
with CH2O at 4.00 ppm (a double triplet, which resembles a quartet), which shows a coupling 
with the phosphorous nucleus. Similarly, the CH2N protons of Tau at 3.26 ppm (triplet) are 
detected through the correlation with CH2S at 3.42 ppm (triplet). An estimation of relative 
contributions of these metabolites to the integral value of signals between 3.32 and 3.15 ppm, 
usually attributed to the in vivo spectra of ChoCC, can be derived from the evaluation of areas 
of selected signals (weighted on the basis of the relative proton numbers). This calculation 
leads to the presence of 20% PE, 18% Tau, 55% PC + Cho, and 7% Myo. The same 
experiments highlight a contribution from the CH2N Lys and CH2COO- asparagines (Asn) 
signals to the in vivo signal at 3.0 ppm, usually attributed to NCH3 Cr protons (Figure 5b). Cr 
participates in 60% of the total area of the region 3.10-2.90 ppm, as deduced by comparison 
of the integral of the signal at 3.92 ppm (CH2 protons of Cr). Finally, ex vivo 1H NMR 
experiments indicate the presence of alanine (Ala) and lactate (Lac) and the absence of NAA. 
The absence of NAA in the HR-MAS spectra and presence of only a trace of acetate suggest 
that the peak at 2.0 ppm in the in vivo spectrum could be principally due to the CH2(β) and 
CH2(α) signals of glutamate plus glutamine. A direct comparison between the in vivo and ex 
vivo MR profiles of medulloblastoma can be made after applying a broadening processing 
function to the HR-MAS signal which, although implying the loss of a higher degree of 
information furnished by the HR-MAS spectrum, shows the close correspondence between 
the two spectra (Figure 6), especially when the region of ChoCC and Cr signals is considered. 
The highest signal is that usually attributed to ChoCC, which we have shown above to receive 
contributions from a number of other metabolites, accompanied by low intensity peaks due to 
glutamate plus glutamine at 2.3 and 2.0 ppm, and Cr (plus Lys and asparagine) at 3.0 ppm. 
More difficult is the comparison between regions at higher frequencies of the two spectra, 
where signals due to Tau, Myo, Gly and PE are expected. These signals are evident in the ex 
vivo spectrum, but they are less clear in vivo because of more distortions from the evolution of 
coupling constants. The estimation of the ratio ChoCC/Cr from the in vivo spectrum (5/1) 
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compares well with that from the HR-MAS spectrum (6.5/1) obtained, considering the regions 
3.15-3.32 and 3.10-2.90 ppm. Myo, Tau, Gly and PE have already been reported as 
significant metabolites from in vitro MRS studies on medulloblastoma (8,9). Accordingly, 
prominent Tau, Gly and PE peaks are easily observed in our ex vivo spectrum (Figure 4), and 
the presence of Tau in in vivo spectra of the medulloblastoma has been reported (10,11). 
Further considerations can be argued from the analysis of ex vivo MR spectra. Mobile lipids, 
which are already visible in the standard presaturated 1D spectrum (Figure 3a), are further 
evidenced in the diffusion-edited spectrum (Figure 3c) by the broad signals at 0.89, 1.30, 3.26 
and 5.32 ppm. In particular, the 3.26 ppm resonance, deriving from the trimethylammonium 
of the choline residue, strongly suggests that phospholipids are present in substantial amounts 
in the examined medulloblastoma. It is worthwhile to underline the presence of broad signals 
at 3.02 and 1.72 ppm (which are correlated by the TOCSY experiments also to the 1.48 and 
1.91 ppm signals), attributable to Lys in non-negligible amounts and possibly involved in 
lysyl-phosphatidylglycerols. These findings provide a deeper insight into the lipid 
composition of brain neoplasms to be pursued. It has been reported that the presence of 
mobile lipids, both in ex vivo and in vivo MR spectra of brain neoplasms, is correlated to 
necrosis in the lesions (12,13). This spectroscopic datum directly correlates to a 
morphological aspect of the histopathological assessment. Moreover, Tzika et al reported that 
in vivo and ex vivo MR spectra of several pediatric brain tumors exhibited substantial levels of 
lipids, which may be due to apoptosis and/or necrosis (14). As a consequence, the histological 
features of apoptosis and necrosis, evidenced in the histological analysis of this 
medulloblastoma, are reflected by the presence of lipid signals in our ex vivo HR-MAS MR 
spectra. 
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Figure 4. HR-MAS 1H spectrum of the medulloblastoma. CPMG spectrum obtained with 360 ms total spin-echo 
time; the major metabolites are labelled.  
 
 
Figure 5. Partial regions of the TOCSY spectrum of the medulloblastoma. 
 
In this case report, we have demonstrated that the ex vivo HR-MAS NMR 
spectroscopy can reach a high resolution degree, thus providing a link between in vivo MRS 
and neuropathological analysis. The present study demonstrates that ex vivo HR-MAS 1H 
NMR is able to strongly improve the clinical possibility of in vivo MRS and can be used in 
conjunction with in vivo spectroscopy for clinical purposes, in which case a large number of 
samples can be analyzed and histologically classified.  
The identified metabolites are denoted with labels according to Table I. 
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Figure 6. Comparison of the in vivo 1H spectrum, recorded at 1.5 T, of the medulloblastoma (a) and its ex vivo 
1H HR-MAS spectrum, recorded at 9.4 T (b); an exponential function with a 30-Hz line broadening (LB) was 
applied prior to the Fourier transformation with the aim of having a spectrum line width comparable to the in 
vivo spectrum. 
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MENINGIOMAS 
The most frequent tumors of the central nervous system are represented by 
meningiomas. They typically manifest in adults and they are more common in women than in 
men. Meningiomas are generally slow-growing, benign tumors attached to the dura mater and 
composed of neoplastic meningothelial (arachnoidal) cells. Meningiomas have a wide range 
of histopathological appearances, among which meningothelial and fibrous are by far the most 
common. Moreover, 10-15% of meningiomas present an atypical pattern with rim like 
enhancement, cyst formation, intralesion hemorrhage and metaplasia. Meningiomas with 
these morphological features resemble metastases or malignant gliomas with cystic or 
necrotic aspects (1). Although meningiomas have characteristic neuroimaging features, 
hemangiopericytomas, schwannomas, and dural metastatic tumors may mimic meningiomas 
(2).  
The purpose of this study was: to identify the metabolic patterns of meningiomas; to 
assess the presence and the relevance of the metabolic alterations linked to different subtypes 
of meningiomas; to compare the ex vivo and the in vivo spectra to clarify and validate the in 
vivo MRS. 
 
Clinical Materials. This study was approved by the local ethics committee and the 
patients provided a written informed consent. Six patients underwent surgical resection of the 
tumors and the specimens were snap-frozen in liquid nitrogen and stored at -80˚C until ex vivo 
MRS analysis. Histopathological analysis of the 6 lesions identified them as meningiomatous 
in nature. According to the WHO 2000 criteria (3), three out of the six meningiomas were 
classified as classic meningothelial, grade I, one as classic fibrous, grade I, and one as classic 
transitional, grade I. One of them showed oncocytic differentiation, demonstrated both by 
conventional histology and immunohistochemistry (4). The neoplastic cells showed 
prominent nucleoli and focally high nucleus/cytoplasm ratio. The mean mitotic index (total 
counts per ten high-power fields) was 6/10 HPF, increasing up to 12/10 HPF in some areas. 
The lesion was therefore classified as grade II. The cellular proliferation index, determined by 
MIB-1, and expressed as LI, ranged from 1-3% for 4 meningiomas of the meningothelial, 
transitional and fibrous subtypes, consistent with grade I lesions. In one meningioma of the 
meningothelial subtype MIB-1 LI was slightly increased to 5%, but was still in keeping with a 
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grade I lesion. The MIB-1 LI for the oncocytic meningioma was much higher; its mean value 
was 5%, and approached 14% in some areas, thus classified as a grade II lesion. The clinical 
data and MRS experiment types of the 6 patients are shown in Table II. 
 
Table II. Patients’ clinical data and NMR experiments. 
Patients 
Age 
 
(sex) 
Meningioma 
 
Subtype and grade 
MIB-1 LI 1% 
In vivo 1H-MRS Ex vivo HR-MAS MRS 
TE 
38 ms 
TE 
144 ms 
1D 1H 
zgcppr 
1D 1H 
cpmgpr 
1D 1H 
led 
1 66 (M) 
Meningothelial, 
grade I MIB-1 LI 
1% 
+7 1a 11b 1c 
2 53 (F) 
Meningothelial, 
grade I MIB-1 LI 
3% 
X X 2a 2b 2c 
3 61 (F) Fibrous, grade I MIB-1 LI 1% X X 3a 3b 3c 
4 26 (M) 
Oncocytic, grade II 
MIB-1 LI 5%, up to 
14% 
X X - - - 
5 50 (F) 
Meningothelial, 
grade I MIB-1 LI 
5% 
X X 5a 5b 5c 
6 74 (M) Transitional, grade I 
MIB-1 LI 2%   6a 6b 6c 
 
In vivo 1H MRS. The patients underwent MRI and in vivo 1H MRS of the head on a 3T 
clinical imager (Philips Intera, Best, The Netherlands). In vivo 1H MR spectra were performed 
using a spin-echo sequence with 38 and 144 ms TE, 2s TR, 2048 data points, PRESS 
localization technique and averaging the signal of 128 scans. The VOIs (6-8 cm3) were placed 
and shaped according to the size of the lesion. Water signal suppression was performed using 
a CHESS sequence with two Gaussian chemical shift selective pulses of 70 Hz. The data were 
processed and analyzed using software developed by one of the authors (C.T.) on IDL 
platform (Research System, Inc., Boulder, CO, USA). DC correction, zero filling factor 2, 
Gaussian filter with LB 3.0 Hz (time domain), high pass filter bandwith 50 Hz (to suppress 
water peak) and baseline correction were applied to the spectral data.  
 
For the NMR experiments details see Chapter II. 
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Results and Discussion 
HR-MAS spectra. Figure 1 shows the ex vivo 1D 1H conventional HR-MAS MR spectra 
of three subtypes of meningiomas diagnosed as meningothelial (patient 2), fibrous (patient 3) 
and transitional (patient 6).  
 
 
 
Figure 1. Ex vivo 1D 1H conventional presaturated HR-MAS MR spectra of samples: 2, meningothelial; 3, 
fibrous; and 6, transitional. #, denotes PEG. 
 
 
2 
3 
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Figure 2. Ex vivo CPMG spectra of samples 2, 3 and 6 obtained with a 360 ms total spin-echo time. 
 
The spectra highlight both narrow and broad signals, which can be separated by using a 
CPMG spin-echo and a diffusion-edited sequence. Figure 2 shows the spin-echo spectrum 
displaying signals due to the resonances of small metabolites, and Figure 3 displays the 
diffusion-edited spectrum in which contributions from mobile lipids and macromolecules 
were found. The labels were chosen to indicate the more abundant and visible metabolites 
(Figures 1 and 2) and macromolecules (Figure 3) in each spectrum. The efficacy of the above 
sequences at clarifying tissue components is remarkable when considering the region at ~3.2 
ppm, which is of great importance in in vivo spectroscopy, because it contains signals due to 
ChoCC. This region, as is particularly evident in samples 2 and 6 (Figure 1), is formed by 
overlapping broad and narrow signals. In the CPMG experiment (Figure 2) the narrow signals 
2 
3 
6 
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due to Cho, GPC, PC, Tau, and a low percentage Myo, are highlighted, whereas the broad 
component due to the N+(CH3)3 of phospholipids is evident in the diffusion-edited spectrum 
(Figure 3). The detection of metabolites was obtained, not only through 1D 1H NMR spectra, 
but also through selected 2D experiments such as COSY, TOCSY and HSQC, and their 
assignment was confirmed by comparison with literature data. The full experiments provided 
complete and unambiguous identification of the metabolic pattern characterising the 
examined tissues. The main metabolites are labeled in Figures 1-6 and the pool of metabolites 
especially osmolites, free amino acids and mobile lipids are reported in Table I. 
Low molecular-weight metabolites. Abundant metabolites such as Lac, Ala, glutamate 
(Glu), glutamine (Gln), Cr, ChoCC, Tau and Gly can be identified by direct inspection of the 
1D 1H NMR spectra obtained using the spin-echo sequence, whereas, the identification of 
metabolites hidden under the more abundant ones can be obtained through COSY, TOCSY 
and HSQC spectra. For example, the presence of the glutathione (GSH), particularly abundant 
in sample 1, was established by the COSY cross peaks between the signals at 8.57 and 8.36 
ppm with signals at 4.57 and 3.77 ppm, respectively (Figure 4). These correlations are 
attributed to the NH/CH(α) pair of cysteine (Cys) and NH/CH2 of Gly in GSH and their 
detection indicates that the NH protons of glycyl and cysteinyl amidic groups are in slow-
exchange with water. This assignment was confirmed by a TOCSY spectrum (showing a 
further correlation between NH at 8.57 ppm and CH2 at 2.96 ppm of Cys), and by the HSQC 
spectrum, showing the H,C correlation at 3.77/44.0 ppm, attributable to the CH2 group of a 
bonded Gly, clearly distinguishable from free Gly, whose H,C correlation is found at 
3.56/42.3 ppm (Figure 6). It is also to be noted that the resonances of the glutamyl moiety of 
GSH were well distinguished from those of free Gln and Glu (Figure 5, left). The other 
resonances due to cysteinyl and glutamyl moieties of GSH are reported in Table I. HTau was 
identified by the triplet at 2.65 ppm, which correlated with a triplet at 3.35 ppm in the COSY 
spectrum, whereas β-Ala, which is the major product of uracil catabolism, displayed a 
correlation between a triplet at 2.55 ppm and a triplet at 3.18 ppm. 
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Figure 3. Ex vivo diffusion-edited spectra of samples 2, 3 and 6 obtained with ¢=200 ms, ‰=4 ms and a 
gradient strength of 32 G/cm.  
 
Figure 4. COSY spectrum of sample 1. 
2 
3 
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The resonances of the methyl groups of Leu, Ile, Val were in the range between 0.94-
1.04 ppm and appeared, in 1D 1H spectra, as a shoulder of a broad band at 0.9 ppm due to 
methyl resonances of lipids and macromolecules. The identification of these amino acids was 
easily obtained through the COSY and TOCSY spectra. Val was identified by the correlation 
between the methyl resonances at 0.99 and 1.04 ppm with the β-CH at 2.25 ppm. Ile was 
characterized by the resonances at 1.02 ppm and 1.97 ppm, and Leu was identified by the 
correlations between the signals at 0.95 and 0.97 ppm with that at 1.72 ppm. The signals of 
Lys, more evident in sample 3, and Arg were partially overlapped with those of Leu and Ile; 
their clear identification was achieved, from COSY spectra, by the correlations at 3.02/1.73 
ppm for Lys and at 3.23/1.70 ppm for Arg. Further confirmation came from the correlations in 
the TOCSY spectra (Figure 5, right). The same 2D homonuclear experiments revealed the 
methyl doublet of Thr at 1.33 ppm (hidden in all samples under that of Lac) by its correlation 
with α·-CH at 4.26 ppm. The region of the 1H spectra at around 3.2 ppm, which displayed 
resonances usually attributed to ChoCC (GPC, PC and Cho) in the in vivo spectra, received 
contributions, in the reported samples, from PE, Myo, β-Glc, Tau, Arg and GPE, as already 
observed in the case report of medulloblastoma. Regarding ChoCC, Cho and PC were the 
main metabolites, whereas GPC was not detected. In all meningiomas, traces of ascorbate (a 
doublet at 4.52 ppm correlating with a signal at 4.01 ppm), aromatic metabolites such as 
phenylalanine (Phe), adenosine, uracil, uridine-monophosphate (UMP), uridine-diphosphate 
(UDP), tyrosine (Tyr), histidine (His) and fumarate were found in varying percentages. 
 Samples 1 and 6 were the richest ones in GSH, whereas it was present only at trace 
level in samples 3 and 5. GSH is expected to be present in meningiomas, but it is difficult to 
find in extracts (2,5). The detection of GSH in tumoral tissues is important in relation to its 
documented tumor chemoresistance (6-8). Moreover, GSH is metabolically linked to Ala, Gln 
and Glu (5) and this correlation probably indicates why these metabolites are present in 
appreciable amounts in the meningiomas studied. GSH participates in many cellular reactions 
and its metabolism is implicated for health (9) and with respect to cancer, it is able to play 
both protective and pathogenic roles (6). The presence of hipoturine (HTau) together with Tau 
is probably due to the redox balance in these metabolites; indeed HTau is a precursor of Tau, 
the main end product of Cys metabolism in mammals, and is thought to share the same 
physiological function (10). Tau is the most abundant amino acid found in the mammalian 
brain and seems to play a role in a wide range of basic physiological functions (11). The 
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presence of these metabolites with antioxidant activity (GSH and HTau) needs further 
investigation, performed by multidisciplinary analytical approaches, to gain new insight into 
the redox state in neoplastic tissues. 
 
Figure 5. Partial TOCSY spectra of sample 1 (left) and sample 3 (right). 
 
Figure 6. HSQC spectrum of sample 1. The insert shows a selected region of sample 3. 
 
It is worth noting that the ex vivo 1D and 2D 1H HR-MAS experiments showed the 
absence of NAA in all the examined samples, in accordance with the extracerebral origin of 
these lesions. Table III shows the integral ratios with respect to Ala=1 of the main metabolites 
detected in ex vivo CPMG spectra; Ala was chosen since it is a well-known metabolite 
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characteristic of meningiomas (12). It should be noted that Ala intracellular level is intrinsic 
to the identity of the meningeal cell type and it is maintained through neoplastic 
transformation (13). The high amount of Ala in human meningiomas can be explained in light 
of this connection. Glx, free Cho, ChoCC, Ala, Gly, and Tau are known to be the main 
components of meningiomas together with relatively low amounts of Cr, as derived by the 
high Ala/Cr ratio typical of meningiomas (14). 
Lipids and macromolecules. The most significant differences among the meningiomas 
appear to be in the large components of 1D 1H presaturated (Figure 1) and in 1D 1H diffusion-
based MR spectra (Figure 3). The profiles of samples 2 and 3 represent two limit situations. 
Sample 2 displays large components due to phospholipids (identified by the signals of 
N+(CH3)3 at 3.23/54.8 ppm) and mobile peptidic residues. The amino acidic components of 
these residues were found from the resonances of bonded amino acids CH- (broad signal 
centered at 4.35 ppm) (15) and their correlations with the relevant protons. An accurate 
analysis of TOCSY and HSQC spectra permitted the following amino acids to be found: Thr 
(1.22 ppm), Ala (1.41/17.1 ppm), Lys (3.02, 1.80 and 1.68 ppm), Glx (2.50÷2.20, and 2.10 
ppm), Gly (3.92/43.5 ppm) and proline (Pro) (4.44/61.2 ppm, 2.28 ppm). A similar profile is 
displayed by sample 5 (meningothelial) and sample 6, identified by the histopathological 
analysis as transitional. The profile of sample 3 is characterised by the dominant resonances 
of triglycerides and by a trace of cholesterol (Chol) (identified by the methyl resonances at 
1.04 and 0.73 ppm). The analysis of the spectrum showed that the triglycerides were formed 
by saturated, mono- and polyunsaturated fatty acids. Unsaturated acids were identified by the 
signals at 5.33 ppm, due to the ethylenic protons, and by the signals at 2.02 ppm, due to the 
methylenic protons of the -CH2-CH= moiety of mono- and poly-unsaturated fatty acids. The 
signals centered at 2.78 ppm are attributable to the methylenic protons between two double 
bonds (=C-CH2-C=) in poly-unsaturated acids (linoleic and γ-linolenic). The spectrum of 
sample 1 (meningothelial) is characterised by bonded amino acids and phospholipids, and by 
a large amount of triglycerides and represents an intermediate situation between that of 
sample 2 and 3. 
Polyols. All spectra show the presence of mannitol (Man), which was given to the 
patients before surgery for cerebral decompression, in varying amounts. Man is identified by a 
characteristic group of signals in the region 3.4 ÷3.9 ppm, and through 1H,13C correlations 
[3.68, 3.88/63.3 ppm (CH2OH); 3.76/71.3 ppm and 3.80/69.7 ppm] (Fig. 6). The H-1 signals 
of α- and β-glucose (Glc) (at 5.24 and 4.67 ppm, respectively) are clearly detected in samples 
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3 and 6. In addition, sample 3 displays resonances attributable to α-Glc-(1→4) units, 
embedded in small oligosaccharides. The two doublets at 5.41 and 5.39 ppm are due to H-1 of 
α-Glc-(1→4), as confirmed by the C-1 chemical shift at 100.2 ppm (16). Other signals due to 
α-Glc-(1→4) units are found by the inspection of the TOCSY and HSQC spectra (Figure 6): 
H-1 protons correlate with H-2 protons at 3.64 and 3.55 (C-2 at 72.2 ppm), and with H-3 
protons at 3.97 and 3.68 ppm (C-3 at 74.0 ppm). The pairs H-4/C-4 at 3.68/77.2 and at 
3.43/70.0 ppm are attributable to central α-Glc-(1→4) units and the nonreducing terminal 
unit, respectively. The resonances of the reducing terminal unit are hidden under the signals 
of α- and β-Glc and only the signal due to H-1 (4.66 ppm) of the reducing β-Glc unit can be 
detected. The resonances of CH2OH in Glc and α-Glc-(1→4) are found at 3.85/61.7 ppm. 
These data suggest the presence of oligosaccharides, probably maltotriose or maltotetraose. 
To our knowledge, it is the first time that these small sugars have been detected by MRS in 
human meningiomas. Other minor signals due to Myo and scillo-inositol are found in all 
samples, whereas ribose signals, bonded to UMP and UDP nucleotides were detected, 
especially in samples 1 and 2.  
In vivo MR spectra. The in vivo MR spectra (TE=38 ms) of three different subtypes of 
meningioma, 3 (fibrous), 4 (oncocytic) and 5 (meningothelial), are reported in Figure 7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. In vivo MR spectra of meningiomas: 3, fibrous; 4, oncocytic; and 5, meningothelial recorded at 3 T 
with TE=38 ms. 
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The three subtypes of meningioma are characterised by different metabolic profiles and 
on the basis of the analysis of the corresponding ex vivo spectra, it is possible to interpret the 
main features of each spectrum. The in vivo resonances at 0.9, 1.3, 2.1 and 2.8 ppm of sample 
3 are mainly due to lipids and the broad signal around 2.1 ppm, besides triglycerides, receives 
a contribution from Glx, but not from NAA. 
Regarding the ChoCC at 3.2 ppm, it should be underlined that this signal, usually 
assigned in the in vivo spectrum to ChoCC, receives substantial contributions from Tau, Myo 
and PE, and minor ones from Arg and β-Glc. Furthermore, in the in vivo spectrum the 
abundant signal at 3.4 ppm is recognizable due to Tau, and low signals at 3.0 ppm due to Cr 
and Lys. A direct comparison between in vivo (TE=38 ms) and conventional (zgcppr) ex vivo 
spectra (after a suitable broadening processing) of sample 3 shows a close correspondence 
between the two profiles (Figure 8). 
 
 
Figure 8. In vivo (a) (TE = 38 ms) and ex vivo (b) MR spectra of sample 3, fibrous. 
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Figure 9. In vivo (a) (TE = 38 ms) and ex vivo (b) MR spectra of 5, meningothelial. 
 
The slight difference between the in vivo and the ex vivo signal at around 3.8 ppm is 
explainable by considering that while the in vivo signal receives contributions from PE and -
CH amino acids, the ex vivo shows additional contribution from Man. The in vivo spectrum of 
sample 5 (meningothelial) in comparison with that of sample 3 (fibrous) (Figure 7) is 
characterised by the lack of the resonances pertaining to triglycerides and by the presence of 
phospholipids and macromolecules. It is to be underlined that in the in vivo spectrum of 5, the 
signals due to Ala and Lac are well recognisable as doublets at 1.47 and 1.33 ppm, 
respectively. A direct comparison between the in vivo (TE=38 ms) and the conventional 
(zgcppr) ex vivo spectra (after a suitable broadening processing) of sample 5 shows a good 
correspondence between the two profiles (Figure 9), the only difference being the increased 
amount of Lac in the ex vivo spectrum. The metabolic profile of in vivo MR spectrum of 
sample 4 (oncocytic; its ex vivo spectrum is not available) is between those of 3 and 5 and 
displays an increased amount of triglycerides with respect to 5. Other well-identified 
metabolites in samples 3 and 5 are marked on the corresponding spectra. The in vivo spectra 
obtained with an echo time of 144 ms, and routinely used for diagnostic purposes, should be 
compared to the CPMG ex vivo ones, permitting evaluation of the ChoCC/Cr ratio. These 
ratios derived from in vivo measurements are 2.3, 7.9 and 9.3 for samples 2, 3 and 5, 
respectively, and are in good accordance with the ex vivo ones: 3.1, 8.0 and 11.0.  
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Table III. Abundance o metabolites. a 
Sample Ala 
1,48b 
Glx 
2.35+2.44b 
Cr 
3.04b 
Cho 
3.20b 
ChoCC 
3.20-3.23b 
Tau 
3.23b 
Gly 
3.56b 
Ala/Cr ChoCC/Cr 
1 1 2.31 0.18 1.14 2.87 0.72 0.63 5.6 16.0 
2 1 1.24 0.50 0.87 1.56 0.29 0.54 2.0 3.1 
3 1 2.72 0.65 2.74 5.34 2.32 1.02 1.5 8.1 
5 1 1.48 0.40 2.26 4.50 1.10 0.95 2.5 11.2 
6 1 2.48 0.20 2.80 4.95 1.54 0.60 5.0 24.8 
a
 The integrals evaluated with respect to that of Ala=1. b The chemical shift values denote the signals used for the 
integration. 
 
 In conclusion, ex vivo HR-MAS MRS allowed us to make an accurate description of 
the metabolic profile of different meningiomas. By using 1D (composite pulse, water 
suppressed spin-echo Carr-Purcell-Meiboom-Gill and diffusion-edited sequences) and 2D 
(COSY, TOCSY and HSQC) experiments, we were able to evidence the presence of several 
metabolites in different histological subtypes of meningioma. The HR-MAS results agree 
with the findings in several reports on the major metabolites (Ala, ChoCC, Glx, together with 
a marked decrease or absence of Cr) found in in vitro and in vivo MRS spectra of 
meningiomas (14, 17- 20). Whereas several in vivo studies on human meningiomas are well 
documented (1, 2, 5, 12, 21-23) only one report (24) exists on the 1H HR-MAS MR spectrum 
of a meningioma in comparison with different brain tumors. The spectroscopic data, obtained 
from the six samples of meningiomas, confirmed the presence of the typical metabolites of 
these benign neoplasms and, at the same time, that meningiomas with different morphological 
characteristics have different metabolic profiles, particularly regarding macromolecules and 
lipids. The ex vivo spectra, permitting a better understanding and interpretation of the in vivo 
MR spectra, show that the HR-MAS MRS technique is a complementary method to strongly 
support in vivo MR spectroscopy and increase its clinical potentiality. 
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Table I. List of 1H and 13C chemical shift (δ, ppm) of metabolites found in HR-MAS spectra of  
brain tumours a,b.  
 
entry Metabolite δ 1H δ 13C  Medullobastoma Meningima 
1 Fatty acids 0.89 
1.31 
1.59-1.60 
2.02 
2.24 
2.78 
5.30-5.32 
14.13-14.17 
29.4-32.2 
25.2 
27.8 
34.2 
26.2 
130.2; 128.4 
CH3 
(CH2)n 
CH2CC=O 
CH2C= 
CH2C=O 
=CCH2C= 
CH=CH 
y y 
2 Isoleucine 0.94 (t) 
1.02(d) 
1.29,1.48 
1.97 
3.69 
11.7 
15.5 
25.1 
 
 
δ-CH3 
γ-CH3 
γ-CH2 
β-CH 
α-CH 
y y 
3 Leucine 0.95(d) 
0.97(d)  
1.70 
1.72 
3.74 
21.5 
22.8 
24.8 
40.4 
δ-CH3 
δ-CH3 
γ-CH 
β-CH2 
α-CH 
y y 
4 Valine 0.99(d) 
1.04(d) 
2.25 
3.61 
17.3 
18.7 
 
d 
γ-CH3 
γ-CH3 
β-CH 
α-CH 
y y 
5 Threonine 1.33(d) 
4.26 
3.60 
20.3 
66.58 
61.22 
γ-CH3 
β-CH 
α-CH 
y y 
6 Lactate 1.33(d) 
4.11 
20.3 
69.1 
CH3 
CH 
y y 
7 Alanine 1.48(d) 
3.78 
16.8 
51.1 
β-CH3 
α-CH 
y y 
8 Lysine 3.02(t) 
1.71 
1.48 
1.91 
3.79 
39.9 
27.1 
22.56 
30.6 
c 
ε-CH2 
δ-CH2 
γ-CH2 
β-CH2 
α-CH 
y y 
9 Arginine 3.23 
1.69 
1.92 
3.78 
41.3 
24.9 
28.1 
c 
δ-CH2 
γ-CH2 
β-CH2 
α-CH 
y y 
10 Glutamate 2.36(t) 
2.06, 2.14 
3.77 
34.0 
27.9 
c 
γ-CH2 
β-CH2 
α-CH 
y y 
11 Glutamine 2.44(td) 
2.14 
3.78 
31.5 
27.2 
c 
γ-CH2 
β-CH2 
α-CH 
y y 
12 Proline 3.43, 3.34 
2.01 
2.34, 2.07 
4.12 
 δ-CH2 
γ-CH2 
β-CH2 
α-CH 
y n 
13 Aspartic acid  2.68, 2.82 
3.90 
37.2 β-CH2 
α-CH 
y y 
14 Asparagine  2.85, 2.96 
4.01 
26.30 β-CH2 
α-CH 
y y 
15 Creatine  3.04(s) 
3.92(s) 
37.5 
54.5 
NCH3 
CH2 
y y 
16 Tyrosine  3.06, 3.20 
3.93 
6.89 
7.23  
 
56.7 
116.5 
131.5 
β-CH2 
α-CH 
Hortho 
Hmeta 
y y 
17 Phenylalanine  3.11, 3.28 
3.99 
 
 
β-CH2 
α-CH 
y y 
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7.34  
7.43 
7.37 
130.1 
129.6 
128.2 
Hortho 
Hmeta  
Hpara 
20 Ethanolamine 3.15(t) 
3.82(t) 
42.1 
58.2 
CH2 
CH2 
y y 
21 Phosphoryl- 
ethanolamine 
3.23 
4.00 
41.1 
61.1 
CH2 
CH2 
y y 
22 Glycerophosphoryl- 
ethanolamine 
3.30 
4.10 
 CH2 
CH2 
y y 
23 free Choline  3.20 
3.53 
4.08 
54.6 
68.2 
56.5 
N(CH3)3 
NCH2 
OCH2 
y y 
24 Glycerophosphoryl- 
choline 
3.22 
3.68 
4.33  
54.7 N(CH3)3 
NCH2 
OCH2 
y n 
25 Phosphorylcholine 3.22 
3.61 
4.22 
54.7 
67.3 
59.0 
N(CH3)3 
NCH2 
OCH2 
y y 
26 β-Glucose  4.67(d) 
3.26 
3.49 
3.40 
3.47 
e 
96.6 
74.8 
76.8 
69.9 
76.8 
e 
1-CH  
2-CH 
3-CH 
4-CH 
5-CH 
6-CH2 
n y 
27 Taurine  3.26(t) 
3.42(t) 
48.1 
35.9 
SCH2 
NCH2 
y y 
28 Myo-inositol  3.53(dd) 
4.06(t) 
3.63(t) 
3.29(t) 
71.8 
72.9 
73.1 
75.0 
1,3-CH 
2-CH 
4,6-CH 
5-CH 
y y 
29 Scyllo-inositol  3.35 (s) 73.9 CH y y 
30 α-Glucose  5.24(d) 
3.54 
3.73 
3.42 
e 
 
72.5 
73.8 
70.7 
e 
1-CH  
2-CH 
3-CH 
4-CH 
6-CH2 
n y 
31 Glycine  3.56 42.3 CH2 y y 
33 Glycerol (in lipids) 4.10, 4.30 
5.26  
 1,3-CH2 
2-CH 
n y 
34 Glycerol 3.56, 3.65 
3.81 
63.3 
72.7 
1-CH2 
2-CH 
- y 
35 UDPG 5.92 
4.35 
5.90(d) 
7.89(d) 
 1-CHrib 
2-CHrib 
5-CHur 
6-CHur 
y y 
36 Uracil 5.80(d) 
7.54(d) 
 5-CHur 
6-CHur 
n y 
38 Fumarate  6.52  CH n y 
39 Tryptophane 7.73 
7.19 
7.29 
7.52 
 4-CH 
5-CH 
6-CH 
7-CH 
  
40 Adenine 8.23(s) 
8.36(s) 
6.10 
4.77 
4.43 
 2-CH 
8-CH 
1’-CH 
2’-CH 
3’-CH 
y y 
41 N-Ac 2.01-2.12 23.0 NC=OCH3   
42 Acetate 1.92 24.8 CH3C=O y y 
43 Hypotaurine 2.65(t) 
3.35(t) 
38.73 
41.19 
CH2 
CH2 
- y 
44 UMP 5.98  1-CHrib n y 
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4.37 
5.97(d) 
8.11(d) 
2-CHrib 
5-CHur 
6-CHur 
45 α-Glu-(1→4) 5.39,5.41 
3.62 
3.98 
3.68 
3.73 
100.2 
72.2 
74.0 
77.2 
73.5 
1-CH 
2-CH 
3-CH 
4-CH 
5-CH 
n y 
46 Glutathione 
 
4.57 
2.96 
3.80 
2.16 
2.55 
3.77 
8.57 
8.36 
56.18 
26.3 
 
 
 
44.0 
α-CH-Cys 
β-CH2-Cys 
α-CH-Glu 
β-CH2-Glu 
γ-CH2-Glu 
CH2-Gly 
NH-Cys 
NH-Gly 
n y 
47 OH-butyrate 1.18 
4.14 
 CH3 n y 
48 Histidine 7.78 (s) 
7.05(s) 
 2-CH 
4-CH 
n y 
49 Ascorbate 4.52(d) 
4.01 
 4-CH 
5-CH 
- y 
50 β-Alanine 2.56 
3.18 
32.14 
40.01 
CH2 
CH2 
- y 
51 Serine  3.96 
3.84 
61.2 
57.0 
1,3-CH2 
2-CH 
n y 
a 1H chemical shift are referred to alanine doublet at 1.48 ppm. 
b 13C chemical shift are referred to alanine at 16.8 ppm. 
c C_ probably contributes to the 3.77, 55.1 ppm cross-peak. 
d C_ probably contributes to the 3.61, 61.1 ppm cross-peak. 
e Contribute to the broad correlation between CH2 protons in the region 3.9-3.6 ppm and carbons around 62 ppm in 
HSQC spectra. 
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HIGH- AND LOW-GRADE GLIOMAS 
 
Glioma is a type of primary central nervous system (CNS) tumour that arises from glial 
cells. The most common site of involvement of gliomas is the brain, but gliomas can also 
affect the spinal cord or any other part of the CNS, such as the optic nerves (1). Gliomas can 
be either benign (slow growing) or malignant (fast growing). Gliomas are further categorized 
according to their grade, which is determined by pathologic evaluation of the tumour. Low 
grade gliomas are well-differentiated (not anaplstic); these are begnin and portend a better 
prognosis of the tumour. High-grade gliomas are undifferentiated or anaplastic; these are 
malignant and carry a worse prognosis. 
Adequate discrimination between high and low glioma grade remains a vital diagnostic 
decision determining the most effective chemotherapeutic or surgical treatment and having an 
important impact in patient management and outcome (2-5). In vivo 1H NMR spectroscopy 
examinations are often used to assign glioma grade, many times based on the relative 
intensities of the total Choline (tCho) and Cr resonances in the tumour (6-8). This diagnostic 
decision has been helped more recently through the implementation a variety of pattern 
recognition methodologies (9). The accuracy of these methods is increasing progressively, but 
difficulties remain currently in the unambiguous classification of high and low grade gliomas. 
This may be due to the fact that in vivo 1H NMR spectroscopy approaches as available in the 
clinic, are normally limited in sensitivity and resolution, resulting in relatively large voxel 
volumes and insufficient precision in the spectral assignments. In particular, the in vivo tCho 
peak, normally found to increase in high and low grade gliomas, contains contributions from a 
variety of choline containing metabolites including mainly, free choline (Cho), 
phosphorylcholine (PC) and glycerolphosphorylcholine (GPC). In spite of the crucial 
information that these metabolites could provide on the alterations of phospholipid 
metabolism underlying transformation and progression of astrocytomas, their relative 
contribution to the combined Cho peak cannot be derived from the in vivo detected tCho 
resonance. HR-MAS approaches have been recently proposed to investigate normal and 
diseased tissues, to overcome some of the limitations of in vivo spectroscopy (10,11). The 
HR-MAS approach uses small biopsies of the tumours, providing similar sensitivity and 
resolution to that previously obtained from the high resolution 1H NMR analyses of tumour 
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extracts. However, few studies to date have investigated the metabolism of choline derivatives 
in human gliomas using this methodology (12,13). 
Genomic approaches in tumours are currently envisioned to provide complementary 
information to the metabolic pattern obtained by HR-MAS, revealing the genomic “finger 
print” of the tumour (14). In this respect, DNA microchips provide comprehensive 
information on complete genome expression but the analysis of the fifty seven thousand genes 
dataset normally investigated is complex, and much of the information obtained is unrelated 
to the genes controlling choline transport and metabolism (15). The use of microfluidic cards 
containing exclusively the genetic probes for the pathway of interest may provide a valuable 
alternative, thus reducing the complexity of the genomic analysis and interpretation. 
 In this work we hypothesized that HR-MAS could improve the performance of in vivo 
clinical 1H NMR because of its enhanced resolution of the choline compounds and that the 
microfluidic card analysis of the expression of choline metabolism genes could provide 
complementary information to interpret the observed HR-MAS alterations. Our results 
indicate that it is possible to discriminate unambiguously between high grade and low grade 
gliomas on the basis of the choline metabolite profile as detected by HR-MAS and quantified 
with the LCModel program. The increased choline peak observed in high grade gliomas is 
shown to be derived from an increase in phosphorylcholine while the increase in the tCho 
peak detected in low grade gliomas is caused by augmented glycerolphosphorylcholine 
content. The changes detected by 1H HR-MAS are consistent with the upregulation of the 
choline kinase β or phospholipase C genes and the downregulation of the cytidyltransferase 
gene in high grade gliomas or the upregulation of Phospholipase A and lysophospholipase 
and the downregulation of phosphoilipase D detected in low grade gliomas.  
 
Methods 
 Clinical Materials. Tumour specimens were provided by the Department of 
Neurosurgery, Univerisity Hospital “La Paz”, Madrid, complying with all bioethical criteria 
of the local ethics committee of the Hospital. Tumour biopsies were obtained from the 
patients in the operating room following intracranial surgery, immediately frozen in liquid 
nitrogen and stored at -70° C until 1H HR-MAS analysis. An adjacent biopsy of the tumour 
was obtained for histological classification. Tumour specimens from 23 patients were 
histologically classified according to the revised WHO criteria. The samples included 9 low-
grade astrocytomas (WHO grade II), 6 anaplastic astrocytomas (WHO grade III) and 8 
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glioblastoma multiforme (WHO grade IV) (16). Grades III and IV were grouped as “high 
grade” gliomas, to favour a more robust clinical classification between low and high grade 
gliomas. Normal brain samples were obtained from patients undergoing partial lobotomy 
indicated in the treatment of epileptic seizures (17). The main goal of our work was to 
distinguish between low and high grade gliomas of our work was to classify gliomas between 
low and high grades. 
 Quantification. Quantification of tumor metabolites detectable in the ex vivo spectra 
was performed using the software program LCModel (Linear Combination of Model 
Spectra, (18)). LCModel fits spectra as a linear combination of model spectra from twenty 
eight brain metabolites and optional contributions for lipids and macromolecules. For the 
analysis of our ex vivo data a customized set of cerebral metabolites was prepared using the 
model solutions recommended by Dr. S. Provencher including; alanine, lactate, taurine, 
phosphocreatine, creatine, choline, glycerolphosphorylcholine, phosphorylethanolamine, 
phosphorylcholine, glycine, aspartic acid, glutamine, glutamate, myo inositol, N-acetyl-
aspartate, acetate, threonine, glutathione, valine, isoleucine, leucine, glucose and GABA. The 
LC Model program found the best fit between the spectrum of the biopsy and the linear 
combination of the metabolite components, yielding values of metabolite content (µmol/g 
wet weight), with the fitting error expressed as the SD. Only metabolite fittings with errors 
below 20% SD were included in the final analysis. Since accurate tissue content and volume 
distribution in the HR-MAS rotor is difficult to determine, relative concentrations to the total 
choline or creatine peaks were used in the calculations. 
 Sample preparation and RNA extraction. Total experimental RNA was prepared from 
biopsies of normal brain and tumours using the RNAspin Mini RNA Isolation Kit (GE 
Healthcare). Approximately 20 mg biopsies were used. The purity and integrity of the 
labelled cRNA was evaluated from the A260/A280 ratio and on an Agilent 2100 bioanalyzer, 
being always between 1.9-2.1. RNA integrity number was evaluated using the Agilent 2100 
bioanalyzer, assuming appropriate intensities as those depicting 28S:18S ratio higher than 2. 
RNA Integrity Number (RIN) values were normally ≥7.  
The human tissues are solid (preserved at -80° C) and must therefore be broken up 
mechanically as well as lysed. About 20 mg of biopsy are uded and it is grinding with a 
pestle and mortar for disruption. Grid the sample to a fine powder in the presence of liquid 
N2. Add 350 µl buffer RA1 and 3,5 µl β-mercaptoethanol to ground tissue and vortex 
vigorously, filtered the lysate for clear and reduce viscosity through RNAspin Mini Filter 
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units, centrifuge for one minute at 11000g, add 350 µl ethanol (70%) to the homogenized 
lysate and mix by vortexing. For each preparation use one RNAsion Mini column placed in a 
2 ml microcentrifuge. Pipet lysate up-and-down 2-3 times and then load the lysate onto the 
colum. Centrifugate for 30s at 8000g. Add 350 µl MDB (Membrane Desalting Buffer) and 
centrifuge at 11000g for 1 minute to dry the membrane. (Prepare the DNase reation mixture 
in a sterile microcentrifuge tube: for each isolation, add 10 µl reconstituted DNase I to 90 µl 
DNase reaction buffer). Apply 95 µl of DNase reaction mixture directly into the center of the 
silica membrane of the column and the incubate at room temperature for 15 min. Wash and 
dry silica membrane with 200 µl buffer RA2 and centrifuge at 11000g for 1 minute (the RA2 
will inactive DNase I), a second wash with 600 µl buffer RA3 and centriguge at 11000g for 1 
minute, and another wash with 250 µl buffer of RA3 and centrifuge at 11000g for 2 minute 
to dry the membrane completely. Elute the RNA in 100 µl H2O and centrifuge at 11000g for 
1 minute. Eluted RNA was immediately placed on the ice to prevent potential degradation 
and stored at -80° C. 
 Analysis of gene expression using microfluidic cards. The expression of the genes of 
the choline pathway was assayed using the individual probes for each gene as 
commercialized by Applied Biosystems using the Agylent 2100 analyzer (Foster City, CA, 
USA). TaqMan® probes for Gene Expression provide the most comprehensive set of pre-
designed Real-Time PCR assays available including specifically most genes of the Kennedy 
pathway. All TaqMan® Gene Expression Assays were run with the same PCR protocol, 
eliminating the need for primer design or PCR optimization. Table I summarizes the 
transporters or enzymes of choline metabolism and the corresponding genes investigated in 
this study. The expression profiles of the different genes in tumor and healthy brain tissue 
were compared, assuming as a unit the value of the corresponding gene expression in the 
healthy brain.  
Statistical analysis. From the LCModel analysis 6 variables were selected and tested as 
possible classifiers to differentiate between Low and High grade gliomas: Cho/tCho, 
GPC/tCho, PC/tCho, Cho/Cr, GPC/Cr, PC/Cr. For this purpose a Logistic Regression (LR) 
was applied. LR regresses a dichotomous dependent variable (Low or High Grade) on a set of 
independent variables (19,20)( Cho/tCho, GPC/tCho, PC/tCho, Cho/Cr, GPC/Cr, PC/Cr). 
Backward stepwise was used to select independent variables. Basically, the method enters all 
the variables (or interaction terms) together into the model and then the variables are tested 
for removal one by one. Also, another variable (tCho/Cr), which is assumed to be an 
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approximation to the in vivo situation, was tested by the same LR method to differentiate 
between Low and High Grade. 
For NMR experiment details see Chapter 2 
 
Table I. Transporters or enzymes of choline metabolism and the corresponding genes investigated. 
 Enzyme or Transporter  Abbreviation  Gene Name  Assay ID  
1 Choline transporter 
 CTL1 Hs00223114_m1 
 CTL2 Hs00220814_m1 
2 Choline kinase (EC 2.7.1.32) 
ckα CHKA Hs00608045_m1 
ckβ CHKB Hs00193219_m1 
3 
Phosphocholine 
cytidylyltransferase 
(EC 2.7.7.15) 
ctα PCYT1A Hs00192339_m1 
ctβ PCYT1B Hs00191464_m1 
4 Phosphocholine transferase 
(EC 2.7.8.2) 
ptc CHPT1 Hs00220348_m1 
5 Phospholipase D (EC 3.1.4.4) 
plD1 PLD1 Hs00160118_m1 
plD2 PLD2 Hs00160163_m1 
6 Lysophospholipase 
(EC 3.1.1.5) 
lpl LYPLA1 Hs00272216_s1 
7 Glycerol-3-phosphate acyltransferases 
(EC 2.3.1.15 and EC 2.3.1.51) 
at GPAM Hs00326039_m1 
8 Phospholipase C 
(EC 3.1.4.3) 
plC PLCG1 Hs00234046_m1 
10 Phospholipase A2 (EC 3.1.1.4) 
plA2 VI PLA2G6 Hs00185926_m1 
plA2 IV PLA2G4A Hs00233352_m1 
11 Phospholipase A1 (EC 3.1.1.32) 
plA1 PLA1A Hs00210729_m1 
12 Phosphatidate Phosphohydrolase 
(EC 3.1.3.4) 
pap PPAP2A Hs00170356_m1 
 
 
Results and Discussion  
 Figure 1 shows representative 1H HR-MAS 1D spectra of healthy brain (1a), low and 
high grade gliomas (1b and 1c), respectively. The main metabolites observed include: Lac, γ-
amino butyric acid (GABA), of NAA, Glx, creatine/phosphocreatine (Cr/PCr), Cho, GPC, 
PC, Myo. The broadened signals in the spectra originate from the presence of lipids and 
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macromolecules (MM). 
 
 
Figure 1. Ex vivo 1D water-presaturated 1H HR MAS NMR spectra: a) healthy brain tissue, b) low glioma and c) 
high glioma grade. 
 
The comparison between the glioma and the normal brain spectra show the decrease, 
or absence, of the neuronal markers NAA and GABA and a progressive increase in the lipid 
content (see resonances ca. 0.89 ppm), from low to high grade gliomas.  
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Figure 2. Left: the partial COSY spectra of a) healthy brain, b) low grade and c) high grade. Right: the partial 
CPMG spectra of a) healthy brain, b) low grade and c) high grade. 
The spectra show significant differences in the 3.22 ppm region corresponding to 
choline metabolites. This region is expanded in Figure 2, to better illustrate the increased 
resolution attained through the use of 1D CPMG spectra (total spin-echo time 2nτ = 144 ms, 
figure 2 right panels). Under these conditions, the broad resonances from lipids or 
macromolecules are attenuated from the spectra, and mainly low molecular weight 
metabolites become observable. Figure 2 illustrates the typical metabolic profile of healthy 
brain (2a), low (2b) and high (2c) grade gliomas in the region from 3.0 to 4.4 ppm. The most 
noticeable difference between healthy and diseased tissue is the increased of the Cho-
containing metabolites both in low and high grade gliomas. GPC appeared to be the main 
contributors to the total choline increase in low grade gliomas, whereas in high grade gliomas, 
PC depicted the dominant contribution. A more detailed inspection of the corresponding 2D 
COSY 1H HR-MAS spectra (left panels) confirmed GPC as the dominant contributor to the 
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total choline peak in low grade and PC in the high grade gliomas. It is interesting to show that 
the 2D approach allows the identification of additional metabolites like ethanolamine (E), 
Tau, and PE, not detectable in 1D spectra of the same biopsies. Interestingly, Mannitol (Man), 
a compound normally used during surgery of high grade gliomas to decrease cerebral oedema, 
is clearly detected in many of these spectra. However, these spectra provide only qualitative 
information on the choline containing metabolites of each tumour. To achieve a more 
quantitative interpretation we adapted the LC Model approach, currently used for in vivo 
spectroscopy (21,22), to the quantitative processing of 1H HR-MAS spectra. 
 
Figure 3. 1H CPMG spectra acquired from low glioma grade (a) and a high glioma grade (b). Top row: 
differences between spectrum obtained from biopsis and the simulated spectrum obtained using the new 
metabolites data set. 
Figure 3 illustrates representative LCModel fits of HR-MAS spectra from low (panel 
a) and high (panel b) grade glioma biospies, respectively. The corresponding inserts show the 
a) 
b) 
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expanded regions containing the choline and creatine resonances. The use of LCModel allows 
the correct quantification of the complete metabolite profile of the tumour, rather than 
providing isolated deconvolutions of specific resonances. This allows the proper fit of 
partially overlapping resonances, such as those of PC, GPC and Cho. In particular, the insert 
to Figure 3a depicts more clearly the higher contribution
 
of GPC to the tCho resonances, the 
PC contribution remaining very low. In this case, the GPC content, appears to reach the same 
intensity as the Cr/PCr combined resonance. The metabolic profile shown in the insert to 
Figure 3b is clearly different, showing a dominant contribution of the PC peak with a virtually 
undetectable contribution of GPC. In the high grade tumours, the combined Cr/PCr resonance 
is decreased. 
 
Figure 4. Report a relative contribution of Cho, PC and GPC respect to tCho (a) and to Cr (b). Mean differences 
were statistically compared by performing a Student t-test. *(P<0.05), **(P<0.005), ***(P<0.001). 
Figure 4 summarizes the results obtained in the LC Model quantification of the ratios 
of free choline, PC and GPC to either total choline (panel a) or total creatine (panel b) peaks. 
While the ratios to the creatine peak do not provide an accurate differentiation between low 
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and high grade gliomas, the relative contributions of PC and GPC to the total choline 
resonance depict statistically significant differences between low and high grade gliomas.  
Up till now it has been shown that the means of PC/tCho and GPC/tCho are 
statistically different when comparing low and high grade glioma. However, in order to find 
classifiers that discriminate between both tumours types, Logistic Regression analysis was 
performed. The independent variables tested by the LR analysis were Cho/tCho, PC/tCho, 
GPC/tCho, Cho/Cr, PC/Cr and GPC/Cr. From these, Cho/tCho, PC/tCho and GPC/tCho were 
selected as classifiers (Table II). The combination of these three variables allows the 100% of 
the tumours to be discriminated between low and high grade glioma (Table III and Figure 5). 
 
 Table II. Selected Variables for Classification 
 B 
Step 4(a) Cho/tCho 8132,223 
 PC/tCho 9118,222 
 GPC/tCho 7775,408 
 Constant -8359,676 
 
 
Table III. Classification based on Logistic Regression analysis. 
Observed 
Predicted 
Groups Percentage 
Correct 
Low High 
Step 4 Grade Low 8 0 100,0 
High 0 7 100,0 
Overall Percentage   100,0 
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Figure 5. Predicted probability obtained from the LR analysis for the classification of Low and High Grade 
Gliomas using Cho/tCho, GPC/tCho and PC/tCho ratios as a classification variables. 
 
The classification using the relative contributions of Cho, PC and GPC to tCho, which 
can only be calculated from high resolution spectroscopic data, was compared with the 
classification provided by the tCho/Cr ratio. This last variable was chosen as an 
approximation to the information obtainable from in vivo spectra (23). For this purpose a 
similar LR analysis was performed, yielding a much worse classification for Low and High 
grade Gliomas (Table IV and V and Figure 6). 
 
Table IV. Selected Variable (tCho/Ct) for Classification 
  
 B 
Step 1(a) tChoCr 1,053 
 Constant -1,164 
(a)  Variable(s) entered on step 1: tChoCr. 
 
 Table V. Classification based on Logistic Regression analysis. 
 Observed 
Predicted 
Grade Percentage 
Correct 
Low High 
Step 1 Grade Low 7 1 87,5 
High 2 5 71,4 
Overall Percentage   80,0 
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Figure 6. Predicted probability obtained from the LR analysis for the classification of Low and High Grade 
Gliomas using tCho/Cr ratio as the classification variable.  
 
Figure 7 depicts the expression of the genes of choline metabolism in high grade (red) 
and low grade (blue) glioma biopsies relative to the expression found in normal brain, using 
the microfluidic cards approach. 
 
 
Figure7. Genes expression of the enzymes involve in the Choline Cycles in low and high grade of glioma 
tumours. X: the single gene, Y: the Relative Quantification (RQ) of the expression of the each gene. Mean 
differences were statistically compared by performing a Student t-test. *(P<0.05). When RQ>1 the genes are 
upregulated, while RQ<1 the genes are downregulated, in comparison with healthy tissues RQ=1. 
 
Ratios with values higher or lower than one reveal upregulation or downregulation of 
the corresponding gene as compared to its expression in the normal brain. In high grade 
gliomas, the following genes were found to be upregulated; choline transporter (CTL2), 
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choline kinase (CHKβ), phospholipases A, C and D (PLA2G4A, PLCG1 and PLD2) and 
lysophospholipase (LYPLA1), the upregulation being significant in phospholipases A and C. 
The remaining genes investigated in high grade gliomas were downregulated. In the low 
grade gliomas, upregulated genes were; choline transport (CTL1, CTL2), cytidylyl-transferase 
(PCYT1A, PCYT1B), phospholipases A and D (PLA2G4A, PLA1A and PLD2) and 
lysophospholipase (LYPLA1), the remaining being downregulated. Notably, some genes were 
upregulated in high grade gliomas and downregulated in low grade gliomas as choline kinase 
(CHKβ) and phospholipase C (PLCG1) while others were upregulated in low grade gliomas 
and downregulated in high grade gliomas as the choline transporter (CTL1), 
citydyltransferase (PCYT1B) and phospholipase A (PLA1A). Of these, only the differences in 
phospholipase C (PLCG1) upregulation and downregulation between high grade and low 
grade gliomas, became statistically significant. In general, high grade gliomas depicted 
significantly upregulated phospholipase A2 and C expression as compared to low grade 
gliomas. 
 
The present work illustrates how ex vivo 1H HR-MAS analysis of tissue biopsies can 
help in the discrimination of high grade and low grade human astrocytomas, by investigating 
quantitatively the profile of choline containing metabolites. Previous studies have used 1H 
HR-MAS to investigate the metabolic profile of cerebral tumors (12,13,24). These initial 
studies described the methodology and provided the assignments, but the spectral 
information remained at the qualitative level without the implementation of multivariate 
statistical methodologies. In general, the analysis of the resonances from choline containing 
compounds remained limited, since they overlapped to some extent and it is not possible to 
obtain accurate quantification without the use of adequate spectral deconvolution algorithms. 
 The present work overcomes this limitation by implementing a robust procedure for 
the quantification of the different choline containing compounds in 1H HR-MAS spectra 
using the LCModel approach. LC Model allows to obtain the relative quantification of the 
complete metabolite profile of the biopsy, using a linear combination of the spectra of the 
different metabolites. In our case, we used a database containing the spectra of twenty three 
cerebral metabolites to calculate the corresponding linear combination that would optimally 
fit the experimental spectrum. In this report we focus only in the profile of choline 
containing metabolites. Our results show that the total choline peak is elevated both in low 
grade and high grade gliomas, but the profile of choline containing metabolites underlying 
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this increase is different in both cases. We show here that the total choline peak increase is 
derived from an increase in phosphorylcholine in high grade gliomas and an increase in 
glicerolphosphorylcholine in low grade gliomas. This results in a characteristic choline 
metabolite pattern in high and low grade gliomas, that allows the unambiguous classification 
of our complete data base of sixteen biopsies of human gliomas. 
 An important aspect of the present study is the genetic basis of the metabolite 
alterations observed by 1H HR-MAS. Current molecular biology concepts indicate that the 
sequence of genetic information proceeds from the genome, to the transcriptome, to the 
proteome and finally to the metabolome. On this basis, it seems reasonable to propose that 
the genome constitutes the ultimate determinant of the metabolic phenotype or metabolome. 
Few studies have investigated previously this aspect (25)(Cheng1997). In many cases, high 
resolution 1H NMR spectra of body fluids were used to investigate global system dynamics 
in drug metabolism and its disturbances (26) or the relationship between HR MAS spectra of 
tumor biopsies and the complete genome analysis (14). Much less information is available on 
the relative expression of the genes of the Kennedy pathway and the pattern of choline 
metabolites as detected by 1H HR MAS. 
 
Figure 8. Choline metabolic patway. Cellular compartemnts: ER, endoplasmatic reticulum; cyt, cytosol; memb, 
membrane.  
Figure 8 provides an adequate frame to discuss these aspects, by showing in more 
detail the metabolism of choline phospholipids, the enzymes involved and the different genes 
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coding for them (ck, choline kinase; ct, cytidylyl-transferase; ptc, phosphocholine cytidylyl-
transferase; pla, phospholipase A1 and A2; lpl, lysophospholipase; pd, glycerophosphocholine 
phosphodiesterase; at, glycerol-3-phosphate acyltransferases; plc, phospholipase C; pld, 
phospholipase D).  
Modern gene expression technologies allow to investigate specifically the genes 
related to a specific pathway, rather than the complete genome as previously done. In this 
work, we used microfluidic cards to investigate the expression of sixteen genes of the choline 
metabolism, to improve our understanding of the genetic basis of the metabolic profile of 
choline metabolites observed by 1H HR-MAS. The most interesting changes found are those 
corresponding to genes depicting a crossover of genetic expression, becoming upregulated in 
one type of gliomas and downregulated in the other. The increase in PC in high grade gliomas 
can be explained by the increase in the expression of the choline kinase β gene and the 
phospholipase C gene, respectively. Several authors have described increases in the 
expression of the genes of choline transport (27) and choline kinase (28,29). Our results 
confirm these, suggesting that it is the gene of the choline transporter β or the choline kinase β 
are the ones responsible for the increase in the corresponding processes. In addition we show 
that there are significant increases in the expression of the phospholipase C gene in high grade 
gliomas, another potential source of PC. This is, to our knowledge a novel finding, indicating 
that the increase in PC is derived not only from an increase in its synthesis by choline kinase 
but by an increase degradation of phosphatodylcholine through the phosphoilipase C pathway. 
Taken together these results suggest an increase in the turnover rate of phosphatidylcholine 
with glioma grade. Moreover, some cancer therapies have proposed the use of choline kinase 
inhibitors (28,30,31). Present results indicate that the additional inhibition of the 
phospholipase C pathway, may provide a very useful complement of these therapies. The 
increase in GPC in the low grade gliomas reflects a positive balance between its production 
and degradation pathways. Net GPC synthesis is favoured by the increased expression of the 
choline transporter gene (α-isoform), cytidylyl-transferase gene (β isoform) and 
phospholipase A, respectively. GPC breakdown may be reduced because of the decrease in 
glycerol 3-phosphtae acyltransferase. In addition the relative amount of GPC to PC in low 
grade gliomas may be also favourable to the former, because of the reduced expression of the 
phospholipase C gene in low grade gliomas. Summarizing, the net balance between increased 
synthesis, reduced degradation and diminished PC synthesis through phospholipase C, may 
lead ultimately to relative GPC accumulation in low grade gliomas. This is an interesting 
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finding since only one previous study to our knowledge, reported on the genes regulating 
GPC metabolism in mammary tumours (32,33).  
 In summary, we provided a novel application of 1H HR-MAS spectroscopy to the 
classification of human glioma biopsies. Our results show that high and low grade gliomas are 
characterized by increases in PC or GPC, respectively, and that these appear to be reflected by 
changes in the expression of the genes of the Kennedy pathway of choline metabolism. 
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General Introduction 
The neoplasms of the human gastrointestinal tract are an important public health 
problem due to their high incidence (1) and the high rates of recurrence and metastasis after 
resection. The outcome of treatment is highly dependent on correct and early diagnosis and 
the detection of early lesions, without lymph node involvement or distant metastases, results 
in a reduction of mortality (2). Thus the possibility to add new knowledge to the biochemistry 
of gastric and colon-rectal adenocarcinomas assumes great importance and the development 
of non conventional methods able to perform an early diagnosis based on the molecular 
composition instead of the morphology is highly desirable. Whereas organs, such as the brain, 
prostate, breast have been widely studied, and MRS is used routinely in clinical medicine to 
analyze them, MRS in the evaluation of neoplasms of human gastrointestinal mucosa is at the 
beginning. From this perspective my research work was to investigate the biochemical 
composition of normal and neoplastic human gastric and colorectal mucosa tissues by means 
ex vivo NMR, performed directly on biopsies or surgical tissues using HR-MAS NMR. The 
aim of this study is to relate the biochemical composition, obtained by using HR-MAS and 
quantitative histopathologic findings from the same gastrointestinal mucosa and to determine 
the metabolic profiles associated with functional, benign and malignant tissues.  
The complete characterization of the metabolic composition of this tissue, will set the 
biochemical basis for the development and application of new protocols for the direct analysis 
of pathological tissues.  
Considering the gastrointestinal tract my thesis work deal with the study of: 
a) Stomach Mucosa 
b) Colon Mucosa 
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STOMACH MUCOSAE 
 
The Healthy Gastric Mucosa 
 Studies reported the application of ex vivo HR-MAS NMR in the characterization of 
the biochemical composition of human healthy and neoplastic gastric mucosa are rare in the 
international scientific literature. 
The first step of my research was to investigate the biochemical composition of normal 
human gastric mucosa by ex vivo HR-MAS NMR.  
 
Clinical materials. Selection of the patients: 5 patients were enrolled and gave written 
informed consent to participate in the study which was approved by the local research ethical 
committee. For each eligible patients, 6 biopsies have been taken (3 biopsies from the antrum 
and 3 biopsies from the gastric body) during endoscopy. Among them, 4 have been used for 
routinal histologic evaluation (hematoxilin-eosin) and 2 will be posed in liquid nitrogen and 
stored at -85°C. Endoscopy was performed using Olympus Instruments 140 series and 
biopsies forceps Olympus FB24Q, after sterilization in acetylacetic acid. The biopsies have 
been performed, on healthy tissues, in the subjects who do not present visible macroscopic 
alterations and the tissue is to be considered healthy only if the histological examination will 
confirm the macroscopic finding.  
 
For the NMR experiments details see chapter II 
 
Result and Discussion 
The 1D proton spectra obtained from two representative samples of normal gastric 
mucosa (1 and 2), acquired by using a presaturation sequence with composite pulse (Bruker 
zgcppr), are reported in Figure 1.  
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Figure 1. HR-MAS proton spectra of two representative samples of normal gastric mucosa: a) 1 and b) 2 
samples, respectively. 
 
The spectra of these samples, which are representative of the all that analysed, show 
the presence of the resonances deriving from metabolites and macromolecules with short T2, 
but not so short to be NMR invisible, and are characterised by signals with a resolution 
comparable to that obtained for solution spectra. Furthermore, it is to note that in stomach 
tissues the lipid content is very low in comparison with that of other metabolites, as can be 
derived from the low intensity ratio between signals at 1.3 ppm (CH2)n, and at 0.89 ppm CH3 
(usually around 3:1). In order to evaluate the stability of the samples in the HR-MAS probe, 
the spectra were obtained at different times from their preparation. The spectra of sample 1 
obtained after 3h (trace a) and after 6h (trace b) from the preparation are reported in Figure 2. 
These spectra evidence a progressive increase of spectral resolution probably related to the 
increasing mobility of some metabolites, as a consequence of the partial disruption of 
subcellular structures. In any case, the lactate content does not appreciably change, whereas 
changes related to the mobility enhancement of amino acidic fractions are detected: an 
increase of glycine, alanine, other aliphatic and aromatic amino acids, and free choline is 
observed. We are not able to give a straightforward explanation of this behaviour; however 
the prograstrin is cleaved at pairs of basic amino acids by a pro-hormone converter to form a 
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glycine intermediate (G-Gly) that serves as a substrate for peptide-glycine α-amidating mono 
oxigenase (3). Since on overexpression of gastrin, known to promote the growth of several 
neoplasms, in human gastric adenocarcinomas has been demonstrated (4), the presence of 
glycine could merit further investigations. 
 
Figure 2: HR-MAS proton spectra of sample 1 a) after 3 hours and b) after 6 hours. 
 
In order to separate the contribution of resonances due to macromolecules having short 
spin-spin relaxation times, spectra were acquired using a CPMG spin-echo sequence [90°- (τ-
180°-τ)n], choosing τ and n in order to separate signals according to their different T2. Signals 
from macromolecules, having short T2 (or large linewidth) are attenuated leaving only the 
resonances due to mobile small molecules. Diffusion-edited spectra were also acquired 
choosing a diffusion delay (∆) and a gradient-field pulse duration (δ) and strength in order to 
observe components with low diffusion rates, deriving from lipids, glycogen and small 
proteins.  
A conventional presaturated 1D spectrum with composite pulse (trace a), that 
highlights both lipids and small metabolites contribution, a CPMG spectrum (trace b), 
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showing the enhanced resonances of  metabolites, and the diffusion-edited spectrum (trace c) 
of the same stomach sample 3 are reported in Figure 3. 
 
Figure 3 1D proton spectra of sample 3 a) conventional 1H NMR spectrum obtained with water-presaturation 
and composite pulse, b) CPMG spectrum obtained with 360 ms total spin-echo time and c) diffusion-edited 
spectrum obtained with ∆ = 200 ms, δ = 4 ms and gradient strength of 32 G/cm. 
 
The analysis of the COSY spectrum (Figure 4) evidences the presence of a pool of 
metabolites, especially osmolites, free amino acids and a fraction of mobile lipids, whose 
assignments are reported in Table I 
Some correlations, for example those due to glycerol (in lipids) protons at 5.24, 4.30 
and 4.10 ppm are present in COSY spectra, but absent or attenuated in TOCSY spectra 
 Neoplasms of Gastrointestinal Tract 
 
126 
 
(Figure 5). This difference can be explained by considering that in TOCSY spectra signals 
coming from large molecules relax during the mixing time and this, together with the 
characteristic chemical shifts, allows to say that this glycerol moiety is not involved in small 
but belongs to larger lipidic species. The COSY spectra are particularly useful for the 
detection and assignment of α-hydrogens of several amino acids, whereas the presence of 
lysine and arginine is better evidenced in TOCSY spectra. Both COSY and TOCSY 
experiments permit to establish that two metabolites, lactate and threonine, contribute to the 
doublet at 1.33 ppm found in 1H NMR spectra.  
 
Figure 4. Partial COSY spectrum of sample 4. The identified metabolites are denoted with labels according to 
Table I.  
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Figure 5. Partial TOCSY spectrum of sample 4. The identified metabolites are denoted with labels according to 
Table I. 
The HSQC spectrum of sample 5 and relative assignments are reported in Figure 6. 
Some metabolites such as ChoCC, Arg and PE contribute all to the 3.2 ppm signal in the 
proton spectra but can be readily distinguished with HSQC due to the large difference in 13C 
chemical shifts. The 13C δ dispersion is also useful for the assignment of the signals of 
aliphatic amino acids (Ile, Val, Leu). The interpretation of the region between 3.4 and 4.0 
ppm is more problematic, due to the presence of overlapped correlations around 62 ppm, 
presumably due to glycerols. All sample spectra show a strong resonance at 3.72 (s) ppm, 
attributable to PEG (confirmed by the 13C resonance at 70.3 ppm). 
 The observed peaks seem to be principally related to the narrow components 
appearing in the CPMG spectrum (Figure 3b), with the exception of signals due to N-acetyl 
groups, which are instead evidenced in the diffusion-edited spectrum (Figure 3c). 
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Figure 6. Partial 1H,13C-HSQC spectrum of sample 5 (stomsan23). The identified metabolites are denoted with 
labels according to Table I. 
 
All the samples analysed display the same resonances with only slight differences in 
the relative abundance. Through the use of one- and two-dimensional experiments it was 
possible to assign the NMR signals from more than forty species present in healthy human 
gastric mucosa. Among them only few components can to be confidently assigned by direct 
inspection of the 1H NMR spectrum, namely, a doublet at 1.48 ppm is for Ala, a triplet at 2.36 
ppm is for Glu, whereas a triplet at 3.43 ppm is for Tau. Instead, the doublet at 1.33 ppm, 
usually attributed to Lac, is due in our samples to the overlapping of Lac and Thr resonances, 
with the second species prevailing in the same cases. The presence of Lys is normally well 
evident in the one-dimensional 1H spectrum from the triplet at 3.04 ppm (over-lapped to the 
singlet of Cr, while it is harder to distinguish the triplet of Arg from those of Tau and PE 
which are found very close in one-dimensional 1H spectrum (and partially hidden under the 
choline containing compounds singlets). To our knowledge this study is the first one, aimed at 
elucidating the metabolic profile of normal human gastric mucosa by ex vivo HR-MAS NMR. 
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The characterization of the molecular pattern typical of the healthy gastric human mucosa will 
be the bases for the comparison with gastric neoplastic situations.  
 
Human Gastric Adenocarcinomas 
Gastric cancer is the leading cause of cancer related death in many parts of the world 
(5). Gastric carcinogenesis is a multistep and multifactorial process that in many cases 
involves a progression from normal mucosa through chronic gastritis, atrophic gastritis and 
intestinal metaplasia to dysplasia and carcinoma (6). A number of pre-cancerous conditions 
such as atrophic gastritis and intestinal metaplasia have been recognised due to Helicobacter 
pylori (H. pylori) infection or autoimmunity and there are putative associations with 
environmental agents such as dietary constituents and the formation of carcinogenic N-nitroso 
compounds within the stomach (7). The detection of early lesions, without lymph node 
involvement or distant metastases, would result in a 
reduction of mortality (8). Thus, achieving a better understanding of the molecular features of 
gastric cancer and the development of reliable methods for early detection is highly desirable. 
The NMR was used to elucidate the main metabolic characteristics of human 
adenocarcinomas. Only one paper (9) reports a study on gastric adenocarcinoma obtained 
from low resolution ex vivo MR spectrum of composite mucosal/submucosal layer and 
underlines that a decreased levels of lipids together with an increased of lactate and choline 
peaks were marker for malignancy.  
 
Selection of the patients. Sixteen patients, 5 with gastric carcinoma (2 male, mean age 
70.6 +/- 12.9 years, range 59-86 years) and 11 healthy subjects (7 male, mean age 49.3 +/- 
17.3 years, range 30-86 years) were evaluated. Of the sixteen patients examined 14 underwent 
endoscopy, 2 underwent surgery for gastric adenocarcinoma; in all cases, sample of  healthy 
gastric mucosa were collected. 
All 5 patients with gastric cancer showed an H. pylori infection while no healthy subjects 
presented an H. pylori infection. Histological appearance was consistent with adenocarcinoma 
well differentiated in 3 patients, poorly differentiated and undifferentiated in one patient 
respectively.  
 The patients gave written informed consent to participate in the study which is 
approved by the local research ethics committee. For each eligible patient, 8 biopsies were 
taken (4 biopsies from the antrum and 4 from the gastric body) during endoscopy. Among 
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them, 4 were used for routine histologic evaluation (haematoxylin-eosin) and 4 were put in 
liquid nitrogen and stored at -85°C. Endoscopy was performed using Olympus 
Videoendoscope 140 series and biopsy forceps Olympus FB24Q, after sterilization in 
acetylacetic acid. The biopsies were obtained, on healthy tissues, in the subjects who did not 
present visible macroscopic alterations and the tissue were considered healthy only if the 
histological examination confirmed the macroscopic finding. It is reasonable that the tissue 
collections is performed on mucosa and submucosal layer. In the patients with gastric cancer 
the biopsies were taken from the lesion in clearly macroscopic aspect of carcinoma and in 
normal appearing mucosa far from lesion. The gastric biopsies were fixed in neutral buffered 
formalin, routinely processed and stained with Giemsa and haematoxylin-eosin. The Goseki 
classification (10) was used for grading adenocarcinoma. 
 
Results and Discussion 
Conventional presaturated 1D spectra, representative of the healthy (trace a) and 
neoplastic (trace b) gastric mucosa are reported in Figure 7. The healthy mucosa shows the 
presence of the resonances deriving from low molecular weight metabolites and 
macromolecules, whereas the adenocarcinoma is characterized by the presence of 
predominant signals due to triglycerides, which content is very low in healthy stomach. So it 
is possible to evidence the metabolic changes in the neoplastic human gastric mucosae. (For 
the metabolites assignment see table I) 
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Figure 7. HR-MAS proton MR spectra of healthy (a) and neoplastic (b) samples. 
 
As already observed, the 1H MR spectra of gastric adenocarcinomas are dominated by the 
signals due to triglycerides. At first, we examined the type of fatty acids with the aims to 
characterise the relative content of saturated and unsaturated fatty acids. 
Lipids. The proton spectrum of a neoplastic gastric mucosa, reported in Figure 8, 
shows the resonances characteristic of triglycerides, confirmed by the presence of signals due 
to glycerol (5.26, 4.30 and 4.10 ppm) and to long fatty acid chains. It is to remark that all the 
examined adenocarcinomas (5 patients, for the patient 2 nine spectra were obtained from 
sampling in different zone of the lesion tissues) show virtually identical spectral profile. 
 
b 
a 
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Figure 8. 1H HR-MAS MR spectrum of cancerous gastric mucosa. 
 
Signals at 2.02 ppm are to be assigned to methylene protons of CH2-CH=CH moiety 
of mono- and poly-unsaturated fatty acids, whereas those at 2.78 ppm are attributable to 
methylene protons between two double bonds (=C-CH2-C=) in poly-unsaturated acids. 
Furthermore, the unsaturated acids are identified by the signals at 5.33 ppm due to protons of 
-CH=CH- moiety.  
The α-linolenic acid is identified by the signal of the methyl protons at 0.96 ppm and by its 
correlation with methylene protons of CH2-CH=CH moiety at 2.06 ppm, detected in the 
COSY spectrum (Figure 9). 
 
(CH=CHCH2)3 
(CH=CHCH2)2 
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Figure 9. COSY spectrum of sample 2. The correlation CH2-CH3 of α-linolenic acid is evidenced. 
 
The presence of linoleic acid is confirmed by the correlation between the triplet at 2.78 ppm 
(=C-CH2-C=) and the signal at 2.02 ppm (CH2-CH=CH) and by that with signal at 5.33 ppm 
(CH=CH). 
The analysis of the fat components, in percentage of saturated, mono- and poly-
unsaturated was performed through the integration of suitable signals: the starting point is 
represented by the integrated area of the CH2(α) to C=O at 2.24 ppm. The percentage of 
unsaturated acids was evaluated by the ratio between the experimental and theoretical values 
of integrated area of CH2(α) to double bond. The integrated area of CH2(α) to double bond, 
due to mono- and poly-unsaturated acids was corrected by the contribution due to CH2(α) of 
linoleic and α-linolenic acids, which is derived by the integrated area of the signal at 2.78 
ppm, permitting to establish that the ratio of mono- and poly-unsaturated components is 
ca.3:1, in all the examined samples. The α-linolenic percentage was derived by the area of the 
terminal methyl signal at 0.96 ppm. The composition of triglycerides is reported in Table II. 
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Table II. Percentage of different fatty acid components in the adenocarcinoma samples. 
Patients Saturated Unsaturated 
mono-unsaturated poly-unsaturated 
linoleic α-linolenic 
1 20% 64% 14% 2% 
2 28% 56% 13% 3% 
3 23% 65% 10% 2% 
4 26% 48% 24% 2% 
5 28% 46% 24% 2% 
 
Some considerations can be made on the 13C MR spectra obtained with HR-MAS technique. 
A carbon spectrum representative of whole samples analysed is displayed in Figure 10. 
 
 
 
Figure 10. The 13C HR-MAS spectrum of patient 2 biopsy. All 13C resonance are reported in table III. 
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The spectrum is of good quality, with a resolution comparable to that obtained in 
solution, permitting the evaluation of the composition of triglycerides. Three signals are 
present in the carbonyl region, at 172.26, 172.24 and at 171.97 ppm: the more deshielded 
signals are due to the carbonyls in the 1,3 positions (sn1,3) and the other to the carbonyl in the 
2 position (sn2) of glycerol. The slight difference of the carbonyl resonances in sn1,3 suggests 
that the triglycerides are mixed, even if no difference is observed in the sn2 carbonyl 
resonance. The two groups of signals centred at 130.1 and 128.5 ppm are due to olefinic 
carbons: in particular the latters are attributable to internal carbons of double bonds in linoleic 
and α-linolenic acid, whereas the formers are due to carbons of mono-unsaturated acids and to 
external carbons of double bonds in linoleic and α-linolenic acid. The identification of 
saturated fatty acids is obtained by the resonances of the CH2CH3 moiety at 23.2 and 14.60 
ppm, whereas those of mono-unsaturated and poly-unsaturated acids is deducible from the 
resonances of CH2-CH=CH at 27.8 ppm, CH2CH3 at 23.3 ppm and 14.56 ppm. The linoleic 
acid is clearly identified by the resonance of =C-CH2-C= at 26.1 ppm. The 13C resonances of 
the α-linolenic acid were not detected due to its low abundance. 
The NMR date of lipids obtained through the MR analysis is reported in table III. 
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Scheme 1. Triglycerides and relative numbering. 
 
Glycerol H C 
1,3-CH2 4.10, 4.30 62.4 
2-CH 5.22 69.5 
Triglyceride 
Mono-unsaturated Acids (M) 
Linoleic Acid (L) 
α-Linolenic Acid (α-L) 
ψ χ 
α β γ 
Saturated Acids (S) 
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Table III. NMR data (1H,13C) of fatty acids in neoplastic gastric mucosa. For numbering see Scheme 1. 
 
C=O CH2(α) CH2(β) (CH2)n CH2CH=CH CH=CH 
=C-
CH2-
C= 
CH2(χ) CH2(ψ) CH3 
C 
172.26 
172.24 
171.97 
34.2, 
34.3 
25.5 29.7÷30.6 27.8(M+L) 
130.1, 
128.5 
26.1(L) 
32.65, 
32.51, 
32.18(S) 
23.3 
(M+L), 
23.2(S) 
14.60 
(M+L), 
14.56(S) 
H  2.24 - 1.60 
2.02, 
2.06(α-L) 
5.33 
2.78(L), 
2.81 
(α-L) 
1.28÷1.32 
0.89, 
0.96(α-L) 
 
The assignment of 13C MR signals of the triglycerides was made through 1H,13C HSQC 
experiment and by comparison with the literature data (11). The detection of lipids in all the 
gastric adenocarcinomas examined differentiates them from the healthy mucosa in which their 
amounts is very low. This finding is in opposition with that of Mun et al. (9) who reported a 
decreased levels of lipids in gastric adenocarcinomas detected from low resolution ex vivo 
MR spectrum of composite mucosal/submucosal layer.  
Within the panorama of the research on lipidic component of cell and tissues recognised as 
having a fundamental role in cell life and death (12), in recent years analytical studies 
performed by spectroscopic techniques have been gained importance. Indeed, deposits of 
neutral lipids in human cells and tissues have been revealed and identified by NMR. Recently, 
some authors have speculated that 1H resonances, attributed to mobile lipids, originate from 
lipid droplets made of triglycerides and cholesteryl esters located both in the cytoplasm 
(13,14) and in the plasma membrane (15). The importance of these 1H visible lipids in the life 
and death of cells has been highlighted by Hakumaki and Kauppinen (12) and the direct 
relationship between Nuclear Magnetic Resonance-visible lipids, lipid droplets and cell 
proliferation has been demonstrated by Barba et al. (16). Moreover, a positive correlation 
between the presence of lipid droplets detected in vivo by MRS and necrosis in rat brain 
glioma has been reported (17). All of these evidences show how these lipid droplet, formed by 
triglycerides, mainly, are closely involved in various aspects of tumor cell transformation. 
 In agreement with these findings, we have detected a lot of triglycerides in all the 
examined adenocarcinomas collected both by endoscopy or surgery. High amounts of lipids 
in clear cell renal carcinoma sample were detected, by ex vivo HR-MAS NMR, by Nicholson 
et al.(18). The result could be thus not surprising even if ultra-structural further investigations 
 Neoplasms of Gastrointestinal Tract 
 
137 
 
are needed to better elucidate the localization of these compounds and to understand their role 
and significance in gastric adenocarcinomas. 
Low molecular-weight metabolites in gastric adenocarcinoma. The CPMG experiment 
permits to attenuate the signal due to lipids and to evidence the signals arising from small 
metabolites in the neoplastic tissue; in this type of samples a good CPMG spectrum, i.e. a 
good suppression of lipid resonances, can be obtained using a total spin-echo time of 720 ms. 
The corresponding spectrum is reported in Figure 11.  
 Some metabolites can be identified by the comparison with the corresponding healthy 
tissues. In particular, adenosine, Ala, Phe, Tyr, His, α- and β-Glc, PC (trace), Myo, PE, Gly, 
Tau, HTau, Scy, ChoCC, Cho, E, succinate (Suc), Gln, Glu, methionine (Met), acetate (Ac), 
hydroxibutyrate (OH-But), Val and low amounts of Ile and Leu, are recognizable. Polyethylen 
glicole (PEG) is present in small amount in only some samples. 
 
 
Figure 11. The CPMG spectrum of gastric adenocarcinoma tissue. 
 
Different relative ratios of metabolites are found in the healthy and neoplastic tissues as 
clearly evident in the two spectra reported in Figure 12. 
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Figure 12. The CPMG spectra of healthy gastric mucosa (trace a) and adenocarcinoma (trace b). 
 
At a glance, the major differences are found in the increased amount of Gly in 
neoplastic tissues with respect to the healthy ones. It has been suggested that intermediates of 
a more bioactive glycolitic pathway in neoplasms are responsible of an increasing of Gly 
amount, involving phosphoglycerate and serine (19). In agreement with these findings, 
several authors reported Gly as the most notable peculiarity in glioblastomas (20,21) and 
breast tumors (18). Moreover in the case of breast tumors, high amount of Gly were correlated 
to tumor size, cellularity and presence of positive lymph node (22). 
Another difference, recurrent in all the examined adenocarcinomas, besides the change 
in the ChoCC/Cr ratio which passes from 16:1 in all the healthy samples to 2.5:1 in the 
neoplastic ones, is found in the relative abundance of Cho with respect to ChoCC. The 
healthy gastric mucosa is characterised by high amount of PC and low amounts of Cho and 
GPC, with a mean ratio Cho/ChoCC of 1:5. Instead, the adenocarcinoma samples are 
characterised by large amount of Cho and very low amounts of PC and GPC with a mean 
ratio Cho/ChoCC of 4:1. 
a) 
b) 
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PEG is a component of the anesthetic formulation administered to patients before 
endoscopy, and its presence was detected, through the strong singlet at 3.72 ppm only in 
healthy gastric mucosa; whereas it is absent or only in traces in all the gastric adenocarcinoma 
samples. It is interesting to note that this molecule is preferentially fixed in the healthy tissues 
only.  
 
Evolution of normal mucosa to gastric cancer 
Gastric carcinoma of the intestinal type originates from dysplastic epithelium, and may 
also develop from gastric adenomatous polyps, representing dysplastic epithelium arising in 
an elevated lesion (23). As already pointed out, the main causes of chronic atrophic gastritis 
and gastric atrophy are the autoimmune diseases (AAG) due to pernicious anemia or chronic 
Helicobacter pylori (H. pylori) infection (24,25). The intestinal metaplasia may be of the 
enteric (grade I), enterocolic (grade II), or colonic (grade III) type. Grade III intestinal 
metaplasia has traditionally been thought to be the riskiest, and the extent of atrophy and 
metaplasia could be a better marker for premalignancy than the mere identification of small 
intestinal metaplasia areas (26). Over the years, there has been much disagreement on the 
identification of the different grades of dysplasia and early gastric cancer. There is still a 
limited knowledge on metabolic alterations occurring in dysplastic/cancer cells, despite 
increasing indications of the involvement of some molecular components in tumor growth and 
invasiveness (15). Identifying molecular patterns of the different stages of gastric mucosa by 
advanced molecular techniques may result in rapid and effective methods for gastric 
adenocarcinoma diagnosis.  
The metabolic profiles, associated with healthy and malignant human stomach tissue, 
can be now established through ex vivo HR-MAS NMR. The results of the study was to apply 
ex vivo HR-MAS NMR to human tissues, with the aim to have information on the molecular 
evolution of the gastric carcinogenesis. This data could be the basis for the development of in 
vivo MRS methodologies to diagnose gastric pathologies in clinical situations (9). Since ex 
vivo HR-MAS spectra allowed the detection of high lipid amount, especially in 
adenocarcinoma tissues, the study was continued with a microscopic investigation to identify 
and locate the lipids in the cellular and extra-cellular environments. The study try to correlate 
the morphological changes detected by transmission (TEM) and scanning (SEM) electron 
microscopy, with the metabolic profile of gastric mucosa in healthy, AAG, H. pylori-related 
gastritis and adenocarcinoma subjects. 
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Methods  
Tissue protocols. We included 27 patients (15/12: male/female, mean age 56.6 ± 16.9 
yrs): twelve normal subjects (7/5: male/female, mean age 53.2 ± 15.2 yrs); 5 with AAG (2/3: 
male/female, mean age 64.3 ± 17.6 yrs); 5 with H. pylori infection (4/1: male/female, mean 
age 46.2 ± 21.1 yrs) and 5 with adenocarcinoma (2/3: male/female, mean age 70.6 ± 12.9 yrs). 
Twenty-two patients underwent upper gastrointestinal endoscopy, and 5 gastrectomy for 
adenocarcinoma. Ten biopsies (antrum/gastric body), 4 for histologic evaluation, 4 for TEM 
and SEM and 2 for MRS analysis, were taken from each subject during endoscopy. The 
specimens (biopsies and surgical samples) in patients with gastric cancer were obtained 
exclusively from the carcinoma site, assuring the absence of any contaminants. The study was 
approved by the local ethics committee. All patients received detailed information regarding 
the procedure and written informed consent was obtained. 
TEM. The biopsies were fixed in 5% glutaraldehyde in 0.1 M sodium phosphate buffer 
pH 7.2, post fixed in 1% osmium tetroxide in the same buffer, dehydrated and embedded in 
resin. Semithin sections (2 µm thick) cut with an ultramicrotome Reichert OM-2, were 
observed under a light microscope. Ultrathin sections (70 µm thick) were obtained from 
pathological areas chosen by light microscopy, stained with uranyl acetate and lead citrate 
were examined at TEM Philips CM10. 
SEM. The biopsies were fixed in 5% glutaraldehyde in 0.1 M sodium phosphate buffer 
pH 7.2, critical point dried with Emitech K 850, coated with gold palladium film with an 
Emithech K500 sputter coater and observed under a Philips 515 SEM at 9-14 kV.  
Statistical Analysis. NMR data were processed using the Bruker software applying 0.5 
Hz line broadening, prior to Fourier transformation, phased and then the baseline was 
corrected. The results were based on a matrix consisting of 33 spectra. The NMR data points 
were reduced from 32k to 8k data points. The spectral width was selected to the chemical shift 
range δ 8.60-δ 0.78 by reducing the number of data points to 1600. The values of data points 
around the water signal in the range δ 5.03-δ 4.69 and δ 1.34-δ 1.29, were set to zero, where 
the lactate doublet occurs. Each data set was then normalized to unit area and analyzed by the 
statistical package SPSS (SPSS Inc., Chicago, IL) to get principal component analysis (PCA). 
The statistical method of PCA was used to differentiate spectra of gastritis from the healthy 
and neoplastic gastric mucosa. The number of principal component analyses (PCs), that gave 
the minimal total % variance, was considered to be the required number of PCs. The score 
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plot of the various PCs was interpreted, to reveal specific grouping and the relationship 
among samples.  
In the present context, the eigenvalue represents the amount of the total test variance 
(%), accounted for a particular factor. However, the variance of the original data can be 
explained by the first few principal components and the remaining can be ignored. In this 
analysis three components with an eigenvalue greater than 1 were found and they account for 
about 70 % of the variance. A plot of PC1 against PC2 and PC2 against PC3 showed the maximum 
data spread in two dimensions. They included those data point intensities that were most correlated 
with the class and values of the PCs based on data point regions. Many of the data points were 
significantly (p < 0.05) correlated with the class index. 
 
Results and Discussion 
The 1D proton spectra of healthy, H. pylori–related gastritis, AAG and 
adenocarcinoma, acquired by using a presaturation sequence with composite pulse (Bruker 
zgcppr), are reported in Figure 13 (a-d, respectively). The spectra of these samples .show the 
presence of the resonances deriving from small metabolites and macromolecules with short 
T2, but not so short to be MRS invisible. The profiles of the spectra in Figure 13a and 13b 
were quite similar, both displaying broad and narrow signals. The broad signals were due to 
lipids and macromolecules (MM). A progressive increase of fatty acids (FA) esterified in 
triglycerides (TG) passing from healthy tissue and H. pylori-related gastritis to AAG (Figure 
13c), and adenocarcinoma (Figure 13d), was observed. In particular, the spectra of all the 
adenocarcinoma specimens analyzed, showed the exclusive presence of TG. 
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Figure 13. Proton HR-MAS MR spectra of: (a) healthy, (b) H. pylori- related gastritis, (c) AAG and (d) 
adenocarcinoma. * TG glyceryl residues, FA fatty acids chains. 
 
Spectra acquired using a CPMG spin-echo sequence demonstrated the contribution 
due to mobile small molecules. The analysis of these spectra permitted a direct identification 
of a lot of metabolites (27,28) and their differences in percentage were obtained by the 
inspection of CPMG spectra reported in Figure 14a-d. The spectrum representative of H. 
pylori-related gastritis (Figure 2b) was very similar to that of the healthy gastric mucosa 
(Figure 14a). 
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Figure 14. CPMG MR spectra of: (a) healthy, (b) H. pylori-related gastritis, (c) AAG and (d) adenocarcinoma. 
 
The relative concentration of choline-containing compounds (ChoCC) and creatine (Cr) 
measured by the ChoCC/Cr ratio and the distribution of ChoCC [glycerophosphorylcoline 
(GPC), phoshorylcholine (PC) and free choline (Cho)], were similar. PC was the most 
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abundant in both situations. A slight increase of aliphatic aminoacids, valine (Val), leucine 
(Leu), isoleucine (Ile) at around 1.0 ppm, and Ala at 1.48 ppm, was revealed. The spectrum of 
AAG (Figure 2c) was instead characterized by enhanced resonances due to Val and Ala. In 
addition, strong signals due to Gly and free Cho could be detected along with the marked 
reduction of PC. The spectrum of the adenocarcinoma (Figure 14d) displayed a dramatic 
increase of free Cho, accompanied by very low amounts of GPC and PC and high amounts of 
Gly and Ala.  
 A progressive increase of free Cho, Gly and Ala, as already seen for TG, was observed 
passing from healthy tissue and H. pylori-related gastritis to AAG and adenocarcinoma 
(Figure 13). The behaviour of ChoCC and Gly is better shown in figure 15, reporting an 
enlarged region between 3.6 and 3.0 ppm of CPMG MR spectra of healthy gastric mucosa 
(Figure 15a), H. pylori-related gastritis (Figure 15b), AAG (Figure 15c) and adenocarcinoma 
(Figure 15d). 
 
Figure 15. Enlarged region (3.6 ÷ 3.0 ppm) of CPMG MR spectra of: (a) healthy, (b) H. pylori-related gastritis, 
(c) AAG, (d) adenocarcinoma. 
 
 Neoplasms of Gastrointestinal Tract 
 
145 
 
Diffusion-edited spectra (Figure 16a-d) were acquired in order to observe components 
with low diffusion rates deriving from lipids, carbohydrates and small proteins. The profile of 
the spectra 4a and 4b were very similar and characterized by phospholipids (Ph), MM, 
oligopeptides and polysaccharides. The Ph were identified, in particular, by the resonances of 
N+(CH3)3 at 3.23 ppm (1H MR spectra) and 54.8 ppm (13C MR spectra) for 
phosphatidylcholine (Ptd-Cho). The remaining signals arose mainly from mobile peptidic 
residues and polysaccharides. The peptidic residues were recognizable by the broad signals 
around 4.30 ppm relative to the CH-α of bounded aminoacids, by the signals at 3.0 and 1.7 
ppm for lysine (Lys), at 2.30 for glutamate (Glu), and they all contributed, with Ph, to the 
signals between 1.5 and 0.8 ppm (28). The broad signals between 3.5-4.0 ppm and the intense 
signal at 2.02 ppm suggested the presence of N-acetylated polysaccharides referable to mucin 
mucopolysaccharides.  
 
Figure 16. Diffusion-edited MR spectra of: (a) healthy, (b) H. pylori-related gastritis, (c) AAG, (d) 
adenocarcinoma. * TG glyceryl residues. 
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The spectrum in Figure 16c showed an increased amount of the components due to 
TG, signalling the molecular evolution of gastritis towards adenocarcinoma, characterized by 
the almost exclusive presence of TG (Figure 16d). The analysis of the spectrum showed that 
the TG were formed by saturated, mono- and poly-unsaturated FA. The unsaturated acids 
were identified by the signals at 5.33 ppm, assigned to the ethylenic protons, and by the 
signals at 2.02 ppm, due to the methylenic protons of the -CH2-CH= moiety of mono- and 
poly-unsaturated FA. 
The ex vivo 1H HR-MAS spectra (not shown) of the 9 specimens collected from the 
margin towards the core of a large adenocarcinoma sample, were all coincident and 
corresponded to those reported in Figures 13d and 13d. The only detectable resonances in all 
of these spectra were referable to TG. 
The factor score plots PC1 versus PC2 and PC2 versus PC3 showed that there were clear 
differences (p < 0.05) between adenocarcinoma and healthy samples, H. pylori-related 
gastritis and AAG, but not between healthy and H. pylori-related gastritis samples (Figure 
17).  
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Figure 17. a) PC1 vs. PC2 and b) PC2 vs. PC3 score plots: clusters of adenocarcinoma vs. healthy and H. pylori-
related gastritis samples. (○): adenocarcinoma, (◊) H. pylori-related gastritis and AAG, (+) healthy mucosa 
samples. 
 
The TG, previously shown in AAG and adenocarcinoma samples by HR-MAS NMR, 
were detected as lipid bodies in gastric mucosa cells examined by TEM and SEM, but they 
were not visible in the light microscope (LM). AAG samples, by TEM, showed the presence 
of lipid vescicles, diffuse atrophy of parietal cell mass, disappearance of cell-cell contacts, 
cell shrinkage, mithocondria alteration, degradation of plasma and nuclear membranes. By 
SEM these lipid granules appeared quite often as grape-like shape (Figure 18a). All 
adenocarcinoma specimens by LM showed a low differentiated intestinal type characterized 
by cohesive neoplastic cells forming gland-like tubular structures in which cell cohesions 
were absent and in particular, no lipid granules were detected. Using TEM, a large number of 
globular structures in the cytoplasm were seen like those observed in the AAG samples. These 
lipid vesicles appeared well delimited and surrounded by a membrane-like layer and were 
mostly visible near the nuclei in most of the tumour cells (Figure 18b). Lipid vesicles, with a 
diameter ranging from 0.2 to about 1.5 µm were also revealed in tumour cells observed in the 
SEM (Figure 18c) but not were detected in the healthy samples.  
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a) 
b) 
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Figure 18. (a) TEM: ultrathin section of adenocarcinoma. Presence of intracellular electron dense globular 
bodies in the cytoplasm which could be identified as lipid bodies due to their osmiophilic nature. Scale bar = 
0.95; (b) SEM: AAG. Globular lipid bodies singly or in clusters are visible. Scale bar = 1µm; (c) SEM: 
adenocarcinoma. Globular lipid bodies singly or aggregated are visible. Scale bar = 10µm. 
 
Cancer exhibits a significant altered choline phospholipid metabolism compared with 
normal tissue (29). An increase of PC and ChoCC characterizes the aberrant choline 
phospholipid metabolism in cancers, as demonstrated by NMR studies (30,31). 
This research confirms the previous data reporting that free Cho is the most abundant ChoCC 
metabolite in gastric adenocarcinomas. To our knowledge this is the first study reporting a 
strong elevation of free Cho in the AAG, when compared with H. pylori-related gastritis and 
healthy gastric mucosa. The complex Kennedy network, characterized by biosynthetic and 
breakdown pathways, regulates the choline phospholipid metabolism in which more enzymes 
lead changes in the overall choline metabolite profiles. The unexpected, high free Cho amount 
detected in the AAG and adenocarcinoma, led us to believe that the role of 
phosphatidylcholine specific phospholipase D (PC-PLD), which catalyses the hydrolysis of 
Ptd-Cho to free Cho and Phosphatidic acid (PA), is preminent in the development and 
progression of the gastric cancer. Indeed, PC-PLD has been implicated in cell proliferation 
and cancer (32). Its increased activity and expression has been reported in several human 
neoplasms (33-35), including gastric adenocarcinoma (36) where PC-PLD plays an important 
role in the promotion of cancer. These data could explain the high level of free Cho detected 
in the gastric adenocarcinoma samples examined. In addition, the formation of Cho and PA, 
c) 
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may be important in the molecular pathway of the gastric carcinogenesis, since these 
compounds are lipid derived second messengers involved in mitogenic signaling pathway 
(37). AAG, characterized also by a high level of free Cho, is evolving towards a pre-
neoplastic condition and probably the high free Cho amount detected in gastric 
adenocarcinoma, is due to the synthesis of new cell membranes in the neoplastic cells. Further 
studies are needed to evaluate the activity and expression of the enzimatic pattern, associated 
to the synthesis and breakdown of membrane Ptd-Cho in these tissues. 
The high amount of Gly we detected in gastric adenocarcinoma, has been already 
demonstrated in different human tumors. For example, Griffin and Shockor (38) suggested 
that a preeminent glycolytic pathway in cancer cells is responsible for the Gly increase and 
Finch et al. (39) showed an elevation of the level of the lactic dehydrogenase in AAG gastric 
wash samples. Moreover, other authors reported high level of Gly in glioblastomas, renal and 
breast tumors (18,21,22). Hypoxia could explain the high amount of Gly in gastric 
adenocarcinoma. A significant decrease in Gly, was detected in Hypoxia-Inducible Factor-1β 
(HIF-1β) deficient hepatomas (40). On the other hand, it is well known hypoxia in humans 
causes an up-regulation of different genes by activation of the Hypoxia-Inducible Factor-1α 
(HIF-1α) which has been demonstrated over-expressed in gastric cancer (41-43). In a similar 
way, a gastric cell line study has showed that reactive oxygen species, produced by H. pylori 
infection, lead to an increase of HIF1-α (44). 
The Ala relative concentration was another peculiarity which differentiated AAG and 
adenocarcinoma samples from the healthy and H. pylori-related gastritis. Ala increase has 
been associated with different tumor types (38,45,46). Ala, in conjunction with lactate, 
increases in tissues during hypoxia, in fact, it is formed by pyruvate transamination to prevent 
further increase in lactate. Ben Yoseph et al. (47) showed a strong increase of lactate in mild 
hypoxia, while Ala increased in severe hypoxia. We hypothesize that the Ala increase in the 
AAG and adenocarcinoma samples, is related to a severe hypoxia conditions and could be a 
marker for new real-time metabolic molecular imaging for cancer diagnosis (48). 
Ex vivo and in vivo MRS of most cancers are characterized by signals assigned to FA 
lipid mobile acyl chains. The appearance of mobile lipids in the spectra of intact cells is 
generally attributed to the formation of non-bilayer lipid structures, occurring either at the 
plasma membrane level  or within cytoplasmic compartments (12,49). The resonances typical 
of mobile lipids, identified as TG, were detected in all the ex vivo 1H HR-MAS MR spectra 
relative to AAG and adenocarcinoma, where the distribution of the mobile lipids appeared to 
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be homogeneous. The intra-and extra-cellular lipid accumulation and mitochondria 
degeneration, revealed by TEM and SEM, are probably associated to a severe perinecrotic 
hypoxia in AAG and adenocarcinoma samples. Our data are supported by Goto et al. (50) 
who demonstrated that the cytoplasmic accumulation of TG in human fibrosarcoma cells 
occurred in response to hypoxic conditions, and that mitochondria degeneration were 
probably caused by the reduction of β-oxidation of FA. A similar hypothesis was previously 
asserted by Freitas, who described lipid accumulation as a consequence of mitochondria 
degeneration in malignant solid tumors (51,52). Zoula et al. correlated lipid droplets in C6 rat 
brain glioma to a severe prenecrotic hypoxia (17). We suppose that the harmful effect of the 
increase of free FA concentration in gastric adenocarcima could be avoided by sequestring FA 
as TG in form of lipid droplets. 
In conclusion, ex vivo HR-MAS MRS has been shown to be feasible even for small 
endoscopic biopsies and allows identification of Gly, Ala, Cho and TG, as the possible 
biochemical mediators for human gastric mucosa differentiation towards neoplastic 
conditions. Further studies on the enzymatic pathways of these metabolites will be useful. 
Moreover, the biochemical information obtained on gastric pathological tissue could represent 
the basis for clinical applications of in vivo MRS, which reliability is based on the 
identification of molecular markers. 
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COLON TISSUE 
 
Colorectal cancer (CRC) is the fourth most common cancer and the second leading 
cause of cancer death in the United States with high morbidity and mortality. Currently, there 
are four tests for the early detection of CRC, including fecal occult blood testing (FOBT), 
sigmoidoscopy (SIG), colonoscopy (COL), and double contrast barium enema (DCBE) (1–3). 
The strongest evidence for a mortality reduction comes from three randomized controlled 
trials of FOBT (4–6), whereas three case-control studies have demonstrated support for SIG 
in reducing CRC mortality (7–9). Although the ability of COL to reduce mortality has not 
been determined from clinical trials, there is evidence to support the effectiveness of 
screening COL in reducing incidence and mortality (10 –12). 
The recommendations of the American Cancer Society (ACS) have been shown to be 
those most widely recognized by primary care physicians (13). Currently, for CRC screening, 
the ACS recommends one of the following screening options: (a) annual FOBT by 3-day kit; 
(b) SIG every 5 years; (c) a combination of an annual FOBT plus SIG every 5 years; (d) a 
DCBE every 5–10 years; or (e) a COL every 10 years (2).  
Complete “conventional” staging concepts require additional imaging procedures to 
assess potential metastatic spread to lymph nodes and solid organs (14-17). Of these 
conventional imaging procedures, contrast-enhanced computed tomography (CT) is the most 
common for both the abdomen and the thorax (16, 18-23). However, CT offers only 
morphological data for the evaluation of the tumor stage. Glucose analog [18F]-
fluorodeoxyglucose-positron emission tomography (FDG-PET) can display functional 
information and has been found to be accurate in the detection of colorectal cancer and its 
distant metastases (24-29). Furthermore, based on its limited spatial resolution, FDGPET 
often makes difficult exact anatomical localization of the lesion. The combination of PET/CT 
scanners have been introduced into clinical practice because of their ability in detecting and 
characterizing malignant lesions, with advantages over morphology and function alone. The 
fusion of functional with morphological data, beneficial for the tumor staging, have been 
documented for different tumors including colorectal cancer (30-35). The stepwise 
multimodality diagnostic workup could be shortened by performing PET/CT colonography, 
as a whole-body imaging procedure. PET/CT protocols might not be specific enough to 
evaluate all clinically important aspects of the cancer entity (36-37). 
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The study of colon cancer by HR-MAS NMR has not been reported yet but to our 
knowledge, there is only one paper on the variation of the metabolic profile of healthy human 
gastrointestinal tract (GIT) (38). 
We report a study on the ex vivo HR-MAS NMR of healthy and neoplastic colon tissues in 
combination with multivariate methods Principal Component Analysis (PCA) and Partial 
Least Squares Discriminant Analysis (PLS-DA). In particular PCA has been carried out as 
explorative analysis in order to obtain an overview on the whole data set without forcing any 
model and to extract relevant information. PLS-DA (39) has been used to build a 
classification model able to separate the classes of healthy and neoplastic human tissues on 
the basis of their ex vivo HR-MAS NMR spectra. Moreover, the biochemical data obtained on 
colorectal pathological tissue could represent the basis for accurate and non invasive clinical 
applications of in vivo MRS, which reliability is based on the identification of molecular 
markers. 
 
Sample collection. Samples of 23 patients, 14 with colon cancer (7 male, range 52-78 
years; and 7 women, range 48-90 years, and 9 healthy (9 male, range 30-86 years) were 
evaluated. Five biopsies, 4 for histologic evaluation and 1 for NMR analysis, were taken from 
each subject during endoscopy. The specimens (biopsies and surgical samples) in patients 
with colocancer were obtained exclusively from the carcinoma site, assuring the absence of 
any contaminants. Moreover, during surgery we also collected specimens at least 15 cm far 
from the adenocarcinoma, from the 14 colon cancer patients. The tissue samples were put in 
liquid nitrogen, after surgery, and stored at -80° C until MRS analyses.  
Histologic evaluation. Four specimens from each patient fixed routinely with 10% buffered 
formalin and embedded in paraffin, after which the entire tumor was cut into serial 2- to 3-
mm thick slices. Microscopic examination of hematoxylin and eosin-stained sections was 
performed by one pathologist unaware of other features of the case. Adenocarcinomas were 
classified as well (D), mild (MD) and poorly differentiated (PD). According to previously 
proposed measuring methods (40,41), the depth of submucosal invasion was determined using 
a micrometer under a microscope, and taken as the distance from the muscularis mucosae to 
the point of the deepest invasion (tumor apex). Demographic and histological data are 
reported in Table II. 
 
For NMR experiments details see chapter II. 
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Table II. Demographic and histological data. 
 
Age Sex Type Histology 
Control subjects 60.89 ± 8.64 3 male normal Normal 
Adenocarcinomas 63.33 ± 9.22 6 male Adenocarcinomas 1D, 8MD, 2PD  
 
Data handling and pretreatment. HR-MAS 1H NMR data (normal 1H sequence with 
water-presaturation) were processed by using the Bruker software, applying 0.5 Hz line 
broadening prior to Fourier transformation, then phased and baseline corrected (polynomial of 
order 6). The spectra, acquired for 31 samples of colon human tissues, are referenced to the 
chemical shift of the CH3 peak of alanine at δ 1.48 ppm.  
The NMR data points were reduced from 32k to 16k. The selected spectral width 
spans from δ 9.05 ppm to δ 0.05 ppm and the number of data points is 7500. The regions 
corresponding to water and PEG signals between δ 5.03-4.69 ppm and δ 3.75-3.68 ppm, 
respectively, were removed (6341 final data points), since these are regions of high variance 
that is mainly due to sample acquisition/manipulation and it is not interesting from the point 
of view of healthy-canceregenous tissues discrimination.  
As is well known, pre-treatment of data is a critical and case dependent issue in 
multivariate analyses, above all as far as NMR spectra are concerned. In this study, several 
preprocessing were tested and the best performance was obtained by normalizing each 
spectrum to the sum of the intensity data. As far as scaling is concerned, working with 
unscaled data seems preferable, since in this case there is the risk of dramatically up-
weighting components present in very small amounts and showing little variation (such as 
spectral background or baseline). However, given the presence of major and minor 
constituents, it is desiderable to give to different compounds a comparable influence in the 
data analysis. Taking into account this consideration, the data set was scaled using the block-
scaling procedure called “block-adjusted non-scaled data (42). In particular, NMR spectra 
signals were divided in different regions (blocks) whose values were scaled in order to attain 
the same block-variance after pretreatment. In Figure 1, the block regions (figure 1a) and the 
pretreated signals (figure 1b) were reported, respectively.  
As a first explorative tool, PCA was carried out on a data set organised as a 
bidimensional matrix of 31 (human colon samples) x 6341 points (ppm). Four samples seem 
to behave as outliers from PCA: samples c15 and c15t were not acquired with water-
presaturation and samples c17 and c17t, that showed an higher signal at 2.0 ppm (not present 
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in the other samples); hence they were excluded. Thus, these samples were excluded and PCA 
and PLS–DA analyses were carried out on the reduced data array of dimension 27 samples (9 
healthy, 9 neoplastic and 9 peritumoral tissues) x 6341 points, i.e. δ 9.05 -δ 0.05 ppm. The 
PCA and PLS –DA analyses were carried out on the reduced data array of dimension 27 
samples (9 healthy, 9 neoplastic and 9 peritumoral tissues) x 6341 points, i.e. δ 9.05 -δ 0.05 
ppm. Six spectra acquired on 3 different patients tissues (3 spectra belonging to neoplastic and 
3 to peritumoral section of colon region, respectively) were used as a test-set in order to 
validate and to test the performance of the different models. 
PCA and PLS-DA analyses was carried out by using PLS-Toolbox 4.1 for 
MATLAB© (distributed by Eigenvector Research, WA, USA).  
 
 
Figure 1. (a) Raw NMR spectra. The vertical line highlights the four regions selected for performing the block-
scaling pre-treatment; (b) the corresponding ‘blockscaled’ signals. 
 
Result and discussion 
Representative 1D ex vivo HR-MAS 1H NMR spectra of healthy colon tissues are 
shown in Figure 2: trace 2a displays a conventional 1D 1H HR-MAS spectrum with water 
presaturation. The spectrum highlights both narrow and broad signals, which can be separated 
by using a CPMG spin-echo (trace 2b) and a diffusion-edited sequence (trace 2c). The spin-
echo spectrum displays signals due to the resonances of small metabolites, whereas the 
diffusion-edited spectrum shows contributions from mobile lipids and macromolecules (MM).  
The assignment of metabolites derives not only from the analysis of 1D 1H NMR 
spectra, but also from that of selected 2D experiments such as COSY, TOCSY and HSQC, 
a) b) 
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and was confirmed by comparison with literature data. COSY and TOCSY spectra are very 
effective for the identification of hidden resonances: COSY spectra enable coupled proton-
proton pairs to be found, whereas the TOCSY spectra permit 1H,1H connectivities up to five 
or six bonds and metabolite spin systems to be identified. HSQC spectra reveal directly 
bonded carbon-proton pairs, thus enabling the assignment of singlets (which do not give 
correlations in homonuclear COSY and TOCSY spectra), and the discrimination among 
compounds having similar proton but diverse 13C chemical shifts. The full experiments 
provide complete and unambiguous identification of the metabolic pattern characterizing the 
examined tissues.  
The TOCSY spectrum of a specimen obtained at least 15 cm far from a well 
differenziated adenocarcinoma with the deepest submucosal invasion (identified as 4h in 
figure 4) is reported as an example in figure 3. This experiment permits to detect hidden 
resonances, such as those of Lys, Arg, PE, and those due to bonded aminoacids (-Ala-, and -
Thr-), to discriminate the resonances at 3.78 ppm due to the α-CH protons belonging to 
different α amino acids, and to distinguish PC, GPC and Cho.  
The identification of metabolites can be improved exploiting the 13C chemical shift 
dispersion in the second dimension of a HSQC experiment. The HSQC spectrum (Figure 5) 
permits to differentiate between free and bonded amino acids, (-Ala- , -Thr-, -Glu-, and –
αCH-), between free glycerol and glycerol in lipids, and to better evidence signals due to 
proline (Pro). 
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Figure 2. Representative ex vivo HR-MAS 1H NMR spectra of colon biopsies: a) water-presaturated pulse 
sequence with composite pulse, b) CPMG spectrum and c) diffusion-edited spectrum. (*) Signal at 3.72 ppm due 
to PEG, an exogenous compound used as an excipient in pharmaceutical preparations before biopsies or surgery, 
is present in different amount in some samples. 
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Figure 3: TOCSY spectrum of a colon specimens obtained at least 15 cm far from the adenocarcinoma 
(identified as 4h in figure 4). 
 
The CPMG spectra of the healthy colon tissues permit to identify amino acids (Ala, 
Val, Leu , Ile, Glu and Lys), osmolites (Lac, Tau, Cr and ChoCC) and polyols (Myo and Scy). 
By inspection of the diffusion-edited spectra it is possible to assign resonances mainly due to 
fatty acid chains and to glycerol in triglycerides, but also to macromolecules, as already 
observed in other tissues (43). The main metabolites, characterizing the colorectal tissues are 
labeled in Figure 2 and the pool of metabolites especially osmolites, free amino acids and 
mobile lipids are reported in Table I. 
The NMR spectra obtained, applying the same experimental set to neoplastic and 
peritumoral tissues, present different metabolic profiles with respect to the healthy ones. 
Furthermore, different metabolic profiles are also detected for the same tumour subtypes. As 
an example, we report in figure 4 (left), the spectra of two adenocarcinoma subtypes. The 
spectra 4a and 4b derive from two patients affected by well differenziated adenocarcinoma 
with the deepest submucosal invasion, whereas 4c and 4d are from two patients affected by 
undifferenziated adenocarcinoma with the deepest submucosal invasion.  
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Figure 4. HR-MAS 1H NMR water presaturated spectra of some colon biopsies: a) and b) well differenziated 
adenocarcinomas with the deepest submucosal invasion from two different patients; c) and d) undifferenziated 
adenocarcinomas with the deepest submucosal invasion from two different patients. e-h) tissue specimens 
obtained at least 15 cm far from the adenocarcinoma from the same patients.  
 
The spectrum 4a (well differenziated adenocarcinoma with the deepest submucosal 
invasion) is characterized by a predominant amount of lipids, in particular triglycerides, 
whereas 4b well differenziated adenocarcinoma with the deepest submucosal invasion) and 4c 
(undifferenziated adenocarcinoma with the deepest submucosal invasion) reveal, besides the 
presence of lipids, that of metabolites. The 4d (undifferenziated adenocarcinoma with the 
deepest submucosal invasion) spectrum evidences the presence of metabolites and 
macromolecules, and the absence of lipids.  
The spectra of the specimens obtained at least 15 cm far from the adenocarcinoma of 
the same patients, collected during surgery, are reported in Figure 4e-f (right). The inspection 
of the these spectra suggest that there is a great variability also among these samples. Even 
though the samples (e, f, g, h) are classified as healthy by the histological analysis, the NMR 
spectra reveal that metabolic profiles are quite different. Moreover, the comparison with the 
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corresponding neoplastic tissues does not reveal any systematic difference. In fact, spectrum 
4e (classified as healthy) is quite similar to 4a (neoplastic), 4f and 4h (both classified as 
healthy) display an increased amount of triglycerides in different percentage with respect to 
4b and 4d (neoplastic), whereas 4g (classified as healthy) shows the absences of triglycerides, 
in contrast to the other samples obtained at least 15 cm far from the adenocarcinoma.  
 Since the NMR spectra display variations in the metabolic profile not only for 
neoplastic tissues with different histological diagnosis, but also for those classified identical 
from the histological analysis, we conclude that the family of colon carcinoma is 
characterized at a certain degree by metabolic heterogeneity, also within the same subclass of 
tumours. As a consequence, a statistical multivariate approach to the analysis of HR-MAS 
NMR data is vital in order to find metabolic markers of the healthy and the neoplastic state of 
colorectal tissues, and to correctly classify the samples. 
 
      
Figure 5. a) and b) partial region of 1H,13C-HSQC NMR spectrum of colon specimens obtained at least 15 cm 
far from the adenocarcinoma. The identified metabolites are labelled according to Table I. 
In order to extract as more information as possible by considering all the source of 
variability, i.e. healthy and tumoral tissues of all HR-MAS NMR spectra, PCA was performed 
on a pretreated data set.  
PCA were carried out on zgcppr spectra acquired because these highlight both narrow 
and broad signals due to small metabolites and lipid plus macromolecules, respectively. 
The PCA model was built by using 5 principal components (PC) according to venetian blinds 
cross-validation criterion. The performance of the model in terms of explained variance and 
root mean square error in cross validation is reported in Table III. 
 
a) b) 
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Table III. PCA results: PCs; number of components used; R2 percentage of explained X-variance by 
the model; R2cv percentage of of explained X-variance in cross validation. 
 
PCs R2fit R2cv 
5 88.06 74.88 
 
Despite the applied pretreatments, the variability captured by the first two components 
(PC1 and PC2) is mainly due to lipids and macromolecules. By looking at PC1 vs PC2 scores 
plot, it is not present any discrimination among the samples on the basis of healthy cancer 
categories. On the contrary, a partial discrimination among the samples belonging to the 
different categories, could be provided by the analysis of the scores  plots of PC3 vs PC4 vs 
PC5 (Figure 6). 
 
 
 
 
In the scores plot of PC3 vs. PC4 vs. PC5 (Figure 6), it is possible to individuate two 
different groups: the first group includes the healthy samples, the second one includes the 
Figure 6. Scores plot of PC3 vs. PC4 vs. PC5. healthy samples, adenocarcinomas,  macroscopically 
normal colon specimens obtained at least 15 cm far from the adenocarcinoma, and  test set samples 
(unknown samples). The number indicates the samples, and t indicates the tumoral samples. 
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neoplastic and colon specimens obtained at least 15 cm far from the adenocarcinoma. 
Furthermore, the healthy samples seem to be mainly discriminated for negative values of PC3 
and positive values of PC4 and PC5. Although c3, c8 and c9 samples belong to the first 
group, they lie far away from it, above all for negative values of PC4. Within neoplastic and 
specimens obtained at least 15 cm far from the adenocarcinoma groups, all the samples are 
very close except for the c13t, which locates in the healthy group. As far as unknown samples 
is concerned, they are correctly predicted by the model as not healthy samples. In fact they are 
particularly close to the second group. 
In Figure 7 are reported respectively a zoom of the loadings plot of PC3, PC4 and PC5 
vs. the ppm region between 5.5 and 0.5 ppm, that show the highest absolute loadings values. 
The combined inspection of both scores and loadings plots (Figures 6 and 7) shows that the 
metabolic profile of healthy samples (negative PC3 score values and positive PC4 ones) 
seems to be characterized by a low contribution of lipids (positive PC3 loadings), a high 
percentage of sugars, such as Myo, Scy, Glc and -Glc- (positive PC4 loadings), and of Cr. 
As far as neoplastic and specimens obtained at least 15 cm far from the adenocarcinoma 
tissues are concerned, they are characterized by an high amount of lipids (positive PC3 
loadings values) and by a discrete presence of PC (phosphorilcholine) (negative PC4 loading 
values). Furthermore, the high contribution of these compounds seem to be the main 
responsible of c3, c8 and c9 sample’s (healthy tissue) discrimination from their belonging 
group.  
Finally, the loadings plot of PC3 confirms the high presence of the Ac moiety (high 
loadings values) in the neoplatic samples (in particular in c14t sample). The c3 sample is 
outlier, because it shows a higher amount of lipids and PC with respect to the healthy ones 
and a lower amount of Ac with respect to the tumoral ones.  
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Figure 7. PC3, PC4 and PC5 loadings plots, respectively. The abscissa has been represented in ppm in order to 
better individuate the metabolites resonance.  
 
By applying PLS-DA, a model describing the maximum possible separation of 
predefined classes is obtained. The validation step is used to predict the class of the test 
samples and compare these predictions to the known classes. A PLS-DA model has been built 
using the NMR data as the dependent X-variables and class information as the Y-variables, 
i.e. 9 healthy samples as class 1, and the 9 adenocarcinomas ones as class 2. Then, the 9 
specimens obtained at least 15 cm far from the adenocarcinoma and the 6 unknown samples 
were used as test samples . 
Determination of the optimal number of PLS latent variables was done by venetian 
blind cross-validation, using 6 numbers of data splits. Three latent variables was determined 
to be optimal. The total explained variation for the Y matrix was 82.50%. It can be also useful 
to known that a sample does not belong to any of the predefined classes.  
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In figure 8, the results for the three latent variables PLS-DA model are shown for the 
prediction of the “healthy” class of the colon tissues. The calculated threshold between groups 
is shown as the horizontal dashed line. This threshold, is estimated by using the Bayes 
Theorem (PLS toolbox 4.0; Barry M. Wise, Neal B. Gallagher, Rasmus Bro, Jeremy 
M.Shaver, Willem Winding, R. Scott Koch. Eingenvector research incorporated) and it is 
obtained by minimizing the total classification errors for the training set samples. All healthly 
samples are correctly assigned, of nine samples belonging to the neoplastic class, eight are 
correctly assigned and one of them is predicted as a border line case.  
 Furthermore, to assess the behaviour of the model in estimating future samples, its 
performance was  evaluated in cross validation too (figure 9). In Figure 9, five samples were 
misclassified, two belonging to healthy class (c8 and c9) and three to the tumorals (c13t, c14t 
and 10t) class, however c10t is just on the threshold value. 
 
Figure 8. PLS-DA 3 latent variables. healthy samples, adenocarcinomas,  macroscopically 
normal colon specimens obtained at least 15 cm far from the adenocarcinoma, and unknown samples. 
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Figure 9: PLS-DA results in cross validation, 3 latent variables model for the healthy class. healthy samples, 
adenocarcinomas. 
 
As far as test samples are concerned all unknown samples are correctly assigned to the 
adenocarcinomas tissues class. Macroscopically normal colon specimens obtained at least 15 
cm far from the adenocarcinoma tissues are also assigned to the adenocarcinomas tissues 
(their predicted values are below the threshold value), it can be noticed that in general they 
have y-values higher, i.e. towards the direction of the healthy class, than their corresponding 
tumoral tissues, e.g. c16, c18, c20 and c21 with respect to c16t, c18t, c20t and c21t. This 
confirms what observed from the NMR spectra that these colon specimens obtained at least 
15 cm far from the adenocarcinoma share some feature of both classes but being more similar 
to the tumoral one. 
In order to identify the metabolites which mainly contribute to the achievement of 
good prediction or which influence the given model, the pseudo regression coefficients plot 
(Figure 10a), corresponding to the characterization of healthy samples, was reported together, 
for efficacy of discussion, with representative NMR spectra for healthy (Figure 10b) and 
tumoral (Figure 10c) samples, respectively.  
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Figure 10. a) PLS-DA regression coefficient vs. ppm. NMR spectra of b) healthy and c) neoplastic colon tissues, 
respectively. 
 
In figure 10a, the magnitude of loadings values  is directly correlated with their 
influences in the prediction ability of the model, the loadings sign is related to the class 
discrimination: positive loadings values are associated with high y-values and hence healthly 
class and viceversa for negative loadings values. In other words, peaks corresponding to a 
positive loading values region indicate a relatively higher intensity of metabolites associated 
with healthy samples in comparison to all other regions.  
Taking into account PCA results, the PLS-DA regression coefficients seem to select the same 
PCA loadings relevant regions. In addition, there is a further contribution of two metabolites 
in the discriminations of healthy and peritumoral classes: Tau (negative PLS-DA coefficients) 
is in low amount in the healthy class, whereas ChoCC (positive PLS-DA coefficients) are in 
high amount, in particular in the samples c8,c9, c10 c13 and c13t. 
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Conclusion. The last two decades have seen many works dealing with the use of 
Nuclear Magnetic Resonance (NMR) spectroscopic studies on healthy and neoplastic 
colorectal cells and tissues (44). These studies were motivated by a desire to refine tumor 
biochemistry with the aim to improve cancer detection, prognosis and categorization. The 
potential of in vitro NMR spectroscopy for grading human colorectal cancer has been 
explored on a set of increasingly tumorigenic cells. Low and highly tumorigenic malignant 
colorectal cell lines have been shown to be differenziated based on lipid, choline and fucose 
resonances (45,46). 1H NMR spectroscopy performed on colorectal tumors and normal 
mucosa biopsies showed elevated taurine levels and reduced polyethyleneglycol absorption in 
neoplasms, which may have diagnostic significances (47). Later NMR studies by the same 
authors demonstrated that significant decreased levels of myo-inositol in colorectal tumors 
can be detected in intact biopsies (40). The study of Lean et al. (49), reported that 1H NMR 
spectral profiles intermediate between normal and malignant situation in histologically normal 
tissue were of particular interest. Based on this spectroscopic datum, they were able to assess 
that NMR spectroscopy is sensitive to pre-malignant metabolic aspect prior to histological 
change. Although excellent spectroscopic data have been obtained from colorectal tissues, in 
vivo NMR studies on humans have not been reported until the recent work of Dzik-Jurasz et 
al. (50). They first demonstrated the feasibility of in vivo 1H-NMR in locally advanced human 
colorectal adenocarcinoma, overcoming complications arising from tissue/air interface, thin 
dimension of the colon, its convoluted shape and peristalsis. 
The NMR spectra of healthy tissues present different metabolic profiles with respect to 
neoplastic and peritumoral one. Furthermore, metabolic variations are detected not only for 
neoplastic tissues with different histological diagnosis, but also for those classified identical 
from the histological analysis. These findings suggest that the family of colon carcinoma is 
characterized at a certain degree by metabolic heterogeneity, also within the same subclass of 
tumours. The statistical multivariate approach applied to the NMR data is vital in order to find 
metabolic markers of the healthy and the neoplastic state of colo-rectal tissues, and to 
correctly classify the samples.  
 
 
 
 Neoplasms of Gastrointestinal Tract 
 
171 
 
References 
1. Pignone M, Rich M, Teutsch SM, Berg AO, Lohr KN. Screening for colorectal cancer in adults at 
average risk: a summary of the evidence for the U.S. Preventive Services Task Force. Ann. Intern. 
Med. 2002; 137: 132–141. 
2. Smith RA, Cokkinides V, von Eschenbach AC, Levin B, Cohen C, Runowicz CD, Sener S, Saslow 
D, Eyre HJ. American Cancer Society guidelines for the early detection of cancer. CA Cancer J. 
Clin. 2002; 52: 8–22. 
3. Ransohoff DF, Sandler RS. Clinical practice. Screening for colorectal cancer. N. Engl. J. Med. 
2002; 346: 40-44. 
4. Mandel JS, Church, TR, Ederer F, Bond J. Colorectal cancer mortality: effectiveness of biennial 
screening for fecal occult blood. J. Natl. Cancer Inst. 199; 91: 434–437. 
5. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, 
Mangham CM. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. 
Lancet 1996, 348: 1472–1477. 
6. Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening 
for colorectal cancer with faecal-occult-blood test. Lancet 1996, 348: 1467–1471. 
7. Newcomb PA, Norfleet RG, Storer BE, Surawicz TS, Marcus PM. Screening sigmoidoscopy and 
colorectal cancer mortality. J. Natl. Cancer Inst. 1993; 85: 1311–1318. 
8. Winawer SJ, Flehinger BJ, Schottenfeld D, Miller DG. Screening for colorectal cancer with fecal 
occult blood testing and sigmoidoscopy. J. Natl. Cancer Inst. 1993; 85: 1311–1318. 
9. Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS. A case-control study of screening 
sigmoidoscopy and mortality from colorectal cancer. N. Engl. J. Med. 1992; 326: 653–657. 
10. Lieberman DA, Weiss DG; Veterans Affairs Cooperative Study Group 380. One-time screening 
for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. 
N. Engl. J. Med. 2001; 345: 555–560. 
11. Anderson WF, Guyton KZ, Hiatt RA, Vernon SW, Levin B, Hawk E. Colorectal cancer screening 
for persons at average risk. J. Natl. Cancer Inst.  2002; 94: 1126–1133. 
12. Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, Ganiats T, Levin T, Woolf S, Johnson 
D, Kirk L, Litin S, Simmang C; Gastrointestinal Consortium Panel. Colorectal cancer screening 
and surveillance: clinical guidelines and rationale-Update based on new evidence. 
Gastroenterology 2003; 124: 544–560. 
13. Klabunde CN, Frame PS, Meadow A, Jones E, Nadel M, Vernon SW. A national survey of 
primary care physicians' colorectal cancer screening recommendations and practices. Prev. Med. 
2003; 36: 352–362. 
14. Byers T, Levin B, Rothenberger D, Dodd GD, Smith RA. American Cancer Society guidelines for 
screening and surveillance for early detection of colorectal polyps and cancer: update 1997. 
 Neoplasms of Gastrointestinal Tract 
 
172 
 
American Cancer Society Detection and Treatment Advisory Group on Colorectal Cancer. CA 
Cancer J. Clin. 1997; 47: 154–161. 
15. Stevenson G. Colorectal cancer imaging: a challenge for radiologists. Radiology. 2000; 214: 615-
621. 
16. Filippone A, Ambrosini R, Fuschi M, Marinelli T, Genovesi D, Bonomo L. Preoperative T and N 
staging of colorectal cancer: accuracy of contrast-enhanced multi-detector row CT colonography--
initial experience. Radiology. 2004; 231: 83-90. 
17. Saunders TH, Mendes Ribeiro HK, Gleeson FV. New techniques for imaging colorectal cancer: 
the use of MRI, PET and radioimmunoscintigraphy for primary staging and follow-up. Br. Med. 
Bull. 2002; 64: 81-99. 
18. European Society for Medical Oncology Web site. http://www.esmo.org. Accessibility verified 
October 24, 2006. 
19. National Comprehensive Cancer Network Web site. http://www.nccn.org. Accessibility verified 
October 24, 2006. 
20. Mulhall BP, Veerappan GR, Jackson JL. Meta-analysis: computed tomographic colonography. 
Ann. Intern. Med. 2005; 142: 635-650. 
21. Bipat S, Glas AS, Slors FJ, Zwinderman AH, Bossuyt PM, Stoker J. Rectal cancer: local staging 
and assessment of lymph node involvement with endoluminal US, CT, and MR imaging--a meta-
analysis. Radiology. 2004; 232: 773-778. 
22. Sosna J, Morrin MM, Kruskal JB, Farrell RJ, Nasser I, Raptopoulos V. Colorectal neoplasms: role 
of intravenous contrast-enhanced CT colonography. Radiology. 2003; 228: 152-156. 
23. Sosna J, Kruskal JB, Bar-Ziv J, Copel L, Sella T. Extracolonic findings at CT colonography. 
Abdom. Imaging 2005; 30: 709-713. 
24. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 
2004; 231: 305-332. 
25. Kantorová I, Lipská L, Bêlohlávek O, Visokai V, Trubaĉ M, Schneiderová M. Routine (18)F-FDG 
PET preoperative staging of colorectal cancer: comparison with conventional staging and its 
impact on treatment decision making. J. Nucl. Med. 2003; 44: 1784-1788. 
26. Valk PE, Abella-Columna E, Haseman MK, Pounds TR, Tesar RD, Myers RW, Greiss HB, Hofer 
GA. Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent 
colorectal cancer. Arch. Surg. 1999; 134: 503-511. 
27. Kalff V, Hicks RJ, Ware RE, Hogg A, Binns D, McKenzie AF. The clinical impact of (18)F-FDG 
PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. 
J. Nucl. Med. 2002; 43: 492-499.  
 Neoplasms of Gastrointestinal Tract 
 
173 
 
28. Abdel-Nabi H, Doerr RJ, Lamonica DM, Cronin VR, Galantowicz PJ, Carbone GM, Spaulding 
MB. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body 
PET: correlation with histopathologic and CT findings. Radiology. 1998; 206: 755-760. 
29. Huebner RH, Park KC, Shepherd JE, Schwimmer J, Czernin J, Phelps ME, Gambhir SS. A meta-
analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J. 
Nucl. Med. 2000; 41: 1177-1189. 
30. Cohade C, Osman M, Leal J, Wahl RL. Direct comparison of (18)F-FDG PET and PET/CT in 
patients with colorectal carcinoma. J. Nucl. Med. 2003; 44: 1797-1803. 
31. Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A, Altman H, Keidar Z, 
Israel O. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic 
imaging and patient management. J. Nucl. Med. 2003; 44: 1200-1210. 
32. Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA. Does the novel PET/CT 
imaging modality impact on the treatment of patients with metastatic colorectal cancer of the 
liver? Ann. Surg. 2004; 240: 1027-1034. 
33. Kamel IR, Cohade C, Neyman E, Fishman EK, Wahl RL. Incremental value of CT in PET/CT of 
patients with colorectal carcinoma. Abdom. Imaging. 2004; 29: 663- 668. 
34. Antoch G, Saoudi N, Kuehl H, Dahmen G, Mueller SP, Beyer T, Bockisch A, Debatin JF, 
Freudenberg LS. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose 
positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in 
solid tumors: comparison with CT and PET. J. Clin. Oncol. 2004; 22: 4357-4368. 
35. Kim JH, Czernin J, Allen-Auerbach MS, Halpern BS, Fueger BJ, Hecht JR, Ratib O, Phelps ME, 
Weber WA. Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for 
restaging of recurrent colorectal cancer. J. Nucl. Med. 2005; 46: 587-595. 
36. Israel O, Yefremov N, Bar-Shalom R, Kagana O, Frenkel A, Keidar Z, Fischer D. PET/CT 
detection of unexpected gastrointestinal foci of 18F-FDG uptake: incidence, localization patterns, 
and clinical significance. J. Nucl. Med. 2005; 46: 758-762. 
37. Gutman F, Alberini JL, Wartski M, Vilain D, Le Stanc E, Sarandi F, Corone C, Tainturier C, 
Pecking AP. Incidental colonic focal lesions detected by FDG PET/CT. Am. J. Roentgenol. 2005; 
185: 495-500. 
38. Wang Y, Holmes E, Comelli EM, Fotopoulos G, Dorta G, Tang H, Rantalainen MJ, Lindon JC, 
Corthésy-Theulaz IE, Fay LB, Kochhar S, Nicholson JK. Topographical variation in metabolic 
signatures of human gastrointestinal biopsies revealed by high-resolution magic-angle spinning 1H 
NMR spectroscopy. J. Proteome Res. 2007; 6: 3944-3951. 
39. Gavaghan CL, Holmes E, Lenz E, Wilson ID, Nicholson JK. An NMR-based metabonomic 
approach to investigate the biochemical consequences of genetic strain differences: application to 
the C57BL10J and Alpk: ApfCD mouse. FEBS Lett. 2000; 484: 169-174. 
 Neoplasms of Gastrointestinal Tract 
 
174 
 
40. Kitajima K, Fujimori T, Fujii S, Takeda J, Ohkura Y, Kawamata H, Kumamoto T, Ishiguro S, 
Kato Y, Shimoda T, Iwashita A, Ajioka Y, Watanabe H, Watanabe T, Muto T, Nagasako K. 
Correlations between lymph node metastasis and depth of submucosal invasion in submucosal 
invasive colorectal carcinoma: a Japanese collaborative study. J. Gastroenterol. 2004; 39: 534-
543. 
41. Ueno H, Mochizuki H, Hashiguchi Y, Shimazaki H, Aida S, Hase K, Matsukuma S, Kanai T, 
Kurihara H, Ozawa K, Yoshimura K, Bekku S. Risk factors for an adverse outcome in early 
invasive colorectal carcinoma. Gastroenterology. 2004; 127: 385-394.  
42. Wold S, Johansson E, Cocchi M. 3D QSAR in drug design: theory, methods, and applications. 
Kubinyi H. (ed), ESCOM Scince Publischer, Leiden, 1993, 523. 
43. Tugnoli V, Schenetti L, Mucci A, Parenti F, Cagnoli R, Righi V, Trinchero A, Nocetti L, Toraci C, 
Mavilla L, Trentini G, Zunarelli E, Tosi MR. Ex vivo HR-MAS MRS of human meningiomas: a 
comparison with in vivo 1H MR spectra. Int. J. Mol. Med. 2006; 18: 859-869. 
44. Smith ICP, Stewart LC. Magnetic resonance spectroscopy in medicine: clinical impact. Prog. 
Nucl. Magn. Reson. Spectrosc. 2002; 40: 1-34. 
45. Lean CL, Mackinnon WB, Delikatny EJ, Whitehead RH, Mountford CE. Cell-surface fucosylation 
and magnetic resonance spectroscopy characterization of human malignant colorectal cells. 
Biochemistry 1992; 20: 306-311. 
46. Mackinnon WB, Huschtscha L, Dent K, Hancock R, Paraskeva C, Mountford CE. Correlation of 
cellular differentiation in human colorectal carcinoma and adenoma cell lines with metabolite 
profiles determined by 1H magnetic resonance spectroscopy. Int. J. Cancer. 1994; 59: 248-261. 
47. Moreno A, Rey M, Montane JM, Alonso J, Arús C. 1H NMR spectroscopy of colon tumors and 
normal mucosal biopsies; elevated taurine levels and reduced polyethyleneglycol absorption in 
tumors may have diagnostic significance. NMR Biomed. 1993; 6: 111-118. 
48. Moreno A, Arús C. Quantitative and qualitative characterization of 1H NMR spectra of colon 
tumors, normal mucosa and their perchloric acid extracts: decreased levels of myo-inositol in 
tumours can be detected in intact biopsies. NMR Biomed. 1996; 9: 33-45. 
49. Lean CL, Newland RC, Ende DA, Bokey EL, Smith IC, Mountford CE. Assessment of human 
colorectal biopsies by 1H MRS: correlation with histopathology. Magn. Reson. Med. 1993; 30: 
525-533. 
50. Dzik-Jurasz AS, Murphy PS, George M, Prock T, Collins DJ, Swift I, Leach MO, Rowland IJ. 
Human rectal adenocarcinoma: demonstration of 1H-MR spectra in vivo at 1.5 T. Magn. Reson. 
Med. 2002; 47: 809-811. 
 
 
 
 
 
 Neoplasms of Gastrointestinal Tract 
 
175 
 
Table I. List of 1H and 13C chemical shift (δ, ppm) of metabolites and exogenous molecules found in HR-
MAS spectra of gastrointestinal mucosaa,b. 
 
entry Metabolite δ 1H δ 13C  Stomach Colon 
Healthy  Neoplastic 
1 Fatty acids 0.89 
1.31 
1.59-1.60 
2.02 
2.24 
2.78 
5.30-5.32 
14.13-14.17 
29.4-32.2 
25.2 
27.8 
34.2 
26.2 
130.2; 128.4 
CH3 
(CH2)n 
CH2CC=O 
CH2C= 
CH2C=O 
=CCH2C= 
CH=CH 
y y y 
2 Isoleucine 0.94 (t) 
1.02(d) 
1.29,1.48 
1.97 
3.69 
11.7 
15.5 
25.1 
 
 
δ-CH3 
γ-CH3 
γ-CH2 
β-CH 
α-CH 
y trace trace 
3 Leucine 0.95(d) 
0.97(d)  
1.70 
1.72 
3.74 
21.5 
22.8 
24.8 
40.4 
δ-CH3 
δ-CH3 
γ-CH 
β-CH2 
α-CH 
y trace y 
4 Valine 0.99(d) 
1.04(d) 
2.25 
3.61 
17.3 
18.7 
 
d 
γ-CH3 
γ-CH3 
β-CH 
α-CH 
y y y 
5 Threonine 1.33(d) 
4.26 
3.60 
20.3 
66.58 
61.22 
γ-CH3 
β-CH 
α-CH 
y trace y 
6 Lactate 1.33(d) 
4.11 
20.3 
69.1 
CH3 
CH 
y y y 
7 Lidocaine 
chlorohydrate 
1.37(t) 
3.37(q) 
2.20(s) 
9.2 
50.6 
17.8 
CH3 
CH2 
2,6-CH3 
y n n 
8 Alanine 1.48(d) 
3.78 
16.8 
51.1 
β-CH3 
α-CH 
y y y 
9 Lysine 3.02(t) 
1.71 
1.48 
1.91 
3.79 
39.9 
27.1 
22.56 
30.6 
c 
ε-CH2 
δ-CH2 
γ-CH2 
β-CH2 
α-CH 
y y y 
10 Arginine 3.23 
1.69 
1.92 
3.78 
41.3 
24.9 
28.1 
c 
δ-CH2 
γ-CH2 
β-CH2 
α-CH 
y n y 
11 Glutamate 2.36(t) 
2.06, 2.14 
3.77 
34.0 
27.9 
c 
γ-CH2 
β-CH2 
α-CH 
y y y 
12 Glutamine 2.44(td) 
2.14 
3.78 
31.5 
27.2 
c 
γ-CH2 
β-CH2 
α-CH 
y trace y 
13 Proline 3.43, 3.34 
2.01 
2.34, 2.07 
4.12 
 δ-CH2 
γ-CH2 
β-CH2 
α-CH 
y n y 
14 Methionine 2.13(s) 
2.62 
2.16 
3.87 
14.9 SCH3 
γ-CH2 
β-CH2 
α-CH 
y y y 
15 Aspartic acid  2.68, 2.82 
3.90 
37.2 β-CH2 
α-CH 
y n y 
16 Asparagine  2.85, 2.96 
4.01 
26.30 β-CH2 
α-CH 
y n trace 
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17 Creatine  3.04(s) 
3.92(s) 
37.5 
54.5 
NCH3 
CH2 
y y y 
18 Tyrosine  3.06, 3.20 
3.93 
6.89 
7.23  
 
56.7 
116.5 
131.5 
β-CH2 
α-CH 
Hortho 
Hmeta 
y y y 
19 Phenylalanine  3.11, 3.28 
3.99 
7.34  
7.43 
7.37 
 
 
130.1 
129.6 
128.2 
β-CH2 
α-CH 
Hortho 
Hmeta  
Hpara 
y y y 
20 Ethanolamine 3.15(t) 
3.82(t) 
42.1 
58.2 
CH2 
CH2 
y trace y 
21 Phosphoryl- 
ethanolamine 
3.23 
4.00 
41.1 
61.1 
CH2 
CH2 
y y y 
22 Glycerophosphoryl- 
ethanolamine 
3.30 
4.10 
 CH2 
CH2 
y y trace 
23 free Choline  3.20 
3.53 
4.08 
54.6 
68.2 
56.5 
N(CH3)3 
NCH2 
OCH2 
y y y 
24 Glycerophosphoryl- 
choline 
3.22 
3.68 
4.33  
54.7 N(CH3)3 
NCH2 
OCH2 
y n y 
25 Phosphorylcholine 3.22 
3.61 
4.22 
54.7 
67.3 
59.0 
N(CH3)3 
NCH2 
OCH2 
y y y 
26 β-Glucose  4.67(d) 
3.26 
3.49 
3.40 
3.47 
e 
96.6 
74.8 
76.8 
69.9 
76.8 
e 
1-CH  
2-CH 
3-CH 
4-CH 
5-CH 
6-CH2 
y y y 
27 Taurine  3.26(t) 
3.42(t) 
48.1 
35.9 
SCH2 
NCH2 
y y y 
28 Myo-inositol  3.53(dd) 
4.06(t) 
3.63(t) 
3.29(t) 
71.8 
72.9 
73.1 
75.0 
1,3-CH 
2-CH 
4,6-CH 
5-CH 
y y y 
29 Scyllo-inositol  3.35 (s) 73.9 CH y y y 
30 α-Glucose  5.24(d) 
3.54 
3.73 
3.42 
e 
 
72.5 
73.8 
70.7 
e 
1-CH  
2-CH 
3-CH 
4-CH 
6-CH2 
y y y 
31 Glycine  3.56 42.3 CH2 y y y 
32 PEG 3.72 69.9  y trace y 
33 Glycerol (in lipids) 4.10, 4.30 
5.26  
 1,3-CH2 
2-CH 
y y y 
34 Glycerol 3.56, 3.65 
3.81 
63.3 
72.7 
1-CH2 
2-CH 
y n y 
35 UDPG 5.92 
4.35 
5.90(d) 
7.89(d) 
 1-CHrib 
2-CHrib 
5-CHur 
6-CHur 
y n y 
36 Uracil 5.80(d) 
7.54(d) 
 5-CHur 
6-CHur 
y n trace 
37 Formiate 8.48   y n y 
38 NADH 8.21   y n n 
39 Tryptophane 7.73 
7.19 
7.29 
7.52 
 4-CH 
5-CH 
6-CH 
7-CH 
y n y 
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40 Adenosine 8.36(s) 
8.23(s) 
 8-CH 
2-CH 
y y y 
41 N-Ac 2.01-2.12 23.0 NC=OCH3 y trace y 
42 Acetate 1.92 24.8 CH3C=O y y y 
43 Hypotaurine 2.65(t) 
3.35(t) 
38.73 
41.19 
CH2 
CH2 
y trace n 
44 UMP 5.98 
4.37 
5.97(d) 
8.11(d) 
 1-CHrib 
2-CHrib 
5-CHur 
6-CHur 
y n trace 
45 αGlc-1-X 5.40 
3.61 
100.2  y n trace 
46 Glutathione 
 
4.57 
2.96 
3.80 
2.16 
2.55 
3.77 
8.57 
8.36 
56.18 
26.3 
 
 
 
44.0 
α-CH-Cys 
β-CH2-Cys 
α-CH-Glu 
β-CH2-Glu 
γ-CH2-Glu 
CH2-Gly 
NH-Cys 
NH-Gly 
trace n n 
47 OH-butyrate 1.18 
4.14 
 CH3 trace y y 
48 Histidine 7.78 (s) 
7.05(s) 
 2-CH 
4-CH 
y y trace 
49 Ascorbate 4.52(d) 
4.01 
 4-CH 
5-CH 
y n y 
50 β-Alanine 2.56 
3.18 
32.14 
40.01 
CH2 
CH2 
y n n 
51 Succinate 2.41(s)  α,β-CH2 trace y y 
52 Bonded Glycerols  3.95-3.70 61.3 1,3-CH2 trace n  
53 Bonded Ala  1.41 
4,32 
17.1 β-CH3 
α-CH 
y n y 
54 Bonded Val 0.93 
2.08 
4.11 
23.0 γ-CH3 
β-CH 
α-CH 
trace n n 
55 Bonded Thr  1.22 
4.24 
4.31 
16.2 γ-CH3 
β-CH 
α-CH 
trace n trace 
56 Cetylpyridinium 5.08 
2.03 
 NCH2 
β-CH2 
trace n n 
57 Unknown 
 
2.44 
3.44 
  y n n 
58 Unknown 1.63 23.5  y n n 
59 Unknown 2.82 s  CH2 n n y 
60 Ethanol 1.18 17.5 CH3 n n y 
a 1H chemical shift are referred to alanine doublet at 1.48 ppm. 
b 13C chemical shift are referred to alanine at 16.8 ppm. 
c C_ probably contributes to the 3.77, 55.1 ppm cross-peak. 
d C_ probably contributes to the 3.61, 61.1 ppm cross-peak. 
e Contribute to the broad correlation between CH2 protons in the region 3.9 _ 3.6 ppm and carbons around 62 ppm in 
HSQC spectra. 
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GENERAL INTRODUCTION 
 
Renal cell carcinoma (RCC) is the sixth leading cause of cancer death. The frequency of 
RCC has constantly increased over the last 50 years, moving from 2-3% of all neoplasms to 
nearly 6% today: it is more frequent in men than in women, and have a higher incidence in the 
age group between 6th and the 7th decade, although onset is non-sporadic at any age (1). 
Specific incidence factors, which would enable the identification of the so-called risk groups, 
are not known. Smoking, obesity and exposure to asbestos, cadmium, vinyl chloride and 
trichloroethylene have been proposed as possible factors (2). Today, more than 50% of cases 
are diagnosed accidentally. Approximately one-third of patients present with disease which is 
already metastatic and for which there is currently no adequate treatment, furthermore no 
biofluid screening tests exist for RCC. The EAU (European Association of Urology) 
guidelines indicate abdominal CT, with or without contrast media, as a standard radiological 
procedure, as it provides an imaging scan of the controlateral kidney, as well as the diagnosis. 
Magnetic Resonance Imaging (MRI) is indicate as an additional diagnostic procedure.  
It is now well established that kidney cancer does not represent a single disease, but 
rather a collection of different types of cancer (3). Five histological types of RCC are seen: 
 Clear Cell (CCC): 60-85% 
 Chromophil (ChL): 7-14% 
 Chromophobic (ChC): 4-10% 
 Oncocytic (ON): 2-5% (benign neoplasm); 
 Collecting duct (CD): 1-2% 
 
According to Fuhrman in 1982, four grades are determined as a function of nuclear 
anaplasia and cell morphology (4). 
The identification of these different types of cancer requires the monitoring of their 
molecular signature and of their alterated metabolic profile.  
In this field, basic MRS studies are needed to elucidate the main metabolic profiles in 
the comparison between healthy and neoplastic kidney. In the urological field, MRS has been 
applied to the study of the biochemical composition of biological fluids (5,6), as well as renal 
tissue metabolism and function (7-10). In previous studies (11,12), were described the 
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biochemical composition of human renal tissues with regards to both aqueous and lipid 
extracts studied by monodimensional low field in vitro MRS. In vitro studies yielded 
information on the marked decrease in renal osmolytes in nephrocarcinomas and on the 
cholesteryl ester content in malignant tumoral tissues.  
Here, a preliminary ex vivo HR-MAS NMR study performed on human renal tumor 
tissue samples taken from five patients at the time of radical nephrectomy is reported. A 
sampling of macroscopically normal renal cortex and medulla from the same kidney was also 
performed. This study is performed in order to differentiate the full metabolic pattern of 
human intact renal cortex, medulla and tumor tissues. 
 
Clinical materials. Specimens were collected from five patients undergoing radical 
nephrectomy for solid renal tumors. The clamping and/or division of the main renal artery 
was performed carefully immediately before collecting the specimens to minimize the warm 
ischemia time. In all cases, sample of normal cortex, normal medulla and tumor were taken. 
Pathology. On microscopy, renal tumors were classified according to the WHO classification 
(13) (28) as clear cell (n=3) and papillary renal cell carcinoma (RCC) (n=2); tumor stage was 
based on TNM staging system (14) and grade was assessed according to the Furhman grading 
system (Table I) (4). 
 
Table I. Patient characteristics. 
Patients Age (years) Tumor size (cm) Histological type Fuhrman grade TNM group stage 
1 76 4 Clear cell RCC G3 pT3a Nx 
2 58 5 Clear cell RCC G3 pT1bN0 
3 77 9 Clear cell RCC G3 pT3bNx 
4 86 4 Papillary RCC G2 pT1aNx 
5 70 10 Papillary RCC G2 pT3aN0 
 
For NMR experimental details see Chapter II 
 
Results and Discuss 
Ex vivo 1D proton HR-MAS NMR spectra obtained from human normal cortex and 
medulla samples are shown in Figure 1 and 2, respectively. The spectra shown in Figure 1a 
and 2a, acquired using a 1D 1H sequence with a water-presaturation, shows the presence of 
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narrow resonances derived from low molecular weight metabolites, and broad resonances 
mainly due to the presence of lipids and oligopeptides. 
 
 
Figure 1. 1D 1H HR MAS spectra of normal human cortex: a) Conventional proton spectrum with water-
presaturation (the broad resonances are assigned to lipids and oligopeptides); b) CPMG spectrum; c) Diffusion-
edited spectrum (the resonance at ~3.22 ppm is assigned to the trimethylammonium residue of 
phosphatidylcholine and the broad resonances are assigned to FA (fatty acids) esterified in TG (triglycerides) 
and Ph (phospholipids) with a lesser contribution of oligopeptides). Cho (free choline), Gly (glycine), GPC 
(glycerophosphorylcholine), myo-Ino (myo-inositol), PC (phosphorylcholine), scyllo-Ino (scyllo-inositol), (Tau) 
taurine. 
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Figure 2. 1D 1H HR MAS spectra of normal human medulla: a) Conventional proton spectrum with water-
presaturation (the broad resonances are assigned to lipids and oligopeptides); b) CPMG spectrum; c) Diffusion-
edited spectrum (the resonance at ~3.22 ppm is assigned to the trimethylammonium residue of 
phosphatidylcholine and the broad resonances are assigned to FA esterified in TG and Ph with a lesser 
contribution of oligopeptides) Bet (glycine-betaine), Cho, Gly, GPC, myo-Ino, PC, scyllo-Ino, Tau. 
 
The HR MAS spectra obtained by using a CPMG sequence are given in Figure 1b and 
2b. The cortex and medulla contain many small molecules with different distributions in the 
two kidney regions. Amino acids are present in higher amounts in the cortical tissue than in 
the medullary. In particular, the cortex is characterized by a high percentage of Gly and Tau, 
while the medulla by glycine-betaine (Bet) and myo-inositol (myo-Ino). Other osmolytes, such 
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as scyllo-inositol (scyllo-Ino) and ChoCC, GPC, PC and Cho, are present in approximately the 
same relative amounts in both kidney tissues. Diffusion-edited spectra, are shown in Figure 1c 
and 2c. The spectra of the cortex and medulla are quite similar and are dominated by the 
signals due to fatty acids (FA) of triglycerides (TG) and phospholipids (Ph), with a lesser 
contribution of oligopeptides. The same analyses were also performed on two different 
subtypes of renal cancer, namely clear cell RCC and papillary RCC. The corresponding 
spectra are shown in Figure 3 and 4, respectively. A marked difference between the two 
spectra is evident: the spectrum of the clear cell RCC displays predominant resonances due to 
lipids, whereas the papillary RCC shows a profile characterized by the presence of a large 
amount of amino acids. The analysis of the CPMG spectra (Figure 3b and 4b) indicate that the 
resonances of myo-Ino, scyllo-Ino and Bet drastically decrease or disappear in both the renal 
neoplasms in comparison with the normal cortex and medulla (Figure 1b and 2b) and show 
that Tau is present in high amounts in papillary RCC (Figure 4b), whereas ChoCC is the 
predominant component in the clear cell RCC (Figure 3b). The diffusion-edited spectra, 
shown in Figure 3c and 4c, further confirm that the neoplastic renal tissues present a different 
metabolic profile. That of the clear cell RCC (Figure 3c), is characterized by the exclusive 
presence of FA esterified in TG and cholesterol (CholE), while that of the papillary RCC 
(Figure 4c) shows weak signals due to bonded amino acids (MM), FA esterified in Ph 
(phosphatidylcholine). 
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Figure 3. 1D 1H NMR spectra of human clear cell renal cell carcinoma: a) Conventional proton spectrum with 
water-presaturation (the broad resonances are assigned to lipids); b) CPMG spectrum; c) Diffusion-edited 
spectrum. 
 
In the biomedical field, in vivo volume-localized proton MRS has been used to assay 
the regional biochemistry in isolated perfused rat kidneys (15). The medullary region spectra 
were characterized by signals of osmolytes such as Bet, GPC and myo-Ino, while the spectra 
of the cortex were more complex and contained fewer osmolytes. In previous studies using 1H 
HR-MAS NMR, a biochemical investigation of ten histologically unclassified human renal 
carcinomas has been reported (16) and a distinction between normal cortex and again 
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histologically unclassified eleven renal carcinoma biopsy samples (including 2 renal 
metastases) has been also published (17). Moreover 1H HRMAS NMR studies on intact rat 
renal cortex and medulla have been performed (18). Previous paper, (11) reported the in vitro 
1H NMR spectra of the two different regions of healthy human kidney, i.e. the cortex and 
medulla and showed that many osmolytes, markers of normal renal function, were present in 
the healthy kidney, with a different distribution between the cortex and medulla. In particular, 
Bet and myo-Ino predominated in the medulla, while tetramethylammonium (TMA) and 
succinate (Suc) were predominant in the cortex. Further it reported that a marked decrease of 
these osmolytes was typical of clear cell RCCs with respect to the histological Fuhrman 
grade. On the contrary, the ChoCC signal intensity remained unchanged, assuming in the 
tumoral sample the significance of a cell proliferation marker. Renal cells under physiological 
conditions are exposed to extracellular NaCl and urea and respond to hypertonic stress by 
accumulating small organic molecules, the so called osmolytes. In the medulla of the 
concentrating kidney, the accumulation of osmolytes, which do not perturb cell function, 
permits the mantainance of normal intracellular concentrations of inorganic electrolytes and 
are thus termed "compatible osmolytes". It has been shown that in the mammalian kidney 
these include the trimethylamines Bet and GPC, the polyols sorbitol (Srb) and myo-Ino, and, 
quantitatively less important, free amino acids and their derivatives (19,20). 
The ex vivo HR-MAS data permitted the evaluation of the different distribution of the 
metabolites in intact specimens of the human kidney cortex and medulla. Tau and Gly are the 
more important markers of the cortical region, whereas Bet, myo-Ino and GPC characterize 
the medulla. In the spectra, there is no evidence of any substantial amounts of Srb detected, in 
contrast to that in intact rat renal medulla (18). The data are in agreement with the findings of 
Schmolke et al. (21) who measured, by liquid chromatography, the osmolyte concentration in 
homogenates of five different human kidney zone from the cortex towards the papillary tips. 
The authors showed that the major osmolytes were myo-Ino, GPC and Bet, whereas Srb was 
detectable in negligible amounts. The spectroscopic data show that both kidney regions 
present signals ascribable to scyllo-Ino and myo-Ino. To our knowledge, the presence of 
scyllo-Ino has not yet been reported in normal human kidney. This metabolite may be 
involved in osmoregulatory processes as more abundant stereoisomer myo-Ino. 
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Figure 4. 1D 1H NMR spectra of human papillary renal cell carcinoma: a) Conventional proton spectrum with 
water-presaturation (the narrow resonances are assigned to low molecular weight metabolites, and the broad 
resonances are due to lipids and bonded amino acids); b) CPMG spectrum; c) Diffusion edited spectrum (the 
broad resonance at ~3.22 ppm is assigned to the trimethylammonium residue of phosphatidylcholine).  
 
As regards the presence of TMA and Suc, no traces were found in the intact cortical 
samples, indicating that they may have been generated by the extraction process. Clear cell 
and papillary RCCs are characterized by a metabolic pattern markedly different from those of 
cortical and medullary tissues not macroscopically affected by tumor invasion (Figure 3 and 
4). By inspection of Figure 3b and 4b, relative to the resonances pertaining to the low 
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molecular weight metabolites, a marked decrease of Bet, myo-Ino and scyllo-Ino in the 
malignant lesions can be seen. The general decrease of the relative amounts of the osmolytes 
is a recurrent finding of all the tumors studied, thus confirming on intact specimens that these 
osmolytes are the markers of normal kidney function. Furthermore, ChoCC content is higher 
in clear cell RCC (Figure 3b) with respect to the papilla and the latter is characterized by a 
high level of Tau (Figure 4b), which participates in osmoregulation, stabilizes the membrane 
potential in skeletal muscle, affects calcium ion kinetics, has antioxidant and anti-
inflammatory properties and acts as a neurotransmitter (19,20). The high amount of ChoCC 
may be attributed to the "nonphysiological" condition of neoplastic renal cells, considering 
that changes in osmolyte levels are not uniform when renal function is impaired (19). ChoCC, 
GPC in particular, behave differently from the other osmolytes, substantially maintaining 
their relative intensity in the ex vivo spectra of intact normal and tumoral renal tissues. It is 
difficult to account for this phenomenon, which is probably caused by multiple concomitant 
factors, but we assume that in the renal tissues ChoCC are not only implicated in osmotic 
balance. Since these compounds are also involved in cell membrane synthesis and breakdown 
processes and are thus related to cell replication, high levels in clear cell RCCs could be 
ascribed to tumor cell proliferation, as observed in brain malignancies (22-25). Another 
important difference between the normal and the neoplastic tissues arises from the analysis of 
Figure 1c, 3c and 4c. The spectrum in Figure 3c relative to a clear cell RCC shows a strong 
increment of the lipid component due to TG and confirms the presence, in the intact biopsies, 
of CholE, which we have previously demonstrated to be present as cholesteryl oleate in the 
extracts (12,26). These results are relevant in the light of theories that correlate the presence 
of CholE to cell proliferation in different experimental models and in several types of human 
neoplasms. Indeed, Batetta et al. (27) have hypothesized that "proliferative processes are 
characterized by a specific pattern of cholesterol metabolism, namely an increase in 
cholesterol synthesis and an accumulation of cholesterol esters in proliferating cells." The 
hypothesis that CholE play a leading role in the regulation of tumor growth, particularly 
within the tumor itself, thus find a possible explanation. Indeed, abnormal CholE storage in 
clear cell RCCs has already been reported in literature (28) and is paralleled by an increase in 
AcylCoA-cholesterol acyltransferase (ACAT) activity. Lipid components due to TG and 
CholE are present in a very low amounts or absent in the spectra of the papillary RCC (Figure 
4 c). The spectroscopic comparison between clear cell and papillary RCC tissues shows 
important metabolic differences. Literature data (11,12,29,30) demonstrated that benign 
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oncocytomas and malignant chromophobe RCCs are characterized by a typical and different 
metabolic pattern if compared with clear cell RCC, the latter having a worse prognosis. 
Indeed, metabolic differences can be related to the different histological RCC types and 
nuclear Fuhrman grade, which are two of the most important prognosticators for survival (3). 
Further studies are needed to confirm the hypothesis that the metabolic profile of renal 
neoplasms are correlated with their prognosis. In conclusion, ex vivo HRMAS is a viable and 
powerful means of probing for molecular information on human normal and neoplastic renal 
tissues. This technique allows the identification of metabolic indicators of general renal 
condition in both the physiological and pathological situation, such as depleted osmolyte 
concentrations and increased lipid components. These observations are consistent with 
evident changes in renal tissue metabolic profiles. These preliminary results encourage further 
investigations on a wider range of kidney tumors of different histhological type and grade. 
Such research will constitute the basis for a biochemical classification of renal neoplastic 
pathologies which can thus be evaluated by in vivo MRS for clinical purposes. Moreover, 
these data contribute to a better knowledge of the molecular processes fundamental to the 
onset of renal carcinogenesis. 
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CONCLUDING REMARKS 
 
This thesis shows that HR-MAS NMR spectroscopy is well suited for clinical 
applications to cancer diagnosis and grading. I concentrated on the use of the technique in 
different types of tumour, in order to characterize the metabolic pathways of the tissues, to 
identify possible metabolic markers using statistical analysis and to explore the potentiality of 
a combined HR-MAS and genetic analysis. 
HR-MAS NMR is an ideal method for the study of intact tissue samples. Sample 
preparation is easy and quick to perform and this makes me envisage the possible application 
of this technique as an alternative method or complementary to histopathology for immediate 
cancer diagnosis. It is possible to plan larger evaluation studies, in which split samples are 
taken for HR-MAS NMR and histopathological analysis. This would further test the 
reliability of the method which could then result in a rapid diagnostic mean to perform and 
which could help to guide surgical procedures. Statistical pattern recognition techniques 
would help to simplify the interpretation and, given the development of robotic sample 
preparation and data collection methods, the clinical application of high resolution MAS 
NMR spectroscopy in tumour diagnosis would become a new possibility. 
Single 1D experiments can be performed in ~ 5-10 minutes, and a set of three 
experiments covering the different metabolic profile in cancer tissues takes currently about 30 
minutes. Techniques like water presaturation (for detecting low- and high-molecular weight 
metabolites), CPMG (detecting mainly water-soluble, low-molecular weight metabolites) and 
diffusion-edited spectroscopy (mainly lipids and high-molecular weight metabolites such as 
oligopeptides) have been found to be most suitable for this work. This pool of experiments is 
further completed by the use of 2D NMR techniques for the identification of hidden 
resonances, helping the analysis of complex spectral pattern due to signal overlapping.  
The ex vivo HR-MAS NMR analysis permits to relate the biochemical composition 
with quantitative histopathologic findings from the same tissues and to determine the 
metabolic profiles associated with functional, benign and malignant tissues. Furthermore, 
correlation between some metabolites and proliferative markers allows to gain insight into the 
relationship between cellular proliferation and the metabolic changes associated with the 
presence and aggressiveness of a neoplasia.  
The selection of a certain tissue or area for HR-MAS NMR spectroscopic analysis is 
an essential step, as well as the selection of the size and location of the voxel(s) for in vivo 
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MRS. Generally the voxel or sample should contain at least 50% or more of the tissue under 
investigation. If there is not enough tumour for example in the volume, this could results in 
some degree of misinterpretation. With this method, the HR-MAS spectra obtained are 
comparable to in vivo MRS results, showing higher resolution and a signal-to-noise ratio 
similar to NMR spectra of tissue extracts.  
It is also possible to take several samples either for statistical validation or for the 
study of tissue/tumour heterogeneity. Ex vivo 1H HR-MAS of tissue sample improves the 
analysis of micro-heterogeneity in grade tumours, and can provide insights into the 
relationships between clinically relevant cell processes and specific metabolites, such as 
choline-containing compounds involved in phospholipid metabolism, or lipids involved in 
apoptosis leading to necrosis.  
Currently, a major focus in cancer research is to identify genes, using DNA-
microarrays, that are aberrantly expressed in tumour cells, and to use their abnormal 
expression as biomarkers. These approach facilitates precise diagnosis and/or therapy 
outcomes of malignant transformation. Furthermore, comprehensive understanding of gene 
expression changes in specific tumour types should also greatly support tumour analysis and 
the development of new treatment regimens. Notably, the HR-MAS and genomic data 
strongly correlate, further demonstrating the biological relevance of HR-MAS for tumour 
typing. The levels of specific metabolites, such as choline containing metabolites, that are 
altered in gliomas tissue. These changes correspond to the differential expression of Kennedy 
cycle genes. Kennedy cycle genes responsible for the biosynthesis of choline phospholipids 
(such as phosphatidylcholine) and appear to be altered by malignant transformation. These 
data demonstrate the validity of our combined approach to produce and utilize MRS/genomic 
biomarker profiles to type brain tumour tissue. 
Ex vivo HR-MAS of human tissue samples offers a potential new goal for the 
characterization of human cancer. This new technique allows the pathological diagnosis and 
the detection of tumoural biomarker and seems to be promising in developing the 
management of cancer disease. 
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conselhos. Muito obrigada por tudo! “Mi compañera de Colegio” no olvidaré esos 
momentos!!  
Y como no agradecer mi companeros de laboratorio de Madrid!!! A todos Muchas Gracias 
para el apoyo, amistad, cofiancia y estima qué me habéis concedido, siempre todas las veces 
qué estuve allí con vosotros fue como estar en mi casa: Patricia, Pilar, Rui, Tiago, Laura, Ines, 
Rosa, Teresa N., David!! Un gracias my especial desde mi corazón para Teresa D. y Jesus.  
Deseo agradecer también dos amigas: Elena y Mgiò, os amistad y cariño me ayudó 
mucho…!!! 
 
Ringazio tutti gli amici della montagna, gli ex compagni di liceo: Claudia, Dani, Jessy, Rudy, 
Manuel, Richy, Monte, Marco e il grande Stefano (a te grazie perché in ogni momento, felice 
e non, ci sei sempre stato!!!!). E grazie a tutti quelli che in questi tre anni hanno incrociato il 
mio cammino che sono tantissimi, e che ognuno a modo suo ha lasciato qualcosa!! 
 
Un grazie speciale a Paolo! 
 
Grazie, infinitamente grazie ai miei genitori, in ogni momento siete stati presenti dandomi la 
forza e spronandomi sempre a dare il meglio. Un ringraziamento speciale al mio insostituibile 
fratello Fabio per essere riuscito a sopportarmi anche nei miei momenti peggiori! 
Per voi non solo un grazie ma anche tutto il mio amore e la mia eterna riconoscenza! A voi 
dedico tutto questo lavoro! 
 
